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SUMMARY 
Antibodies are dominating the biopharmaceutical market and are expected to grow further. Aiming to 
improve existing treatments, new antibody derivatives of improved efficacy and safety are being 
developed in a competitive market. Antibody derivatives include but are not limited to antibody-drug 
conjugates and Fc-fusion proteins. Due to their higher complexity, they are often less stable as liquids, 
increasing the demand for lyophilized formulations to ensure protein storage stability over the desired 
shelf life. In many cases, these antibody formats require lower doses, posing challenges to formulation 
and freeze-drying process development. Commercialized lyophilized antibodies typically contain 
disaccharides, most frequently sucrose, as a stabilizer and bulking agent. The low glass transition 
temperature of sucrose requires time- and energy-intensive, thus expensive freeze-drying cycles. At 
lower protein concentrations, this becomes even more relevant, raising the risk of product collapse 
during freeze-drying. Collapse occurs when primary drying is performed above the glass transition 
temperature or collapse temperature of the formulation. It is current dogma to design freeze-drying 
cycles that provide pharmaceutically elegant lyophilisates as collapse leads to batch inhomogeneity 
causing rejects, higher complaint rates, and most importantly may potentially be detrimental to 
protein storage stability. Thus, there is a need to look into alternative excipients for future freeze-dried 
antibody formulations. 
The presented work investigated amorphous excipients to be used as alternative excipients to sucrose 
for freeze-dried antibody formulations, increasing the formulation’s glass transition temperature. The 
main objectives were to investigate their ability to render pharmaceutically elegant lyophilisates upon 
short freeze-drying cycles, and to stabilize antibodies during freeze-drying and subsequent storage. 
Special focus was given to storage stability at elevated temperatures with the aim to study the 
potential for room temperature stable formulations.  
At first, an imaging technique was established to evaluate the impact of excipients and freeze-drying 
cycles on cake appearance and structure. Different imaging techniques were compared regarding 
qualitative and quantitative characterization of the entire lyophilisate, and their potential for non-
invasive evaluation of structure and morphology in the glass vial (Chapter 1). The comparative analysis 
revealed limitations of scanning electron microscopy, the current state of the art technique to 
characterize cake morphology. Micro-computed tomography was introduced as a technique allowing 
for comprehensive and reproducible imaging of cake structure and morphology. 
Having established a method for evaluation of cake appearance, the next step of this work was focused 
on formulation development. Dextrans of different molecular weight from 1 to 500 kDa (Chapter 2) 
followed by HPBCD-based formulations in combination with other amorphous compounds (Chapter 3) 
were investigated. Their impact on thermal properties, cake appearance, other physico-chemical 
product quality attributes, and protein stability of two model antibodies was characterized. In 
particular, HPBCD was found to be a promising excipient, while dextran showed several limitations. 
Large dextrans of 40 kDa or higher were shown to increase the viscosity of the formulations leading to 
long reconstitution times, and did not sufficiently stabilize the antibodies during freeze-drying 
compared to smaller dextrans and HPBCD. The work highlighted limitations of dextrans with regards 
to protein stability, due to antibody glycation during storage at elevated temperatures. HPBCD 
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rendered lyophilisates with good product quality attributes and ensured antibody stability during 
freeze-drying and even at elevated storage temperatures. Best antibody stability was obtained in 
combination with sucrose, highlighting the fact that disaccharides will remain a mandatory part of 
freeze-dried antibody formulations. To further maximize protein stability, a thorough characterization 
of the optimal ratio of HPBCD and sucrose will be essential. 
These formulations which provided good stability and product quality attributes were subsequently 
used for freeze-drying process optimization (Chapter 4). Primary drying parameters were optimized 
for a short freeze-drying cycle that renders pharmaceutically elegant lyophilisates. The presented work 
demonstrated that amorphous excipients with higher glass transition temperatures allow for shorter 
freeze-drying cycles while providing lyophilisates with improved cake appearance. Ultimately, the 
HPBCD-based formulation with addition of sucrose enabled the development of a short, single-step 
freeze-drying cycle while maintaining pharmaceutically elegant lyophilisates eventually reducing cycle 
time by 50%.  
Overall, the current work demonstrated the potential of alternative amorphous excipients, which in 
contrast to crystalline bulking agents contribute to protein stability while avoiding additional 
complexity in the freeze-drying cycle. The combined use of HPBCD with sucrose may provide a 
formulation for low concentrated protein formulations that enables the development of short freeze-
drying cycles while maintaining pharmaceutically elegant lyophilisates. The presented work may 
encourage considerations to store freeze-dried formulations at (controlled) room temperature rather 
than refrigerated conditions in the future. 
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INTRODUCTION 
Biopharmaceuticals and the prevalence of antibodies  
The era of biopharmaceuticals started in 1982 with the approval of Humulin®, a recombinant human 
insulin, which was created using recombinant DNA technology. The growing acceptance of 
biopharmaceuticals due to their potential to cure diseases while having less side effects at the same 
time, led to their fast dispersion. By 2018, 374 biopharmaceuticals had been approved in the United 
States or the European Union, containing 285 distinct active pharmaceutical ingredients (API) [1]. The 
global biopharmaceutical market has reached $237.3 billion in 2018 and is expected to grow to $389 
billion by 2024, witnessing an annual growth of 8.6% [2]. Biopharmaceuticals comprise different 
product types such as monoclonal antibodies (mAb), hormones, vaccines, and coagulation factors. 
Recently, new modalities such as nucleic acids (genes) and cell therapies entered the 
biopharmaceutical market. mAbs are the largest class of biopharmaceuticals, accounting for more than 
36% of all biopharmaceuticals approved by 2018 [3-5]. Figure 1 shows that the number of mAb 
approvals increased strongly over the last four years and there is a huge pipeline of mAbs still to be 
commercialized, thus driving further substantial market growth [6]. 
 
 
Figure 1. First time mAb approvals as a percentage of total biopharmaceutical approvals in the indicated time 
periods. Adapted figure from [1].  
The origin of mAbs can be either murine, chimeric, humanized or human, with a subsequent decreased 
immunogenicity. The group of mAbs includes full-size mAbs and derivatives, such as bispecific 
antibodies, antigen-binding fragments (Fab), antibody-drug conjugates (ADC), and Fc-fusion proteins. 
Therapeutic mAbs have various indications but the vast majority is used for cancer treatment, followed 
by anti-inflammatory applications [5]. 
Biopharmaceuticals need to be administered parenterally, as they have very limited bioavailability 
when administered orally. Typical routes of administrations are either intravenous by infusion or 
injection, which shows the highest bioavailability, or subcutaneous injection, which is more convenient 
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compared to intravenous administration. Other less common routes of administration are 
intramuscular (e.g. Synagis) and intravitreal (Lucentis®). Parenterally administered biopharmaceuticals 
are formulated as liquid solutions, filled into vials, syringes, or cartridges, or as lyophilized (freeze-
dried) powders, typically packaged in vials, that need to be reconstituted prior to injection. In general, 
liquid formulations are preferred to lyophilisates due to a less complex and more economical 
manufacturing process as well as higher convenience for administration. However, proteins in liquid 
formulations are susceptible to chemical and physical degradation during storage and transportation. 
Therefore, in some cases, it might not be possible to ensure stability over the desired shelf life. In such 
cases, lyophilized formulations are chosen due to slowed down degradation mechanisms in the dried 
state. Looking at the entire market, roughly 40% of all biopharmaceuticals are freeze-dried [3, 7]. 
Among these, mAbs cover the largest group with ~34% of all lyophilisates, followed by ~27% for 
coagulation factors, which are all manufactured as lyophilized formulations (Figure 2). 
 
Figure 2. Share of lyophilized and liquid products that have been approved by the EMA from 1995 until 2018 
shown for Biopharmaceuticals. [3]. 
In particular, new mAb derivates such as bispecific mAbs (e.g. Blincyto®), ADCs (e.g. Mylotarg®, 
Cablivi®, Adcetris®, Bespona®, Kadcyla®), and Fc-fusion proteins (e.g. Elocarte®, Alprolix®, Orencia®) 
are often marketed as lyophilisates. This suggests that these new, more complex mAbs require 
lyophilized formulations, potentially leading to a growing demand for lyophilized formulations in the 
future [8]. To date, liquid as well as lyophilized mAbs (with exception of Nucala® which can be stored 
at <25°C) require refrigerated storage conditions at 2-8°C. This necessitates complex and expensive 
supply chains, and raises the risk of recalls in case of temperature excursions. Moreover, supply to 
developing countries is challenging as there is often limited cold chain capacity.  
The principles of freeze-drying  
Freeze-drying, or lyophilization, is used during drug product manufacturing of parenterals to remove 
water from the product. It is a unit operation, which is applied after compounding, sterile filtration, 
and filling. Vials are stoppered partially, transported, and loaded into the lyophilization unit. After 
freeze-drying, the vials are stoppered within the lyophilizer, unloaded, and crimp-capped. In general, 
the lyophilization process itself comprises of three major steps, as depicted in Figure 3. 
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Figure 3. Schematic illustration of a lyophilization cycle. 1) Freezing, 2) primary drying, and 3) secondary drying.  
1) Freezing 
To achieve more homogenous freezing, a short equilibration phase at 5°C is often applied prior to 
freezing [9]. During freezing, the shelf temperature is decreased, typically at a linear rate [10], to the 
desired temperature and is held there long enough to ensure the entire solution has solidified. During 
cooling, the solution first nucleates, followed by ice crystal growth leading to a mixture of solid ice and 
solute concentrate [11]. In order to ensure complete solidification of the drug product solution, the 
final shelf temperature (Ts) needs to be below the eutectic temperature (Teu) of crystalline compounds 
or the glass transition temperature of the maximally freeze-concentrated solution (Tg’) for amorphous 
formulations [12]. Teu and Tg’ are also important formulation characteristics during the subsequent 
primary drying phase. The freezing step is of importance as the freezing rate and thus the nucleation 
temperature influences the morphology of formed ice crystals, which in turn directly influences the 
primary drying rate and potentially other product quality attributes like residual moisture or protein 
stability [12, 13]. After freezing, an optional annealing step can be applied (not shown in Figure 3) to 
either allow crystallization for formulations containing crystalline excipients or to increase ice crystal 
size [14].  
2) Primary drying 
Primary drying is initiated by reducing the chamber pressure below the water vapor pressure of ice at 
the given product temperature (Tp). This process step is defined by sublimation of frozen water directly 
into the gas phase and removes the majority of the water. During primary drying, Ts is increased to 
supply the energy consumed by ice sublimation. The drying rate dm/dt can be described by the 
following equation [15]: 
𝑑𝑚
𝑑𝑡
=  
(𝑃0 −  𝑃𝑐)
(𝑅𝑠 +  𝑅𝑝)
 
where P0 is the vapor pressure of ice at Tp, Pc is the camber pressure, and Rp and Rs are the product and 
stopper resistance, respectively. Considering the fact that Ts and chamber pressure are the only 
controllable process parameters during primary drying, the sublimation rate dm/dt is thus maximized 
 
INTRODUCTION 
 
 
4 
by using a high Tp and a low chamber pressure in order to maximize the term (P0 - Pc). While Tp is 
influenced by Ts, the consumption of energy by the endothermic sublimation results in Tp being lower 
than Ts. Moreover, it is important to ensure that Tp stays below the collapse temperature (Tc) of the 
formulation during primary drying. If Tp exceeds Tc, which depends on Tg’ of the amorphous 
formulation, the lyophilized product collapses. In brief, collapse during primary drying refers to a 
viscous flow of the glassy matrix leading to the loss of macroscopic pore structure [16]. It is thus 
essential to know Tg’ and Tc of the drug product solution prior to freeze-drying cycle development. 
They are typically determined by differential scanning calorimetry [17] and freeze-drying microscopy 
[18, 19], respectively. Overall, primary drying is ideally performed at a target Tp slightly below the 
formulation’s Tc. Typically, this requires low Ts leading to long primary drying times. This can be 
achieved by multiple chamber pressure and Ts combinations with typical chamber pressures in the 
range of 50 to 200 mTorr [9, 14, 20]. Primary drying is finished when all water has sublimated, i.e. 
additional energy supply results in an increase of Tp, reaching Ts. This can be monitored by using 
temperature probes, pressure rise test, or other techniques such as comparative pressure 
measurement using a Pirani gauge versus capacitance manometer, and tunable diode laser absorption 
spectroscopy [21, 22]. 
3) Secondary drying 
During secondary drying Ts is raised to remove the unfrozen, bound water by desorption. It is well-
established that efficiency of secondary drying is independent of chamber pressure, therefore it is 
typically kept at the level of primary drying [14]. Secondary drying is performed until the residual 
moisture reaches the desired level, typically ≤ 1% [23, 24].  
Overall, freeze-drying is a time-consuming and energy-intensive, thus expensive drug product batch 
manufacturing process. The time-determining process step is primary drying. While both freezing and 
secondary drying typically last for a few hours, primary drying often requires several days [9]. 
Therefore, efforts to achieve shorter and more efficient lyophilization cycles mostly center around a 
solution that shortens the primary drying phase. 
Protein stability in the solid state  
Instabilities of proteins 
While freeze-drying generally increases the marginal stability of proteins in particular upon 
transportation and long-term storage, degradation reactions may also occur in the solid state. Protein 
degradation can be divided into chemical and physical instabilities. Chemical instabilities involve a 
covalent modification of the protein via bond cleavage or formation, including but not limited to 
deamidation, oxidation, as well as glycation reactions. Deamidation is the hydrolysis of preferably 
asparagine residues and has been reported also for freeze-dried products. However, amorphous 
matrices were shown to stabilize proteins against deamidation in the solid state [25, 26]. Glycation or 
Mailllard reaction is the non-enzymatic reaction between reducing sugars and primary or secondary 
amino residuals of the protein occuring preferably at higher temperatures. Physical instabilities include 
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denaturation, which refers to the unfolding of the globular structure, and aggregation. Aggregation is 
the most common instability of antibodies and needs to be characterized and quantified for product 
release [27]. Aggregates form via different mechanisms, which have been discussed extensively in 
several reviews [28-30]. They can form during the manufacturing processes or upon storage and be 
either soluble or insoluble with the latter being present in the form of sub-visible or visible particles.  
Mechanisms of protein stabilization  
During the freeze-drying process, the protein is exposed to freezing stresses such as the ice-liquid 
interface and cryoconcentration, as well as drying stresses when water is removed, which can be 
drivers for protein denaturation or aggregation [31-33]. In order to minimize cryoconcentration, and 
to moreover avoid unnecessarily low Tg’ values, the buffer and salt concentration is reduced to the 
minimum amount needed to control the pH [34]. For freeze-dried formulations amino acid buffers 
such as histidine buffers are preferred as they show smaller pH shifts during freezing compared to 
phosphate buffers for example [3]. To protect the protein from interfacial stresses such as the ice-
liquid interface, surfactants such as polysorbate 20 or 80 or poloxamer 188 are added at low 
concentrations. While both buffer and surfactant are also part of liquid formulations, lyophilized 
formulations require additional excipients, namely cryo- and lyoprotectants. Cryoprotectants stabilize 
the protein during freezing and in the frozen state, whereas lyoprotectants are responsible for 
stabilization upon water removal and in the dried state. The mechanism of cryoprotection has in the 
past often been described by the preferential exclusion/hydration hypothesis [35-37], a 
thermodynamic mechanism that was initially proposed to account for stabilization by e.g. sugars in 
aqueous solutions [38, 39]. However, more recent literature suggests that stabilization by 
cryoprotectants during the freezing step of lyophilization might rather be explained by a kinetic 
mechanism, which is referred to as vitrification and also relevant for protein stabilization in the dried 
state [32, 40]. Vitrification (or glass dynamics) and water replacement theory are the two main 
hypotheses discussed to describe protein stabilization during drying and subsequent storage in the 
dried state [24, 41]. Water replacement theory describes a thermodynamic stabilization of the 
protein’s native structure. It states that lyoprotectants can form hydrogen bonds with the protein, 
acting as a substitute for water molecules, which are removed during drying [42]. Vitrification explains 
the stabilization in the solid state through immobilization of the protein in an amorphous glassy matrix, 
thereby drastically slowing down degradation mechanisms [43]. It thus describes protein stabilization 
by a kinetic mechanism that is linked to the Tg of the amorphous matrix. Both theories are generally 
accepted to be of paramount importance for interpreting protein stability. However, recent literature 
suggests further refinement of these theories is required in relation to the detailed mechanisms of 
protein stabilization [44]. 
The relevance of the glass transition temperature  
The glass transition temperature is generally defined as the temperature above which a glassy matrix 
transitions into a rubbery state, thus lowering viscosity and increasing mobility. A glass transition 
temperature exists in the frozen state and is referred to as Tg’ and is an important characteristic for 
freeze-drying cycle development. The glass transition temperature of the freeze-dried formulation is 
referred to as Tg. The glass transition temperature of a formulation is characterized by the components 
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and their ratio to each other, but not their absolute concentration. Tg is of particular importance for 
protein stability described by the vitrification theory. It is generally accepted that storage above the Tg 
of a formulation increases protein degradation. Moreover, studies by Hancock et al. and 
Grasmeijer et al. have shown that depending on the molecular size and accordingly the molecular 
mobility of the sugar, Tg should be up to 50°C above the intended storage temperature to ensure 
complete vitrification [41, 45]. What is more, Tg is negatively correlated to residual moisture of a 
lyophilisate [46]. A small increase in residual moisture can strongly depress Tg, which is an important 
consideration regarding the intended storage temperature. On the other hand, it has been shown that 
the relationship between protein stability and Tg is not universal. While storage above Tg is a strong 
indicator for accelerated protein degradation, storage below Tg does not conclusively guarantee good 
protein stability [40, 41]. 
 
Excipients used as cryo-/lyoprotectants or bulking agents 
Excipients used as cryo-/lyoprotectants or bulking agents typically belong to the classes of sugars, 
polyols, amino acids, or polymers. Bulking agents are excipients that are added to the formulation, in 
particular for low concentrated protein formulations, to render an intact lyophilisate. Some excipients 
may combine two or more features. Looking at lyophilized mAbs, besides amino acids only a very 
limited number of excipients is used in marketed drug products (Figure 4).  
 
Figure 4. Percentage of non-amino acid stabilizers (cryo-/lyoprotectants) and/or bulking agents used in individual 
marketed mAb lyophilisates from 1995 to 2018. Other includes maltose and dextran [3]. 
The non-reducing disaccharides sucrose and trehalose are by far the most commonly used stabilizers, 
well-known to combine both cryo- and lyoprotective characteristics. As small, amorphous sugars they 
stabilize the protein via both vitrification and water replacement. With regards to the Tg considerations 
discussed above, trehalose (Tg of dry trehalose: ~115°C) would be expected to be preferred over 
sucrose (Tg of dry sucrose: ~70°C) [47]. However, trehalose is known to be more prone to crystallization 
during freeze-concentration, which could impair its lyoprotective properties [48]. This, in addition to 
the higher cost of the raw material [49], could be reasons why trehalose is used far less frequently in 
marketed formulations. In fact, more than 70% of all approved mAb lyophilisates contain sucrose 
(Figure 4). Mannitol is a polyol, which is added as a bulking agent in order to improve cake appearance. 
Its use in marketed freeze-dried biopharmaceuticals other than mAbs is relatively frequent, in 
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particular for low concentrated protein formulations [3]. Mannitol crystallizes during freeze-drying, 
thus is not able to stabilize the protein and is therefore most commonly used in combination with 
sucrose. Moreover, it is important that all mannitol crystallizes during freezing as crystallization during 
storage can be detrimental to protein stability. Although the addition of the polyols glycerol and 
sorbitol was shown to be beneficial for protein stability in the dried state [50, 51], they are typically 
not included in freeze-dried formulations. Due to their plasticizing characteristics, thus their very low 
Tg values, they are not attractive for economic freeze-drying cycles. Addition of amino acids such as 
arginine hydrochloride to sucrose was shown to improve protein stability, however chloride as counter 
ion strongly reduced the formulations Tg’ [52]. Horn et al. recently reported the use of phenylalanine, 
leucine, and isoleucine as promising alternative bulking agents to mannitol [53]. Polymers, such as 
dextran and polyvinylpyrrolidone (PVP), for example, have been reported as excipients for freeze-dried 
protein formulations in the past [54]. To date, Mylotarg® is the only marketed lyophilisate containing 
a polymer (dextran) as an excipient. Polymers may be used as bulking agents but also stabilizers via 
the vitrification theory due to their high glass transition temperatures. Literature indicates that the use 
of polymers necessitates a case by case evaluation. For instance, Allison et al. found that the addition 
of a disaccharide is needed for dextran to ensure stability of freeze-dried actin during storage [55], 
while Larsen et al. reported superior stability of freeze-dried lactate dehydrogenase formulated with 
dextran compared to sucrose [56]. Both studies reported good cryo- and lyoprotective properties for 
dextran.  
Moreover, the use of other classes of excipients has been described in literature and a non-exhaustive 
overview is provided here: A review on cyclodextrin describes the use of hydroxypropyl-
betacyclodextrin (HPBCD) as a protein stabilizer in the dried state [57]. Human albumin can frequently 
be found in marketed freeze-dried cytokines [3].  
The classes of excipients with high glass transition temperatures have the potential to serve as 
promising excipients for future mAb formulations with regards to designing short lyophilization cycles 
and storage at ambient temperatures.  
Quality aspects of freeze-dried products 
For release testing, important quality attributes specific to freeze-dried products include but are not 
limited to protein stability and potency, residual moisture, reconstitution time, and cake appearance 
[58, 59]. Freeze-drying aims to remove water in order to increase protein stability, consequently 
residual moisture levels should be low and specified. Although not necessarily assessed during 
commercial production, residual moisture levels need to be determined during development and 
protein stability has to be investigated for the worst case residual moisture level of the designed 
freeze-drying process. Higher residual moisture levels than specified can evoke or accelerate protein 
instabilities. For lyophilisates, stability of the API is assessed after reconstitution. It is generally 
accepted that reconstitution of a lyophilisate should be fast, although some marketed highly 
concentrated products have reconstitution times of more than 30 min [60]. The endpoint of 
reconstitution of a product is described by the US Pharmacopeia as the point in time, when all solids 
are completely dissolved and no visible particulates should be present [61]. Although recently under 
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diverse discussion, pharmaceutical elegance is generally strived for, i.e. pharmaceutically elegant 
lyophilisates (Figure 5A) are desirable to ensure intra- and inter-batch homogeneity.  
 
Figure 5. Pictures of a pharmaceutically elegant A) and collapsed B) lyophilisate. 
After lyophilization, 100% visual inspection is performed to detect container-closure defects, 
extraneous particulates, or defects in cake appearance [62]. Defects in cake appearance can either be 
cosmetic or critical, with no established standard in characterizing the degree of a defect. Patel et al. 
recently summarized the various types of defects and encouraged for a science and risk-based 
rationale for evaluating whether a defect should be considered acceptable or not [59]. Examples for 
common cosmetic defects are fogging, which describes the phenomenon of solution creeping up the 
inner vials surface [63], or cracking, a result of released drying tension during water desorption [64, 
65]. It has been shown that both fogging and cracking can be mitigated by the use of hydrophobic 
coated vials [66, 67]. On the other hand, there are cake defects which might influence product quality. 
An inspection guide for lyophilized parenterals by the US Food and Drug Administration describes that 
“Critical aspects would include the presence of correct volume of the cake and the cake appearance. 
With regard to cake appearance, one of the major concerns is meltback. Meltback is a form of 
collapse (…)” [68]. As described above, collapse is a loss of pore structure as a result of Tp higher than 
Tc (Figure 5B). This loss of pore structure can lead to increased reconstitution times of the lyophilisate 
[69]. More importantly, collapse can restrict water sublimation leading to higher residual moisture 
levels of the lyophilisate, which may increase protein instability [70, 71]. Although the negative impact 
of collapse on protein stability was shown to be not universal [72, 73], collapse in any case gives rise 
to complaints as it renders inhomogeneous batches [74]. Thus, to date, collapse is generally considered 
unacceptable leading to rejects [59].  
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SCOPE 
The growing market of therapeutic antibodies and particularly their next generation derivatives, which 
are often less stable as liquids, increase the need for lyophilized formulations. In addition, these new 
antibody formats often require lower doses than conventional antibodies, posing challenges with 
regards to formulation and lyophilization process development. Lower protein concentrations may 
require a higher amount of bulking agent to render mechanically stable and elegant lyophilisates. For 
typical sucrose formulations, this results in low glass transition and collapse temperatures due to the 
amended sugar/protein ratio, increasing the risk of collapse during short and aggressive freeze-drying 
cycles.  
The focus of this work was to study alternative amorphous excipients for freeze-dried antibody 
formulations, which have considerably higher glass transition temperatures compared to commonly 
used disaccharides. The aim was to investigate their ability to provide pharmaceutically elegant 
lyophilisates while developing short freeze-drying cycles. Additionally, their ability to stabilize 
antibodies during freeze-drying and subsequent storage with an emphasis on the potential for room 
temperature stable formulations was investigated.  
The first objective was to identify a method that allows for a comprehensive evaluation and 
differentiation of cake appearance and structure of different lyophilisates. In Chapter 1, µ-CT was 
introduced as an imaging technique and compared to different novel and established techniques with 
regards to their ability to provide a comprehensive, qualitative/quantitative, and non-invasive 
evaluation of cake appearance as well as structure and morphology.  
Having established a method that allows for differentiation of cake appearances, the focus of the next 
two chapters (Chapter 2 and Chapter 3) was on formulation development. Alternative excipients in 
low concentrated freeze-dried antibody formulations were characterized with regards to their impact 
on glass transition temperature, cake appearance upon aggressive freeze-drying, and protein stability 
upon freeze-drying and during storage. Particularly, their potential and limitations for storage at room 
temperature were analyzed and compared to a reference sucrose formulation. Chapter 2 described 
the impact of dextrans of different molecular weights from 1 to 500 kDa. In Chapter 3, HPBCD-based 
formulations and the influence of adding other excipients such as recombinant human albumin, PVP, 
dextran, and sucrose were studied.  
Developed formulations, which provided good stability and product quality attributes, were used for 
freeze-drying cycle optimization. The objective of Chapter 4 was to develop a short lyophilization cycle 
using aggressive primary drying conditions resulting in high product temperatures, while maintaining 
pharmaceutically elegant lyophilisates with good physical-chemical product quality attributes and 
protein stability. 
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Imaging techniques to characterize cake 
appearance of freeze-dried products 
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Authors:  
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Abstract 
Pharmaceutically elegant lyophilisates are highly desirable implying a stable and robust freeze-drying 
process. In order to ensure homogenous and intact cake appearance after process scale-up and 
transfer, characterization of lyophilisates during formulation and cycle development is required. The 
present study investigates different imaging techniques to characterize lyophilisates on different 
levels. Cake appearance of freeze-dried BSA formulations with different dextran/sucrose ratios was 
studied by visual inspection, 3D laser scanning, polydimethylsiloxane (PDMS) embedding, scanning 
electron microscopy (SEM), and micro-computed tomography (µ-CT). The set of techniques allowed a 
holistic evaluation of external cake appearance and internal structure providing complementary 
information at macroscopic and microscopic scale. In comparison to state of the art technologies like 
visual inspection or SEM, 3D laser scanning and µ-CT provided quantitative information allowing 
comparison of visual cake appearance. In particular, µ-CT enables a global, qualitative, and quantitative 
characterization of external and internal cake structure with a single measurement detecting 
heterogeneities of lyophilisates. We even demonstrated the use of non-invasive µ-CT for qualitative 
imaging of internal cake structure through the glass vial. Providing meaningful characterization of the 
entire lyophilisate, µ-CT can serve as a powerful tool during development of freeze-drying cycles, 
process scale-up, and transfer.  
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INTRODRUCTION 
Lyophilization is a commonly used technique to enhance storage stability of biopharmaceuticals [1, 2]. 
Major constraints of freeze-drying are the additional time-consuming and costly manufacturing 
process after drug product filling as well as the complex development and scale-up. With biosimilars 
just having entered the pharmaceutical market [3], development of stable but cost conscious drug 
manufacturing is even more important. In terms of lyophilization, this drives the need to develop 
appropriate formulations which endure aggressive (i.e. shorter) lyophilization cycles with the 
prerequisite to deliver consistent product quality by a robust freeze-drying process. This also means in 
most cases to develop pharmaceutically elegant cakes with reproducible cake appearance. A 
homogeneous cake structure with minimal intra- and inter-vial variability is thus desired although 
inadequate cake appearance may not negatively impact product quality as recently reported by 
Schersch et al. [4]. Furthermore, a pharmaceutically elegant cake is not only implying a stable freeze-
drying process, but correct cake volume and cake appearance are considered critical aspects for 
inspection of parenterals by health authorities [5].  
During formulation and freeze-drying cycle development, the freeze-dried cakes are thoroughly 
characterized [6]. Besides cake appearance, this comprises characterization of the freeze-dried 
product in terms of microstructure, reconstitution time, and residual moisture. Microstructure and 
pore structure of the freeze-dried product are typically studied by scanning electron microscopy (SEM) 
[7] and specific surface area (SSA) measurements according to the Brunauer-Emmett-Teller (BET) [8] 
method. Rambathla et al. also showed that an increase in SSA as a result of a higher degree of 
supercooling during the freezing step may subsequently lead to a longer water vapor transition 
time [9]. Crystallinity and the type of polymorph formed in formulations can be assessed using X-ray 
powder diffraction [10]. Finally, residual moisture levels are determined using Karl Fischer titration or 
near-infrared spectroscopy (NIR) [11] for optimization of secondary drying [12, 13] and to characterize 
and control this factor which is critical for product stability.  
Visual appearance of the final drug product is typically inspected by the naked eye. With regard to 
aggressive freeze-drying cycles, macroscopic collapse of the lyophilisate can often be observed when 
the product temperature exceeded the glass transition temperature (Tg’) or collapse temperature (Tc) 
of the formulation during primary drying. A review of the different visual defects providing best-
practice guidance for acceptance criteria was recently published by Patel et al. [14]. Besides external 
visible cake defects, partial collapse inside the lyophilisate or intra-vial heterogeneity have also been 
reported [15, 16], which may not be detected by conventional characterization techniques. However, 
partial collapse inside the lyophilisate can potentially be critical for the drug product, e.g. by leading to 
increased residual moisture. Furthermore, if such defects inside the lyophilisate exist during process 
development in a laboratory freeze-dryer, they can be indicative for an increased risk to process 
transfer to a pilot plant or commercial scale. It is well known that the thermal product history in various 
freeze-dryers is not necessarily the same [17, 18]. Thus, small changes in product temperature can 
then result in visually detectable cake defects after transfer to another freeze-dryer unit. In addition, 
characterization of cake morphology, which is defined during the freezing step by the formation of ice 
crystals, was recently correlated to the cake resistance to water vapor flow by Pisano et al. [19]. 
We therefore believe that holistic imaging of the lyophilisate structure beyond the information 
provided by visual inspection and SEM is advantageous during formulation and process development, 
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scale-up, and transfer. This includes characterization of the lyophilisate in terms of external cake 
appearance and inner macroscopic as well as microscopic cake structure. In particular, methods are 
needed, which provide qualitative information on a global level as well as quantitative data. Ideally, 
such methods are non-destructive, fast, and do not require removal of the cake from the glass vial. 
The scope of the present study was to evaluate different imaging techniques and their applicability to 
study cake appearance of freeze-dried products allowing for a sound evaluation of cake defects on 
different scales. The methods were applied on lyophilisates of bovine serum albumin (BSA) as model 
protein. Different Tc were obtained using blends of sucrose and dextran. This composition enabled to 
obtain lyophilisates with different cake appearances within the same freeze-drying cycle. Freeze-dried 
cakes were visually inspected and classified from collapsed to pharmaceutically elegant cakes. The set 
of characterization methods included the well-established SEM, recently developed methods like 
Polydimethylsiloxane (PDMS) embedding [15] and micro-computed tomography (µ-CT) [20, 21]. In 
addition, a method allowing for non-invasive µ-CT imaging through the vial and three-dimensional (3D) 
laser scanning as a new technique was introduced. The techniques were compared with regard to their 
ability to provide qualitative and quantitative data, the local or global level of information on cake 
structure, as well as time and effort required for sample preparation, measuring time, and data 
processing. The results are discussed with respect to the added value for formulation and process 
development. 
MATERIALS AND METHODS 
Materials 
Preparation of lyophilisates 
Formulation. BSA Fraction V (Roche Diagnostics, Penzberg, Germany) was used as model protein. It 
was formulated at 10 mg/mL in a 20 mM histidine/histidine-HCl buffer pH 6.0 (Ajinomoto, Tokyo, 
Japan) with addition of 0.02% (w/v) polysorbate 20 (Croda International, Snaith, UK) and a total solid 
content of additional excipients of 8%. Six formulations with mixtures of dextran 1 kDa 
(Pharmacosmos, Holbaek, Denmark) and sucrose (Ferro Pfanstiehl Company, Mayfield Heights, Ohio) 
at different ratios (w/w) were prepared: Dex0/Suc100, Dex20/Suc80, Dex40/Suc60, Dex60/Suc40, 
Dex80/Suc20, Dex100/Suc0. All formulations were sterile filtered through 0.22 µm PVDF filter units 
(Millipore, Bedford, MA, USA). 10.6 mL of each formulation (n=20) were filled into 20R TopLyo® vials 
(Schott, Müllheim, Germany).  
Freeze-drying process. Freeze drying was performed on a FTS LyoStar II freeze-dryer (FTS Systems Inc, 
New York, NY). To minimize radiation effects on cake appearance, edge vials were filled with sucrose 
solution and not further evaluated. Formulations were randomly distributed over three shelves. Vials 
were equilibrated at 5°C for 1 h and frozen to -35°C with shelf cooling rate of 0.3°C/min. The shelves 
were kept at -35°C for 3 h before applying vacuum (100 mTorr). For primary drying, shelves were 
heated to 10°C at 0.2°C/min and held for 56 h. Secondary drying was performed at 25°C (ramp rate 
0.2°C/min) and 100 mTorr vacuum for 8 h. The vials were stoppered under nitrogen at 760 mbar.  
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Methods 
Visual inspection 
Lyophilisates were visually inspected in front of black background and classified for cake defects like 
collapse, dents, and cracks. Cake appearance was recorded with a camera. 
3D laser scanning 
3D laser scanning was used to visualize cake appearance and to obtain quantitative information on the 
cake volume. Vials were cut horizontally below the neck with a diamond grinding wheel to allow 
removal of the cake without damage (Fig. 1A). The cake was placed onto a plate, equipped with optical 
reflectors, which served as a reference system for the 3D scanner. The cake was scanned with a 
HandyScan 700TM 3D scanner (Creaform Inc., Leinfelden-Echterdingen, Germany). 50 images per 
second were recorded at a resolution of 0.2 mm until a closed mesh was obtained. In total, three scan 
sessions of 30-40 s were performed per cake rotated by 120° each time. Raw data of the three scan 
sessions were merged with the VXelements software version 6 (Creaform Inc.) into one image. 
Netfabb software (Autodesk Inc., San Rafael, CA) was used to close the open mesh and to calculate 
the cake volume. Each formulation was scanned in triplicates. Cake volumes are given as mean and 
standard deviation (SD).  
Polydimethylsiloxane (PDMS) embedding 
To macroscopically visualize the internal cake structure, PDMS embedding of the lyophilisates was 
performed based on a method recently described by Lam and Patapoff [15]. Embedding was 
performed in duplicates per formulation. PDMS was prepared by mixing Sylgrad 184 Base and Curing 
agent (Dow Corning, Michigan, MI) at a 1:10 ratio. The mixture was degassed under vacuum in a 
desiccator and filled into 50 mL disposable syringes (BD, Drogheda, Ireland), which tips were covered 
with parafilm. Holes that were stitched into the syringe headspace allowed for degassing during the 
embedding process. The syringes were placed into a syringe holder with the tips directing into the 
open vials. A wire was fixed around the syringe opening and placed on top of the lyophilisate to avoid 
floating of the cakes during embedding. The setup was placed into a FTS LyoStar II (FTS Systems Inc, 
New York, NY) and the pressure was reduced to approximately 38 Torr for degassing. After a hold time 
of 30 min, the shelves were gently lowered to push down the syringe plunger and to release the PDMS. 
The setup was left in the lyophilizer under reduced pressure for two hours to let the PDMS fully 
penetrate into the cakes. The samples were subsequently placed into a heating oven (Heraeus 
Instruments GmbH, Hanau, Germany) at 40°C to cure the PDMS. The glass was removed and the 
embedded cake was cut into vertical and horizontal slices (thickness: approx. 2 mm) using a toggle 
press (HK 800, Berg & Schmid, Remseck, Germany). The slices were visualized at a 0.65-fold 
magnification under a Stemi 200 OC Stereomicroscope (Carl Zeiss AG, Feldbach, Switzerland). 
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Scanning electron microscopy (SEM) 
Local morphology and pore structure of the freeze-dried cake were analyzed by SEM using a Sigma VP 
system (ZEISS, Oberkochen, Germany) under high vacuum and acceleration voltage of 3 keV. SEM was 
performed in duplicates per formulation. The vials were opened in a glove box under nitrogen and 
fragments of the top and bottom layer of the lyophilisate were extracted using a spatula. The samples 
were sputtered with gold (120 s, 30 mA, 0.1 bar Ar) using a Cressington 108 Auto sputter (Elektronen-
Optik-Service GmbH, Dortmund, Germany) to increase their conductivity. Images at 50-, 100-, 500-, 
and 1000-fold magnification were recorded.  
 
Figure 1. Sample preparation for innovative imaging techniques: A) 3D laser scanning or B) micro-computed 
tomography (µ-CT) after transfer to sealed plastic cups, and C) non-invasive µ-CT through the glass vial. 
Micro-computed tomography (µ-CT) 
Global 3D information on cake structure of the lyophilisate was obtained using µ-CT measurements. 
Non-invasive µ-CT (within glass vial)  
A nanotomOR instrument (phoenix|x-ray, GE Sensing and Inspection Technologies GmbH, Wunstorf, 
Germany) was used to study the ability of µ-CT to visualize the cake structure through the glass vial 
(Fig. 1C). The lyophilisate was measured without any sample preparation using an acceleration voltage 
of 60 kV and a beam current of 310 µA. To allow for direct comparison with µ-CT measurements 
performed outside of the vial, pixel length was set to 18 µm. Total measurement time was 1.5 h.  
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Invasive µ-CT (removal of lyophilisate) 
Analysis was performed in triplicates using a SkyScan 1275 X-Ray microtomograph (Bruker MicroCT, 
Kontich, Belgium). The freeze-dried cake was removed from the vial, as described above (Fig. 1B). The 
lyophilisate was immediately transferred into a custom made sealable plastic container, overlaid with 
nitrogen, and sealed (Fig. 1B). Thus the cake was protected from atmospheric humidity over the time 
frame of analysis. An acceleration voltage of 20 kV and a beam current of 175 µA were applied and 
pixel length was set to 18 µm. An exposure time of 650 ms with 6 averages per projection was applied. 
The lyophilisate was rotated over 360° with a step size of 0.25°. Total measurement time was 1.5 h. 
Reconstruction of the projections using the NRecon software (Bruker, Kontich, Belgium) resulted in an 
image stack of tomograms. Quantitative results are given as mean and SD.  
High-resolution µ-CT images were obtained on a SkyScan 1272 X-Ray microtomograph (Bruker 
MicroCT, Kontich, Belgium). A piece (approx. 1/3) of the lyophilisate was transferred into a plastic cup 
as described above. Scans were acquired using an acceleration voltage of 30 kV and a beam current of 
212 μA. An exposure time of 500 ms with 10 averages per projection was applied. The lyophilisate was 
rotated over 360°with a step size of 0.05°. With a pixel length of 4 μm, total measurement time was 
18 h.  
Data analysis 
To perform reproducible and accurate data analysis, a central image stack of 600 slices per lyophilisate 
was used. Edge slices of top and bottom showing common µ-CT artifacts (cone beam error, beam 
hardening [22]) were not included.  
Quantitative analysis required binary images, which were obtained by applying a threshold value to 
each image stack. In brief, threshold values were determined in OriginLab (OriginLab, Northampton, 
MA) by a multiple Gaussian fit using the histogram of a 600-slice image stack (see supporting 
information Fig. S1 for details).  
Quantitative evaluation of cake integrity was performed on binary images using the analyze particles 
function in the open-source software Fiji [23], which calculates the number of white pixels per binary 
image. Using the pixel count per slice, the cake volume was calculated according to the following 
equation: 
𝑉 =  ∑ 𝑝𝑖𝑥𝑖
𝑛
𝑖=1  ×  
𝑉𝑝𝑖𝑥
1012
 𝑐𝑚3 (1) 
with V = cake volume [cm3], n = number of slices, Vpix = volume per pixel (18 µm3), and pix = pixel count 
per slice. Surface to volume ratios of the binary image stack were calculated by CTAn 1.17 (Bruker, 
Kontich Begium), which uses the marching cube model to calculate surface and volume [24]. 
RESULTS 
A panel of imaging techniques was investigated for their ability to characterize lyophilisates 
qualitatively and quantitatively with regards to cake appearance and macroscopic as well as 
microscopic cake structure. For a holistic testing, covering a broad range of cake defects, BSA based 
 
CHAPTER 1 
 
 
 
21 
formulations with Dex/Suc mixtures were lyophilized using an aggressive primary drying temperature 
of +10°C in order to obtain a variety of different cake appearances.  
External cake appearance by visual inspection 
External cake appearance was visually inspected and evaluated by taking pictures through the glass 
vial. In general, a more elegant visual appearance was observed with higher dextran concentrations 
(Fig. 2A). Dex0/Suc100 lyophilisates were found to be collapsed for the applied freeze-drying cycle. 
Dex20/Suc80 formulations were slightly improved but showed partial collapse and severe dents at the 
bottom of the cake. Severe to major dents were found for Dex40/Suc60 formulations and Dex60/Suc40 
showed minor dents. The dents were reduced for higher Dex/Suc ratios, resulting in pharmaceutical 
elegant cakes for Dex80/Suc20 and Dex100/Suc0.  
External cake appearance and cake volume by 3D laser scanning 
3D laser scanning was used to investigate visual appearance qualitatively and to obtain quantitative 
information: For this purpose, the intact lyophilisate was removed from the vial (s. Fig. 1A). Cake 
structure integrity was visually confirmed over the scanning processing. The 3D scans of the 
lyophilisates reflected the defects observed by visual inspection for the different formulations (Fig. 2B). 
The qualitatively observed trend to more elegant lyophilisates with increasing Dex/Suc ratio was 
supported with quantitative data on cake volume, which was found to increase from 7.74 cm3 for 
Dex0/Suc100 to 8.43 cm3 for Dex100/Suc0 (Table 1). Variability of the cake volume was higher for 
collapsed formulations with standard deviations of 2.7% and 1.6% for Dex0/Suc100 and Dex20/Suc80 
compared to 0.2% and 0.7% for Dex80/Suc20 and Dex100/Suc0, respectively.  
  
Figure 2. Visual appearance of lyophilisates. A) Pictures of lyophilisates in the intact glass vial. B) Images of 3D 
scans of lyophilisates removed from the vial. Approx. diameter of lyophilisates: 28 mm.  
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Table 1. Cake characterization data for different formulations using different imaging technologies. Quantitative 
data is given as mean of triplicates and standard deviation. The positions of cake defects are indicated in brackets 
with b=bottom, m=middle, t=top, v=vertical, e=edge.  
 
Internal macroscopic structure by PDMS embedding 
The internal macroscopic structure of the lyophilisates was investigated by embedding the lyophilisate 
in PDMS, cutting and microscopically analyzing a vertical middle cross-section and two horizontal slices 
taken from bottom and top regions. Figure 3 shows representative images for formulations which were 
classified by visual inspection as collapsed (Dex0/Suc100), with dents (Dex60/Suc40), and 
pharmaceutically elegant (Dex100/Suc0). The vertical cross-section of Dex0/Suc100 demonstrated the 
intra-vial heterogeneity of the lyophilisate. The region from vial bottom to half height of the cake 
showed an intact cake structure and the vial edges as well as the top region showed collapsed 
lyophilisate structure. This observation became even more prominent with horizontal cross-sections 
of top and bottom regions. Holes and dents were observed at the bottom close to the vial wall 
surrounding the inner intact lyophilisate. In contrast, an overall collapsed cake structure was observed 
for the top region. A more homogenous cake structure was observed for the Dex60/Suc40 lyophilisate. 
Dex60/Suc40 still showed dents for the cross-sections of the bottom region but a homogenous intact 
cake structure for the top region. However, within the vertical cross-section a collapsed part in the 
upper third of the lyophilisate reaching from one vial side to the other was found. This information of 
the internal macroscopic structure was not noticeable upon visual inspection or 3D laser scanning. A 
rather dense and uniform cake structure was observed for formulations Dex100/Suc0, with bottom 
and top regions both showing intact cake structure all over the cross-section. Cracks could be identified 
within the bottom and vertical images of Dex60/Suc40 and Dex100/Suc0. The macroscopic structure 
observed for the different formulations was similar for the duplicates investigated.  
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Figure 3. Analysis of PDMS embedded lyophilisates. Representative images of selected vertical and horizontal 
slices of lyophilisates. Approx. 20 mm sections of the entire lyophilisate are shown.  
Internal microscopic structure and characterization of pore structure by SEM 
To investigate the microscopic structure and in particular the pore structure, small parts of the vial 
bottom and top regions were extracted using a spatula and investigated by SEM. At 100-fold 
magnification, Dex0/Suc100 shows a highly porous microscopic sponge like structure for the bottom 
layer (Fig. 4A), matching the expectations based on the results of the previously described methods. 
For the top region, no intact morphology could be identified on a microscopic scale indicating that the 
formulation was completely collapsed. An intact and less porous microscopic structure was observed 
for top and bottom layers for Dex60/Suc40. At 500-fold magnification of the bottom region merging 
of the matrix in between two pores could be revealed. These fused regions within the material indicate 
onset of physical collapse of the cake. However, the second Dex60/Suc40 lyophilisate analyzed even 
showed fusion of pores in the top layer (see supporting information Fig. S2). With regard to the internal 
partial collapse of Dex60/Suc40 observed by PDMS embedding, this leads to the assumption that the 
samples were extracted from the intact top layer (vial 1) and the collapsed region in the upper third 
(vial 2) indicating criticality of sample preparation for SEM. Dex100/Suc0 formulations showed a 
different microscopic morphology compared to Dex0/Suc100 and Dex60/Suc40, which resembled a 
sponge like structure. In contrast, the arrangement of Dex100/Suc0 in the 500-fold SEM image in 
Figure 4B has a more lamellar, stapled appearance. This morphology for dextran based formulations 
has been observed before in a study performed by Padilla et al. [25].  
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Figure 4. Scanning electron microscope (SEM) analysis of lyophilisates. Representative images from top or 
bottom layer of freeze-dried cakes at A) 100-fold magnification or B) 500-fold magnification. 
Global cake structure by µ-CT in plastic cups  
Qualitative evaluation of 3D reconstruction  
µ-CT was performed to study external and internal cake structure globally on different levels. Greyscale 
images of the entire lyophilisate were obtained by 3D computer reconstruction. In general, material 
of higher density results in higher contrast and consequently, grey to white parts represent solid 
matrix, and black regions represent air. The 3D images of the lyophilisates as shown in Figure 5A 
support the observations made by visual inspection and 3D laser scanning. Formulations with 
Dex0/Suc100, which showed collapse, exhibited voids i.e. collapsed regions. In addition, the majority 
of the solid part had a white appearance compared to the rather grey character in case of Dex60/Suc40 
and Dex100/Suc0 indicating densification of the solid material due to collapse. For Dex60/Suc40 
formulations, dents close to the vial bottom were observed and in addition some voids (black areas) 
all over the lyophilisate which could represent either regions of partial collapse or cracks reaching to 
the glass vial. Finally, the formulation Dex100/Suc0, which was found to provide a visually elegant cake, 
also provided a rather homogenous appearance in the 3D µ-CT reconstruction. 
Representative horizontal cross-sections for bottom, middle, and top regions of the lyophilisates are 
shown in Figure 5B. At the bottom region of Dex0/Suc100 large black regions were staggered around 
the inner cake. The voids increased for slices in the middle of the lyophilisate, completely surrounding 
the cross-section. At the top, almost the total area was black, interspersed only by some light-grey to 
white regions. The same intense contrast was observed for the boundary layer between air and inner 
cake structure for both bottom and middle slices. The light-grey to white parts again revealed matrix 
of higher density where the collapsed and shrunken material concentrates. Replacing 60% of the 
sucrose content with dextran (Dex60/Suc40), less black area was observed. The bottom layer of 
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Dex60/Suc40 showed more grey part compared to Dex0/Suc100, i.e. less dents and less collapse. 
However, partial collapse was observed for the middle slice, reflecting the observations made by the 
PDMS embedding technique. A significant improvement in cake structure for higher dextran 
concentration was observed for the top slice. Dex0/Suc100 showed total collapse, whereas 
Dex60/Suc40 exhibited a rather intact homogenous cake structure. Intact cake structure for all three 
slices was found for Dex100/Suc0. Collapse or dents were not observed for any slice. The cross-section 
from the middle of the lyophilisate showed larger lamellar-like structures particularly around the crack 
in the middle.  
Figure 5C shows vertical cross-sections of the middle of the lyophilisates. Intra-vial heterogeneity was 
observed for all three formulations. For Dex0/Suc100, growth of collapsed regions was observed from 
vial bottom to top. White parts on the edges indicate that collapse and dents close to the vial wall 
occurred. The cross-section of Dex60/Suc40 visualized the collapsed region in the upper third, which 
has also been observed by PDMS embedding. In total, the overall cake structure was more uniform 
compared to Dex0/Suc100. For Dex100/Suc0, collapsed parts were not observed and regions with large 
lamellar-like structures, mainly in the middle of the lyophilisate, were found. For all formulations, 
cracks inside the cakes were observed.  
Figure 5D shows a close-up for selected regions of Dex60/Suc40, obtained by a high resolution scan 
(4 μm) of a selected piece of lyophilisate. The upper image (1) reveals the fusion of microscopic pore 
structure as also observed by SEM for Dex60/Suc40 lyophilisates. In contrary, the lower image (2) 
shows intact sponge-like pore structure as observed by SEM for the very top layer. In addition, the top 
left of the image shows a rather lamellar structure. Based on the SEM observations for Dex100/Suc0 
lyophilisates, this might indicate a region where preferably dextran is present. The distribution of 
protein and excipients within the lyophilisate is subject of ongoing research. 
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Figure 5. Representative µ-CT images of lyophilisates after transfer to plastic cups. A) Representative 3D-images 
of freeze-dried cakes. B) Representative images of horizontal cake structure at different cake heights from 
bottom to top layer. C) Representative images of vertical cake structure (middle of the freeze-dried cake). The 
white box indicates the region that has been used for high-resolution μ-CT. D) High-resolution μ-CT (4 µm) of 
partial cake: (1) collapsed microstructure and (2) intact sponge-like structure. Images are based on 3D computer 
reconstructions. Approx. cake diameter: 28 mm. 
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Quantitative evaluation of binary images  
Quantitative evaluation was based on analysis of 600 slices throughout each lyophilized cake. Binary 
images were obtained for each slice by applying a threshold. In order to perform consistent and 
reproducible analysis, a threshold was chosen that was to the detriment of fine pore structures (see 
supporting information Fig. S3). By summing up the white pixels per slice plotted against the slice 
number, a quantitative measure for intra-vial integrity was obtained as shown in Figure 6. A steady 
decrease in pixel count was observed for Dex0/Suc100 from slice 300 to 600 indicating a loss of 
structure and reflecting the qualitative results obtained by PDMS embedding (Fig. 3) as well as µ-CT 
slices of middle and top regions (Fig. 5B). With higher Dex/Suc ratios the total pixel count per slice was 
increased and found more consistent throughout the cake. The collapsed region within the upper third 
of Dex60/Suc40 was detected by a lower pixel count between slices 300 - 450 which increased again 
for slices 450 - 600. An almost constant pixel count was found for Dex80/Suc20 and Dex100/Suc0. In a 
next step, the cake volume was calculated for each formulation. An increase in volume was found with 
higher Dex/Suc ratios as shown in Table 1. In general, volumes obtained by µ-CT were found to be 
lower compared to calculated volumes for 3D laser scanning (Table 1). In addition, surface to volume 
ratio were obtained, which were in general lower for higher dextran concentrations. This suggests that 
addition of dextran led to more dense and less porous lyophilisates. This quantitative evaluation 
corresponds to the porous morphology of Dex0/Suc100 samples observed in SEM.  
 
 
Figure 6. Quantitative evaluation of cake integrity by µ-CT. Integrity of vertical cake shown by pixel count per 
horizontal slices dependent on cake height. A higher pixel count represents higher integrity of the cake. Cake 
height is divided into 600 slices of equal thickness (18 µm). Pixel count of binary µ-CT images is plotted as mean 
value. For better visualization every sixth point is plotted. 
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Non-invasive µ-CT imaging through the vial 
Additional µ-CT measurements were performed to evaluate the potential of µ-CT to study cake 
structure non-invasively through the glass vial. In order to confirm the validity of images obtained by 
scanning through the glass vial, the results were compared to a µ-CT scan of the identical lyophilisate 
after transfer into a plastic cup. Both images reveal details of the lyophilisate inner structure to the 
same extent (Fig. 7). Overall, a higher contrast between cake matrix and air was achieved by analysis 
after removal from the vial. In addition, a bright region surrounding the lyophilisate, referred to as 
beam hardening [22], is observed when analysis is performed in vials.  
 
Figure 7. Non-invasive µ-CT for imaging of cake structure. Horizontal greyscale µ-CT slice of the same 
Dex60/Suc40 lyophilisate. µ-CT was performed through the glass vial at 60 kV (left image) or after transfer intro 
a plastic cup at 20 kV (right image). 
DISCUSSION 
The aim of the present study was to investigate and compare different imaging techniques for their 
ability to provide information on cake appearance as well as internal cake structure of lyophilisates on 
a local and global level. Special emphasis was hereby given to innovative imaging techniques: 3D laser 
scanning and non-destructive μ-CT methods. In order to evaluate the tested methods with respect to 
their ability to differentiate between cakes of different appearance, formulations with the same solid 
content, but different Dex/Suc ratios were examined. Dextrans, which have previously been used as 
excipients for protein formulations [26-28], were chosen as the Tg’ is higher than that of sucrose. The 
Tg’ and the Tc onset for 80 mg/mL sucrose or dextran 1 placebo solutions were -31.8°C/-30.3°C 
and -19.8°C/-19.5°C, respectively. Product temperature during primary drying was 
approximately -24°C. As a result, different cake appearances were intentionally obtained while using 
the same freeze-drying process parameters. It needs to be mentioned that optimization of freeze-
drying conditions was not within the scope of the present study. Cracks depend on the water 
desorption behavior and were expected under the aggressive freeze-drying cycle conditions [29]. 
Visual inspection was performed representing state of the art for 100% control after lyophilization [30]. 
It allows for a fast and non-invasive evaluation of the visual appearance of a lyophilisate through the 
glass vial. However, this method faces some significant challenges. First, a defect might clearly be 
visible for the operator by eye, but recording the same with a camera in case of fully automated optical 
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inspection can be challenging. For instance, Patel et al. pointed out that in case of fogging camera 
based visual inspection may lead to false rejects [14]. Furthermore, cake appearance and its evaluation 
is one of the most subjective product quality attributes depending on the training of the inspector and 
therefore inter-individual variability in the reporting is common. Last but not least, a lyophilisate might 
appear pharmaceutically elegant upon visual inspection, but partial collapse may occur inside of a 
lyophilisate, hence cannot be seen by pure external inspection [14, 15]. 
We introduced 3D laser scanning as a novel technique for characterization of lyophilized cakes to drive 
the evaluation of visual appearance towards an objective and hence comparable analysis. In order to 
mitigate artifacts due to the curved surface of the glass container, the cake needs to be removed from 
the vial and exposed to the atmosphere during the measurement making it destructive. With this 
technique, a 3D image of the pure lyophilisate was recorded similar to visual inspection providing 360° 
information of the external cake appearance. In addition, quantitative data of the cake volume was 
provided. Higher cake volumes were obtained for formulations of higher Dex/Suc ratios correlating to 
an improved visual appearance (see Table 1). Thus, we could quantitatively demonstrate the 
improvement of visual appearance. This numerical information might be of advantage during 
formulation or process development allowing an objective comparison of the impact of different 
formulation or process parameters. 3D laser scanning was found to be an easy to use method to 
quantify visual appearance but it also revealed some constraints. The technique required removal of 
the lyophilisate from the vial, leading to exposure of the cake to the atmosphere for the timeframe of 
the measurement. Risks associated with this procedure are false cake volume either because of 
deformation or shrinkage of the lyophilisate during measurement or due to cake residuals remaining 
in the vial. Data for imaging techniques in this manuscript were obtained by lyophilization in TopLyo® 
vials and in 20R Fiolax (data not shown). The remaining cake residues in the glass vial when removing 
the lyophilized cake becomes prominent for freeze-drying performed in uncoated vials. The 
lyophilisates tended to stick to the vial bottom. Thus, measurement of triplicates resulted in generally 
higher standard deviations for uncoated vials compared to hydrophobic coated vials (supporting 
information Fig. S4). 
As mentioned above, some cake defects may not be noticeable by external inspection, making imaging 
of the internal cake necessary. An adapted protocol (e.g. imaging without coloration of the embedded 
slices) of the PDMS embedding technique, originally proposed by Lam and Patapoff [15], was used 
allowing for visualization of internal cracks and collapsed regions. It provides a valuable tool for 
imaging selected regions of the cake via vertical or horizontal cross-sections. One drawback of this 
technique is the time consuming sample preparation, with embedding plus curing taking several days. 
Furthermore, within other research studies, we found the applicability of the embedding technique to 
be dependent on the formulation composition. The phenomenon of incomplete encapsulation and 
challenges related to high fill height have previously been described by Lam and Patapoff [15]. 
Attempts to convert pictures into binary images for quantitative assessment were not successful as 
differentiation between embedded cake matrix and pores was insufficient due to little contrast. 
SEM is a very common technique used to study the microscopic structure and the pores of lyophilisates 
during both formulation [7, 31] and process development [32-34]. It provided valuable information on 
the microscopic structure of different Dex/Suc formulations in our study. For instance, a 500-fold 
magnification of Dex60/Suc40 (Fig. 4B) showed onset of pore fusion, which suggests that the product 
was freeze-dried close to or above its Tc. It also revealed that high dextran concentrations seem to shift 
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the microscopic structure from a sponge-like arrangement towards a dense rather lamellar, 
honeycomb-like appearance. We hypothesize that this difference in microstructure is of importance 
as it might impact other product quality attributes, e.g. reconstitution time due to a different 
wettability. SEM is further considered as a powerful technique to visualize “micro-collapse”, which has 
been named by Milton et al. and refers to small holes which appear in an otherwise intact pore 
structure [33]. However, SEM has significant drawbacks. In general, very small pieces are extracted of 
the lyophilisate’s top and bottom regions by using a spatula. This bears the risk that the native 
structure of the lyophilisate is damaged during sample preparation or due to exposure to atmospheric 
humidity. Furthermore, for very porous lyophilisates fixation of the material on the sample holder was 
found to be challenging, resulting in a sample loss in the microscope or potentially severe damage of 
the instrument. Overall, SEM analysis requires considerable effort and immediate analysis of the 
prepared sample. Most importantly, the sample parts investigated by SEM represent only local pore 
structure which might not be representative for the entire lyophilisate, which can be critical 
particularly for lyophilisates that show strong intra-vial heterogeneity. This bears the risk of misleading 
interpretation of inter-vial heterogeneity and makes reproducible SEM analysis difficult. 
The imaging techniques discussed above allowed for qualitative and in case of 3D laser scanning to 
some part quantitative characterization of lyophilisates of either the external or the internal cake 
structure. A comparative overview of the applicability of the methods is summarized in Table 2. In 
order to obtain a comprehensive understanding of both external cake appearance and internal cake 
structure, three different techniques would be required: Visual inspection or 3D laser scanning for 
evaluation of cake appearance and classification of cosmetic defects, PDMS embedding to visualize 
internal macroscopic cake structure and potential intra-vial heterogeneity, and last but not least SEM 
to obtain relevant microscopic information on pore structure. As both SEM and PDMS embedding 
methods are destructive at least a sample size of three (or four, if including 3D laser scanning) is 
required in order to obtain a sound cake characterization. This number of samples may however not 
be available in early development phases. Moreover, due to the invasiveness, macroscopic and 
microscopic evaluation of cake appearance cannot be performed using the same lyophilisate. 
Furthermore, images obtained by PDMS embedding and SEM represent only structural information of 
selected regions of the lyophilisate. Consequently, this drives the need to look into techniques which 
cover analysis of the global internal cake structure and the external cake appearance within the same 
sample. Ideally, these techniques provide qualitative and quantitative data at the same time and allow 
analysis without destroying the sample. 
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Table 2. Comparison of imaging techniques to characterize cake appearance of freeze-dried formulations. The 
overall effort is indicated as low=minutes, medium=hours, high=days. 
 
µ-CT provides detailed cross-sectional and three-dimensional images allowing for a qualitative 
evaluation of cake structure of the entire lyophilisate at much higher resolution (18 µm) compared to 
the PDMS embedding technique and in addition visualizes regions where collapsed material 
concentrates by a higher contrast. We were able to relatively compare vertical cake homogeneity as 
pixel count per slice. In addition, with cake volume as well as surface to volume ratios, µ-CT provided 
quantitative data on cake structure. It is important to mention, that cake volumes obtained from 3D 
laser scanning and µ-CT differed. In general, volumes for total cake height obtained from µ-CT were 
found to be lower compared to those obtained with 3D laser scanning (see Table 1). This discrepancy 
is based on the way the volumes are calculated. 3D laser scanning provides a mesh of the lyophilisate 
outer surface and only dents, shrinkage and other defects exposed to the surface contribute to a 
reduction of the resulting calculated volume. In contrast, cake volume of µ-CT was calculated according 
to equation (1) in the material and methods section. The calculation was performed based on 3D 
reconstructed µ-CT greyscale images converted into binary images. With the applied threshold, 
internal cake structure attributes such as cracks or voids due to collapsed regions contributed to the 
calculated volume compared to volume obtained by 3D laser scanning using information from external 
cake appearance only. Hence, more detailed information is provided by the cake volume derived from 
µ-CT as it considers not only external visual appearance but also internal cake structure.  
Previous studies from Parker et al. and Izutsu et al. compared SEM images with micro-structural 
attributes obtained by µ-CT measurements of lyophilisates extracted from the glass vial. Izutsu et al. 
used SEM and high-resolution µ-CT (pixel resolution 0.5 – 8 µm) to investigate the effect of post-
freezing treatment and controlled nucleation on lyophilisate morphology [35]. They found both 
techniques to provide comparable information of microstructure suggesting µ-CT as alternative to 
SEM. Parker et al. characterized the effect of shelf temperature during primary drying on 
microstructural attributes using µ-CT (pixel size 4.5 µm). They correlated quantitative attributes like 
the pore size and the fragmentation index, which characterizes the connectivity of the cake matrix, to 
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the microstructure visualized by SEM [20]. The focus of both studies was to investigate microscale 
morphology of lyophilisates, in particular of small sample volumes using formulations of 1 µL and 
1.2 mL, respectively. Therefore scans could be performed at very high resolutions with relatively short 
measurement times (e.g. 20 minutes [35]). 
In contrary, the aim of the present study was to probe the ability of µ-CT to characterize external and 
internal global cake structure of the entire lyophilisate in dimensions of common marketed therapeutic 
antibodies. With typical dosage regimens for antibodies between 2 – 10 mg/kg [36], this means vial 
sizes of 10 – 50 mL for the marketed drug products [37-39]. Therefore, a 20 mL vial with a fill volume 
of 10.6 mL was used within our study. The objective was further to characterize the cake appearance 
and internal structure of the entire lyophilisate of approximately 28 mm diameter with a single and 
thus fast scan. For this purpose, we used a SkyScan 1275 with a 1944x1536 pixel detector, which 
allowed for a maximum resolution of 18 µm including a safety margin of approximately 3 µm to 
compensate for deviations of sample position. A single scan of the entire lyophilisate at 18 µm 
resolution clearly visualizes the differences in internal cake structure of the formulations. In order to 
further evaluate regions of intra-vial inhomogeneity on a microstructural level, high-resolution images 
at 4 µm resolution were obtained of a selected part of the Dex60/Suc40 sample using the SkyScan 1272 
instrument. It needs to be mentioned, that high-resolution measurements are generally very time 
consuming. Hence, we propose to first perform a scan of the entire lyophilisate at lower resolution for 
global characterization of the macroscopic cake structure, optionally followed by a high-resolution 
measurement of smaller cake parts to investigate microstructure for selected regions of interest. A 
major advantage of high-resolution µ-CT compared to SEM is that larger parts of the lyophilisate can 
be evaluated on a microstructural level, thus allowing investigation of the “native” microstructure 
inside the partial cake and locating its position within the entire lyophilisate. Therefore, the use of µ-CT 
has the potential to overcome shortcomings of SEM, like potentially altered microstructure due to 
cutting or exposure of the sample to atmospheric humidity, as well as the low reproducibility. In 
addition, high-resolution µ-CT allows to correlate the pore size calculated from 3D reconstructed 
images to the cake resistance, which is linked to the sublimation rate during the drying step. This was 
recently shown by Pisano et al. exemplified for mannitol formulations [19]. Overall, μ-CT analysis 
requires less effort by the researcher than SEM, despite its long scanning time. The time determining 
factor of μ-CT analysis is the long scanning time, which however does not require any human 
monitoring. 
One aim of the present study was to provide quantitative information on cake appearance and internal 
structure. To perform quantitative analysis, binary images are needed, which requires a consistent 
contrast throughout the 3D reconstructed greyscale µ-CT images. Thus, removal of the freeze-dried 
cake was necessary, in order to prevent artifacts due to the different densities of the glass vial and the 
lyophilized cake. The proposed procedure requires little sample preparation only (transfer of the 
lyophilisate from the glass vial into a plastic cup). In addition, overlay of nitrogen followed by sealing 
of the plastic cups assured cake integrity for several days, making it non-destructive. Hence, this allows 
for using the same lyophilisate after µ-CT for further physico-chemical analysis of other quality 
attributes e.g. SSA. Nevertheless, a completely non-invasive approach to qualitatively evaluate the 
internal cake structure is desirable. A first attempt was proposed by Ullrich et al., who performed µ-CT 
measurements to analyze cracks within the 2R glass vial [21]. However, they opened the vial to insert 
a styrofoam between the cake and the stopper for sample preparation. We aimed for a fully non-
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invasive, non-destructive approach. To this end, we performed additional µ-CT experiments using a 
high-power X-ray tube at higher voltage. Higher voltages are needed in order allow penetration of the 
photons through the glass vial. In return, increased voltages are to the detriment of the contrast 
between the porous cake matrix and air in the greyscale images. The obtained greyscale images 
provided the same level of qualitative information as for measurements that were performed after 
removal of the lyophilisate from the vial. It allowed detecting macroscopic cracks and dents, but also 
fine structural changes like partially collapsed regions and even visualized structures of concentrated 
material. Thus, we demonstrated a completely non-invasive µ-CT application to visualize the inner cake 
structure and detect cake heterogeneities. Non-invasive µ-CT provides a powerful alternative tool to 
PDMS embedding in order to qualitatively evaluate the macroscopic structure on a global level and at 
much higher resolution through the vial. This non-invasive approach, however, may not be used for 
quantitative analysis as the resulting artifacts from the glass vial do not allow for accurate thresholding. 
The primary objective of the present study was to examine the applicability of µ-CT for characterization 
and differentiation between lyophilisates and its potential in comparison to other imaging 
technologies, rather than the ultimate optimization of µ-CT measuring and data processing 
parameters. Yet, in an ongoing study, we have further optimized the X-ray parameters (e.g. voltage) 
and reconstruction settings allowing for non-invasive µ-CT using not only the nanotomOR instrument 
but also the SkyScan instrument. In general, µ-CT instruments have different limitations. With regard 
to the SkyScan instruments used in our study, the two models differ in the physical size of the 
detectors, i.e. the field of view, and the number of pixels, which defines the maximum resolution for a 
sample of a given size. The resolution relates to the accuracy of the quantitative read-out during data 
processing when converting into binary images. Hence, for investigation of fine pore structures and 
quantitative analysis, an instrument model with a high pixel number of the detector would be superior, 
like the SkyScan 1272 in our study (16 Megapixel) compared to the SkyScan 1275 (3 Megapixel). 
However, it needs to be mentioned that high resolution scans can create massive data sets, which 
make data analysis challenging. In contrary, when aiming to identify intra-vial heterogeneities during 
process optimization, an instrument allowing to scan various vials formats with a single scan at 
acceptable resolution and thus considerable shorter measurement time would be preferred. The size 
of the sample that can be measured within in a single scan relates to the field of view, meaning the 
maximal distance between the detector and the X-ray source, as well as the physical dimensions of the 
detector. Hence, for this intention an instrument with a larger field of view like the SkyScan 1275 would 
be preferred. Choosing the adequate instrument model is thus a case by case approach depending on 
the desired application and result. 
In summary, while most studies focus on one parameter of cake appearance only, e.g. either 
cracks [21], microscopic structure [20, 40], or visual appearance [14], our study provided a panel of 
imaging techniques giving complementary information on external cake appearance and internal cake 
structure at different scales. An overview of the results obtained by the different methods is given in 
Table 1 showing consistency between the results of cake appearance for the same level obtained by 
different methods. We compared the methods with regard to their ability to characterize cake 
appearance on different levels and in providing qualitative or quantitative data. Table 2 summarizes 
the applicability of visual inspection, PDMS embedding, SEM, 3D scanning, and µ-CT, highlighting that 
only the last two are able to provide a quantitative measure. We identified challenges associated with 
each method and evaluated the effort for sample preparation and measurement time.  
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CONCLUSION 
Reproducible and homogenous cake appearance of lyophilized product is an important quality 
attribute indicating a stable and robust freeze-drying process. Detailed information on cake 
appearance during process and formulation development is thus essential. The combination of imaging 
techniques investigated in our study allowed a sound evaluation and differentiation of cake 
appearance at macroscopic and microscopic scale evaluated for different formulations to detect levels 
of collapse and cake defects. The techniques investigated provided consistent and complementary 
information being able to provide not only qualitative but also quantitative information allowing 
comparison of visual cake appearance. 
In particular, we found µ-CT as a promising and valuable technique for formulation and process 
development as it allows global characterization of cake structure with one single measurement and 
little sample preparation. With our study, we could demonstrate that µ-CT is able to both qualitatively 
and quantitatively detect between changes in cake structure and to provide characterization on 
different levels. Overall, this technique allows detecting cake defects which may have been missed by 
current state of the art techniques like visual inspection and SEM. Information and data quality 
obtained from a µ-CT measurement will depend on the formulation composition, with higher total 
solid content resulting in higher contrast. In addition, the dimensions of the lyophilisate are important 
as the smaller the cake the higher is the resolution achievable when analyzing the entire lyophilisate. 
Finally, in particular non-invasive µ-CT provides a powerful tool during formulation development and 
especially freeze-drying cycle development, scale-up, and transfer to provide meaningful cake 
characterization throughout the lyophilized product. 
X-ray based imaging technologies such as µ-CT are at present rapidly evolving. Future generations will 
potentially allow for a faster and automated measurement of samples. Such novel technologies could 
be used during the manufacturing process for non-invasive at-line monitoring of freeze-dried drug 
products.  
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SUPPORTING INFORMATION 
Figure S1 shows the procedure of transforming a greyscale image stack into binary images for 
quantitative analysis of µ-CT images. Figure S1 (A) shows a typical histogram calculated for an image 
stack of 600 slices. Thresholding was done performing a multiple gauss fit to the histogram using 
OriginLab as shown in (B). The inlection point of the cumulated fit was chosen as threshold value and 
verified experimentally by comparing a greyscale image with the identic binary one. While other 
studies performed thresholding by empirically only (Parker et al., 2010,J Pharm Sci. 4616-4629), we 
aimed for a mathematic based and repeatable thresholding procedure. The applied thresholding 
procedure was found to be the most suitable and for the images obtained by µ-CT using a SkyScan 
1275.  
 
Figure S1. Schematic graphs for thresholding procedure. A) Histogram calculated for 8-bit image stack of 600 
slices. B) Histogram overlaid with multiple gauss fitted curves (2 peak). Threshold value was chosen as inflection 
point of the cumulated fit curve (- - -). 
 
Figure S2 shows the pore structures for the top layer observed by SEM at 100-fold magnification for 
samples of Dex60/Suc40 lyophilisates from two different vials. While vial 1 showed an intact porous 
pore structure of the top layer, fusion of pores was observed for the top layer of vial 2, indicating 
freeze-drying close to the collapse temperature. This reveals the low reproducibility of SEM. 
 
Figure S2. SEM images of Dex60/Suc40 lyophilisates from top layer at 100-fold magnification.  
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Figure S3 shows level of detail of the applied threshold highlighting that in order to keep a constant 
and reproducible thresholding procedure, fine pore structures have not been considered.  
 
Figure S3. Representative binary images from the middle of the image stack (slice 280). 
 
Figure S4 shows the effect of vial type used for freeze-drying on cake volume accuracy derived from 
3D scanning. The figure shows that for hydrophobic coated vials (TopLyo), better reproducibility (i.e. 
lower standard deviation) and higher accuracy (continuos increase of cake volume with higher dextran 
concentration) were obtained.   
 
Figure S4. Cake volume calculated from meshes obtained by 3D scanning. Freeze-drying was performed in either 
Fiolax vials (hatched bars) or TopLyo vials (grey bars). Cake volume is presented as mean value (n=3) with 
standard deviation. 
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Abstract 
Freeze-drying is commonly used to improve stability of liquid formulations of labile 
biopharmaceuticals. Lyo- and cryoprotectants such as sucrose are traditionally utilized as excipients, 
but have low glass transition (Tg’) and collapse temperatures (Tc). Consequently, these formulations 
require low primary drying temperatures making the lyophilization cycle time-consuming and costly. 
We investigated different dextrans (1, 40, 150, and 500 kDa) and mixtures of dextran with sucrose as 
alternative excipients. The influence of dextran on thermal properties, cake appearance, and other 
quality attributes in the solid state was studied using bovine serum albumin as model protein. 
Especially at higher weight ratios of dextran to sucrose, dextrans of medium to high molecular weight 
(MW) of 40-500 kDa showed up to 20°C higher Tc compared to sucrose, which was reflected in elegant 
lyophilisates. However, this resulted in longer reconstitution times. Addition of dextran led to lower 
residual moisture levels and higher Tg values compared to sucrose. We confirmed the thermal 
properties for two monoclonal antibodies (mAb) at two weight ratios of sucrose and dextran with 
different MW and tested for stability at 40°C for 14 days. While no loss in relative potency of the 
antibodies was observed after storage, size exclusion chromatography and isoelectric focusing 
revealed a strong increase in high molecular weight species (HMWs) and acidic species, which were 
dependent on the MW of the dextrans. With further characterization of selected formulations (dextran 
1 kDa) by boronate affinity chromatography and mass spectrometry analysis, we demonstrated that 
HMWs were a result of glycation by free terminal glucose of the dextran. This chemical modification 
was strongly reduced when adding sucrose, which protects the protein possibly by shielding its surface. 
Our results demonstrate that formulation scientists need to use dextrans as excipients in freeze-dried 
mAb formulations with caution. A binary mixture of sucrose and dextran in adequate ratio however 
might potentially be superior to pure sucrose formulations allowing for faster freeze-drying cycles 
resulting in elegant lyophilisates and good protein stability. 
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INTRODUCTION 
Biopharmaceuticals such as monoclonal antibodies are often lyophilized in a final drug product 
manufacturing step in order to improve their shelf life, if liquid formulations show limited stability. 
Instability of the proteins can occur via physical (e.g. unfolding, aggregation [1]) or chemical (e.g. 
oxidation [2], deamidation [3], condensation reactions [4]) degradation pathways. Freeze-drying 
immobilizes the protein in a dry glassy matrix, which retards degradation mechanisms. During the 
freeze-drying process, the protein needs to be protected against freezing and drying stresses, i.e. at 
the ice-liquid interface due to cryoconcentration and water removal, which can lead to protein 
denaturation or aggregation [5]. The added stabilizers can be differentiated into cryoprotectants, 
which stabilize the protein during freezing and in the frozen state, and lyoprotectants, which are 
responsible for protein stabilization upon water removal and in the dry state. Excipients may provide 
both, cryo- and lyoprotection, like e.g. sucrose and trehalose, which are common excipients in 
biopharmaceutical formulations. In addition, particularly for low concentration protein formulations, 
crystallizing excipients such as sugar alcohols or amino acids can be added to the formulation. The 
addition of mannitol for example improves the macroscopic cake structure and decreases the 
likelihood of cake collapse. However, these compounds serve as bulking agent only, as they are inferior 
to amorphous ones in terms of protein stabilization [6]. 
Different mechanisms of protein stabilization by sugars have been described. During freezing proteins 
are stabilized according to the so called “preferential exclusion” theory [7]. According to the theory, 
sugar molecules are preferentially excluded from the protein surface, which results in a loss in entropy. 
Stabilization in the dried state is mainly ascribed to two phenomena, “water replacement” [8] and 
“vitrification” [9]. Water replacement describes a thermodynamic stabilization suggesting that the 
hydroxyl groups of sugars form hydrogen bonds with the protein as water molecules are removed. 
Vitrification describes the kinetic stabilization by immobilizing the protein in a glassy matrix. More 
recent literature refined the vitrification theory hypothesizing that rather local mobility than global 
mobility of the sugar matrix is important for protein stability [10].  
In particular sucrose was found to be a potent stabilizer and is used in most freeze-dried 
biopharmaceutical formulations approved by the FDA within the last years [11]. However, sucrose has 
constraints due to its low glass transition temperature of the maximally freeze-concentrated solution 
(Tg’) as well as in the dry state (Tg) [12, 13]. 
In order to obtain pharmaceutically elegant lyophilisates, collapse during freeze-drying needs to be 
avoided. Collapse is mostly considered an unacceptable defect and may lead to rejects [14]. Therefore, 
the product temperature (Tp) during primary drying should not exceed the collapse temperature (Tc) 
of the formulation. Tc in turn, is generally 2-3°C above Tg’. Collapse is defined as the loss of pore 
structure induced by a viscous flow of the glassy matrix at temperatures above Tg’/Tc. Collapse does 
not only indicate a freeze-drying cycle not under control, but it may also lead to increased 
reconstitution times and residual moisture in the freeze-dried drug product. Higher residual moisture 
results in a lower Tg [15]. The vitrification theory suggests that in the rubbery state above Tg, 
immobilization and thus sufficient stabilization of the protein can get lost. Grasmeijer et al. showed 
that Tg should be at least 10-20°C above the storage temperature in order to ensure protein 
stability [16]. Presumably for this reason, many approved freeze-dried drug products containing 
sucrose need to be stored at 2-8°C [11]. In addition, formulations containing sucrose require 
conservative, thus time-consuming and costly freeze-drying cycles at low Tp. 
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In the view of these challenges, alternatives to sucrose are needed. Polysaccharides such as inulin [17, 
18], hydroxyethyl starch [19], or dextran [20] exhibit markedly higher Tg’ and Tg than sucrose. Hence, 
they could allow for drying at higher Tp and thus faster freeze-drying without collapse. This would have 
multiple benefits: increased production turnover at lower costs per freeze-drying cycle, less rejects 
during 100% visual inspection, and finally easier and thus faster technical transfer due to increased 
cycle robustness. Furthermore, a higher Tg of the freeze-dried product can potentially allow for storage 
at room temperature. 
Dextran is an interesting polysaccharide to include in the freeze-dried products since dextran 40 kDa 
and 70 kDa are approved for parenteral use as plasma expander. Moreover, dextran 40 kDa has 
already been used as excipient in a marketed freeze-dried antibody-drug conjugate formulation [21]. 
The protein stabilizing effect of dextran has been reported diversely for different molecular weight 
dextrans, different proteins, and formulation compositions. Some literature suggests that dextran may 
not be able to sufficiently stabilize proteins upon freeze-drying and subsequent storage, due to limited 
interaction of the rigid polysaccharide with the protein. More precisely, Tonnis et al. reported that 
rigid dextran provided inferior protein stability (hepatitis B surface antigen, lactate dehydrogenase, 
-galactosidase, insulin) compared to flexible inulin molecules of approximately the same size (6 and 
4 kDa) [17]. Allison et al. demonstrated that in order to achieve good protein stability of actin, a 
globular multifunctional 42 kDa protein, sucrose needed to be added to dextran 200 kDa [22]. In 
contrast, Santana et al. and Larsen et al. found improved stability of rhEGF and LDH lyophilisates using 
dextran 40 kDa compared to sucrose upon storage at 40°C [20, 23]. In another study by Gloger et al., 
low molecular weight dextran of 1 kDa was more effective to stabilize a 57 kDa bispecific protein 
during freeze-drying compared to higher molecular weight dextrans [24]. Overall, to the best of our 
knowledge, no systematic research has been presented studying the impact of different molecular 
weight dextrans on the solid state characteristics of proteinaceous lyophilisates. In addition, the effect 
of dextran on the stability of freeze-dried monoclonal antibodies is unclear. 
The aim of this study was therefore to investigate the application of dextran of different molecular 
weight for freeze-dried monoclonal antibody (mAb) formulations. This would allow for aggressive 
freeze-drying cycles resulting in pharmaceutically elegant lyophilisates, which could be stored at 
elevated temperatures. Dextran 1, 10, 40, 150, and 500 kDa alone and mixtures of these dextrans with 
sucrose were investigated in terms of thermal properties, cake appearance, reconstitution time, 
residual moisture as well as specific surface area using bovine serum albumin as model protein. In a 
second step, two mAb formulations containing either dextran alone or 1:1 mixtures (w/w) of dextran 
and sucrose were characterized including protein stability at elevated storage temperatures. 
MATERIALS AND METHODS 
Manufacturing  
Materials and formulations  
BSA formulations. BSA Fraction V (Roche Diagnostics, Penzberg, Germany) was used as model protein. 
It was formulated at 10 mg/mL in a 20 mM histidine/histidine-HCl buffer (Ajinomoto, Tokyo, Japan) at 
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pH 6.0 containing 0.02% polysorbate 20 (Croda International, Snaith, UK) and 80 mg/mL additional 
excipients. The total excipient content consisted of mixtures of different dextrans (1, 40, 150, and 
500 kDa, Pharmacosmos, Holbaek, Denmark) with sucrose (Ferro Pfanstiehl Company, Mayfield 
Heights, Ohio) as shown in Table 1. The formulations were sterile filtered through a 0.22 µm 
hydrophilic PVDF filter unit (Millipore, Bedford, MA, USA). 20 mL Fiolax vials (Schott, Müllheim, 
Germany) were filled with 10.6 mL and partially stoppered with 20 mm Lyo-stoppers D777-1 (DAIKYO 
Seiko Ltd., Tokyo, Japan) before freeze-drying. 
mAb formulations. Two different proprietary monoclonal antibodies mAb1 (IgG1, pI ~9.4, 148 kDa) and 
mAb2 (IgG1 pI ~8.2, 149 kDa) were prepared in formulations with 10 mg/mL mAb in 20 mM 
histidine/histidine-HCl buffer pH 6.0 containing 0.02% polysorbate 20. mAb1 was formulated with 
either 80 mg/mL sucrose as reference, with dextran of different molecular weight (1, 10, 40, 150, and 
500 kDa), or with 1:1 dextran/sucrose mixtures according to Table 1. 2.7 mL were filled into 6 mL 
Fiolax® vials (Schott) stoppered with 20 mm Lyo-stoppers D777-1 (DAIKYO). Formulations were freeze-
dried and subsequently stored at 40°C/75% relative humidity for 14 days.  
Freeze-drying  
Freeze-drying was performed on a FTS LyoStar II freeze-dryer (FTS Systems Inc, Stone Ridge, NY). To 
reduce edge effects, edge vials were filled with sucrose solution and not further evaluated. The vials 
filled with formulations were randomly distributed over the three shelves. After an equilibration step 
at 5°C for 1 h, the shelves were cooled to -35°C with a shelf cooling rate of 0.3°C/min and equilibrated 
at -35°C for 3 h. Vacuum (133 µbar) was subsequently applied and primary drying was performed at 
+10°C (ramp rate 0.2°C/min). For secondary drying, the shelves were heated to +25°C (ramp rate 
0.2°C/min, 133 µbar) and kept for 8 h. The vials were stoppered under nitrogen at 760 mbar. After 
unloading, the vials were sealed with aluminum crimp-caps. 
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Table 1. Composition of protein formulations. All formulations were prepared in 20 mM His/His-HCl buffer pH 6.0 
containing 0.02% polysorbate 20. Pure sucrose (80 mg/mL, Suc) was used as a reference formulation. 
 
Thermal properties 
Differential scanning calorimetry 
Tg’ and Tg were determined by differential scanning calorimetry (DSC) using a TzeroTM DSC Q2000 (TA 
Instruments Inc., New Castle, Delaware) instrument.  
For determination of Tg’, 20 µL solution were pipetted into a Tzero aluminum pan and hermetically 
sealed. The sample was frozen at 3°C/min to -50°C. After an isothermal equilibration phase of 10 min 
the temperature was increased with 1°C/min to 20°C. Tg’ was reported as midpoint at half height of the 
glass transition step. Measurements were performed in triplicates and Tg’ was reported as mean 
(standard deviation < 0.2).  
For analysis of Tg, 5-10 mg of the lyophilisate were transferred into a Tzero aluminum pan, compacted, 
and hermetically sealed under nitrogen. The sample was equilibrated at -20°C and in a first scan heated 
at 20°C/min to either 100 or 150°C (depending on the formulation). After cooling down to -20°C again, 
a second heating step at the same rate to 150°C or 250°C (depending on the formulation) was 
performed. Tg of the second heating step was reported as midpoint at half height of the glass transition 
step. Each formulation was analyzed in triplicates and was reported as mean with standard deviation.  
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Freeze-drying microscopy 
The temperature of onset of collapse (Tc) of BSA-based formulations was determined by freeze-drying 
microscopy (FDM) using a Linkam FDC196 freeze-drying stage (Linkam Scientific Instruments, Surrey, 
UK) and a Zeiss Axio Imager.A1 microscope (Carl Zeiss MicroImaging, Göttingen, Germany) with a 
20-fold magnification. Pictures were captured in a 5 s interval during the freezing step and a 2 s interval 
during heating, using a digital camera. A sample volume of 2 µL was cooled with 3°C/min until the 
respective formulation was frozen, followed by a fast freezing rate of 5°C/min to -45°C and a 10 min 
isothermal equilibration. Full vacuum was applied after 8 min. The samples were heated under full 
vacuum at 3°C/min to 10°C above the expected Tc and then at 1°C/min until the formulation collapsed. 
Tc was determined in single measurements as onset of collapse, where first gaps were visible.  
Product quality attributes 
Cake appearance 
Cake appearance was evaluated by visual inspection and lyophilisates were classified as either 
pharmaceutical elegant or classified by the extent of defects such as cracks, dents, and collapse. Type 
and extent of defects are reported as percentage of in total 20 vials evaluated per formulation. The 
term ‘defect’ is used throughout the manuscript to indicate deviations from pharmaceutically elegant 
cake appearance in order to compare formulations that were lyophilized with the same freeze-drying 
cycle. Defects were not formally classified into critical or non-critical differentiating, which means into 
cosmetic defects and defects relevant to protein stability, but are discussed with regard to this point. 
Residual moisture 
Residual moisture was determined using a C30 Coulometric Karl Fischer titrator (Mettler Toledo, 
Greifensee, Switzerland). The lyophilized vial was weighed and the sample was reconstituted in dry 
methanol. The vial was vortexed, ultrasonicated, and allowed to dissolve in total 1 h before Karl Fischer 
titration. An aliquot was extracted with a 10 mL BD syringe, transferred into the measuring cell, and 
titrated with standardized KF reagent. The vial was washed with water and ethanol and heat-dried at 
40°C for 10 min in order to determine the weight of the cake by reweighing the empty vial. Karl Fischer 
titration was performed for three vials per formulation and the residual moisture was reported as 
mean value in percent per weight of the total lyophilized cake with standard deviation. 
Specific surface area 
Specific surface area (SSA) was determined according to Brunauer-Emmett-Teller (BET) using the 
Quadrasorb evo surface area and pore size analyzer (Quantachrome, Odelzhausen, Germany) with 
Krypton as adsorbate. At least 300 mg lyophilisate were transferred into a 9 mm bulb sample cell. 
Samples were degassed overnight under vacuum at 40°C followed by nitrogen overlay prior to analysis. 
Krypton adsorption at 77 K was measured for nine measuring points over a pressure range of 
0.05-0.25 mbar. SSA was determined by fitting the data points using the BET equation. Each 
formulation was analyzed in triplicates and SSA was reported as mean with standard deviation.  
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Reconstitution time 
Reconstitution time was determined by a stopwatch and reported in minutes and seconds. 10 mL 
water for injection were injected from a 20 mL BD syringe through the stopper onto the inner glass 
wall of the vial, which was held slightly titled. Timing started when injection was completed. The vial 
was gently shaken manually. Timing was stopped when no solid residues were visible. Reconstitution 
was performed in triplicates and was reported as mean with standard deviation.  
Viscosity 
Dynamic viscosity was determined using a MCR 301 plate and cone rheometer (Anton Paar AG, 
Zofingen, Switzerland) at 20°C. The rheometer was equipped with a 25 mm, 0.5° measuring cone 
(Anton Paar AG). A sample volume of 70 μL was used and the shear rate was increased from 0 to 
1000 s−1 within 2 min. Viscosity was reported as mean of 24 measurement points at a shear rate of 
1000 s−1. 
Protein stability  
Size exclusion high-performance liquid chromatography 
To assess monomer loss and soluble aggregates of the mAb during storage, size exclusion high-
performance liquid chromatography (SE-HPLC) was performed on an Alliance 2695 HPLC instrument 
(Waters Corporation, Milford, MA) equipped with a 2475 fluorescence detector (Waters Corporation). 
The reconstituted samples were diluted to a mAb concentration of 1.0 mg/mL with mobile phase. 5 μL 
of diluted sample were injected into a TSKG3000SWxl, 7.8 × 300 mm column (Tosoh Bioscience, 
Stuttgart, Germany) and eluted with mobile phase containing 0.2 M K2HPO4/KH2PO4 and 0.25 M KCl 
of either pH 7 (mAb1) or pH 6.2 (mAb2) at a flow rate of 0.5 mL/min. The auto sampler was set to 5°C 
and the column temperature was 25°C. Fluorescence was measured at λex278/λem350 nm. High 
molecular weight species (HMWs) were reported as percentage of total peak area using the 
Empower 3 Chromatography Data System software (Waters Corporation).  
Capillary isoelectric focusing 
Charge heterogeneity of mAb1 was studied by imaged capillary isoelectric focusing (cIEF) using an 
iCE280 Analyzer (ProtenSimple, San Jose, CA) with a FC-coated capillary cartridge (ProteinSimple). 
Anode solution was 0.08 M phosphoric acid and cathode solution was 0.1 M NaOH, both with 0.1% 
methylcellulose (MC). mAb1 formulations were diluted with purified water to a concentration of 
2.5 mg/mL. A reagent mix of diluted mAb1 samples with 1% MC, Pharmalyte 8-10.5 (GE Healthcare, 
Chicago, IL), Biolyte 7-9 (BioRad, Cressier, Switzerland), lower (8.18) and upper (9.77) pI marker 
(ProteinSimple), and 8 M urea was prepared. Samples were focused for a time period of 11 min and 
detection was performed at 280 nm. Acidic species were reported as percentage of total peak area.  
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Boronate affinity chromatography  
Separation of glycated and non-glycated mAb1 was performed on a TSKgel Boronate 5PW, 
7.5 cm x 7.5 mm column (Tosoh Bioscience) using the same HPLC system as described above equipped 
with a 2487 UV detector (Waters Corporation). The column was equilibrated at 40°C with mobile 
phase A (100 mM Hepes, 200 mM NaCl, 70 mMTris, pH 8.6) at a flow rate of 1 mL/min and conditions 
were maintained after injection for 10 min. Within 5 min, a linear gradient of mobile phase B (mobile 
phase A + 500 mM sorbitol) from 0 to 100% was applied. Conditions were kept for 3 min followed by 
a change of mobile phase to initial conditions within 1 min. These washing conditions were kept until 
a total runtime of 30 min. Signal was detected at 280 nm and percentage of glycated mAb1 was 
reported as area percent. 
Mass spectrometry 
Native size exclusion chromatography with on-line mass spectrometry (SEC-MS) was performed to 
further characterize the HMWs of mAb1. Sample separation was performed using a Vanquish UHPLC+ 
focused chromatography system (Thermo Scientific). 20 μg mAb1 were injected onto an ACQUITY 
UPLC Protein BEH SEC Column, 200A, 1.7 μm, 4.6mm x 300 mm (Waters Corporation) and eluted with 
100 mM ammonium acetate at a constant flow rate of 0.25 mL/min. A column temperature of 25°C 
was used and the autosampler was set to 4°C. On-line mass spectrometry was performed using an 
Exactive Plus EMR Orbitrap mass spectrometer (Thermo Scientific) with electron-spray ionization 
source. Data analysis was performed manually. 25-fold charged spectra were reported. 
Liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS) was used to confirm 
covalent glycation of mAb1. Prior to analysis, samples were derivatized. Reduction was performed by 
addition of 0.4 M Tris, 8 M guanidine hydrochloride and 650 mM DTT, and incubation for 1 h at 50°C. 
The samples were subsequently diluted with a solution of iodoacetic acid in purified water and 
incubated for 30 min under light protection for decarboxymethylation. Finally, the samples were 
desalted via Protein Desalting Spin Columns (Thermo Scientific).  
Sample separation was performed using a UPLC system (Thermo Scientific) on an ACQUITY UPLC 
Protein BEH300 C4 reversed-phase column, 2.1 x 50 mm, pore size 1.7 µm (Waters Corporation). The 
column temperature was set to 80°C and the column was equilibrated with 80% Eluent A (0.1% formic 
acid in purified water) and 20% Eluent B (0.1% formic acid in acetonitrile). Initial conditions were 
maintained for 4 min after injection, then a gradient was applied, increasing Eluent B to 50% within 
5.6 min and up to 100% within further 1.4 min. Conditions were kept for 2 mins followed by a change 
to initial conditions within 5 min. A constant flowrate of 0.4 mL/min was used throughout the gradient. 
Mass spectrometry was performed on an Impact II Mass Spectrometer (Bruker, Billerica, MA) with 
electrospray ionization source. Data analysis was performed with the DataAnalysis software (Ver. 4.3, 
Bruker). The deconvoluted singly charged spectra were generated by using the MaxEnt V. 3.4.1 
software [25]. 
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RESULTS 
Thermal properties (Tg’ and Tc) 
Characterization of the thermal properties of the liquid formulation (Tg’ and Tc) is essential for the 
design of the primary drying process parameters in freeze-drying. The impact of weight fraction and 
MW of dextran on Tg’ is shown in Table 2. In general, a stepwise increase of Tg’ with higher dextran 
fraction was observed. Addition of 20% dextran increased Tg’ by 0.9 to 1.7°C compared to pure sucrose 
formulation. A remarkable increase in Tg’ by approximately 8°C compared to sucrose was observed 
when a dextran/sucrose ratio of at least 60/40 was used, resulting in Tg’ values of approximately -21°C 
for dextran 40, 150, and 500 kDa. For dextran 1 kDa a smaller impact on Tg’ with a Tg’ of -24°C at a 60/40 
ratio was observed. Complete substitution of sucrose resulted in Tg’ values of approximately -10°C for 
dextran 40, 150, and 500 kDa, which is almost 20°C higher compared to the pure sucrose formulation. 
Identical results were obtained for mAb1 and mAb2 formulated in 100% dextran (s. Table S1 in the 
supporting information) and formulations with 1:1 dextran/sucrose mixtures showed a Tg’ of 
approximately -24°C, which also was in line with the trend observed for BSA formulations. There was 
no considerable difference in Tg’ between dextran 40, 150, and 500 kDa. In contrast, 100% 
dextran 1 kDa showed a lower Tg’ of -20.3°C. Tg’ values for placebo formulations compared to 10 mg/ml 
BSA formulations differed most for sucrose as excipient. The sucrose formulation with BSA showed a 
Tg’ of -28.7°C which is 3°C above the placebo formulation, while no significant difference was observed 
for 100% dextran formulations with or without BSA. Tg’ is indicative for the maximal Tp during primary 
drying in order to avoid collapse of the freeze-dried matrix. In order to determine the actual collapse 
temperature, FDM was performed. The Tc values were in good agreement with the Tg’ results obtained 
by DSC. Onset of collapse was generally observed at temperatures slightly above Tg’, as it is often 
described in literature [26-28]. Tc for dextran 1 kDa formulations was 1°C above Tg’, whereas dextran 
40, 150, and 500 kDa showed higher differences (up to 5°C) between Tg’ and Tc when mixed with 
sucrose, which became lower again for formulations with 100% dextran.  
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Table 2. Thermal properties for BSA formulations. (P) = Tg’ for formulations without protein. (Tg’/Tg: n=3, 
Tc: n=1).  
 
Product quality attributes 
Tg values of the freeze-dried product are an important parameter for the upper limit of storage 
temperatures but are also dependent on residual moisture acting as a plasticizer [29]. Residual 
moisture was highest for the sucrose formulation (2.8% ± 0.7) and residual moisture levels decreased 
with higher dextran content and MW (Figure 1a). In general, when using the same freeze-drying cycle, 
residual moisture levels of dextran 1 kDa formulations were higher (2.2% to 0.8%) compared to 
dextran 40, 150, and 500 kDa formulations. Dextran 500 kDa had a moisture level of 1.8% for 20% 
dextran and 0.7% for 100% dextran. Lower residual moisture levels correlated with higher Tg values 
and increasing SSA at higher dextran/sucrose ratio formulations. Freeze-dried BSA with 80 mg/mL 
sucrose showed the lowest Tg with a temperature of 42°C. For all other formulations, Tg was above 
60°C and even above 190°C for 100% dextran 40, 150, and 500 kDa (Table 2). As observed already for 
Tg’, stepwise addition of dextran resulted in higher Tg values following the Gordon-Taylor equation [30], 
which predicts the  Tg of amorphous mixtures. This was independent on the MW of dextran above 
40 kDa (R2 > 0.997). 
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Figure 1. Quality attributes of BSA formulations in the solid state. (a) Residual moisture and specific surface area 
(n = 3). (b) Reconstitution time (n=3) and viscosity.  
 
Additional important solid state characteristics are cake appearance and reconstitution time. 100% 
visual inspection was performed to evaluate cake appearance. Deviations from elegant cake 
appearance were classified in three categories: collapse, dents, and cracks. It was further 
differentiated between minor/partial and major/total defect as shown in Table 3. Overall, Tg’/Tc were 
reflected in cake appearance. All vials of the sucrose formulation were collapsed as Tp during freeze-
drying was 6°C above the collapse temperature. Collapse was slightly reduced for dextran 1 kDa at 
20/80 or 40/60 ratio, but still partially existing. For 100% dextran 1 kDa, neither collapse nor dents 
were observed. While no collapse was observed for dextrans of higher MW at any ratio independent of 
MW, dents were still present particularly at lower dextran fractions. Interestingly, despite the same Tg’ 
and Tc, dextran 40 and 150 kDa at 20/80 ratio with sucrose showed major dents, while dextran 500 kDa 
containing products were pharmaceutically elegant at any ratio with only minor but consistent dents 
at a dextran/sucrose ratio of 20/80. At dextran/sucrose ratios of 60/40 or higher, practically no dents 
(minor dents in two vials of dextran 150 kDa) were observed for dextran 40, 150, and 500 kDa. In 
general, at high dextran weight fractions, cakes showed a higher degree of cracking which was more 
pronounced with increasing MW of dextran. 
Reconstitution times increased drastically at increasing weight fraction of dextran and with increasing 
MW (Figure 1b). Reconstitution of a formulation with dextran 150 kDa at a dextran/sucrose ratio of 
60/40 took more than 10 min and more than 40 min were necessary for complete re-dissolution of the 
product based on 100% dextran 500 kDa. The long reconstitution times were mostly due to a very 
small solid residue which remained in an otherwise clear solution and dissolved only slowly within the 
solution. Longer reconstitution went along with increasing viscosities for higher dextran/sucrose ratio 
formulations (Figure 1b).  
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Table 3. Categories and evaluation of cake defects with exemplary images. The percentage of 20 inspected vials 
with defects is reported. Defects were classified as t=total, p=partial, m=minor, and M=major. 
Defect category 
Type of 
Dextran 
Dex/Suc 
Ratio 
Percentage and extent of defects 
collapse dents cracks 
Collapse 
1 kDa 
100/0 - - 15% (m) 
 
        
Total 
 
 
Partial 
80/20 - 100% (m) - 
60/40 - 100% (m) - 
40/60 30% (p) - - 
20/80 100% (p) - - 
40 kDa 
100/0 - - - 
80/20 - - 40% (m) 
Dents 60/40 - - - 
 
 
Major 
 
 
Minor 
40/60 - 100% (m) - 
20/80 - 100% (M) - 
150 kDa 
100/0 - - - 
80/20 - - 70% (M) 
60/40 - 10% (m) - 
40/60 - 75% (m) - 
Cracks 20/80 - 100% (M) - 
 
 
Major 
 
 
Minor 
500 kDa 
100/0 - - 65% (M) 
80/20 - - 85% (M) 
60/40 - - - 
40/60 - - - 
20/80 - 85% (m) - 
none 0/100 100% (t) - - 
Protein stability 
Protein stability of two different mAbs was investigated after freeze-drying and after storage at 40°C 
for 14 days for formulations in either pure dextran 1, 10, 40, 150 or 500 kDa or 1:1 mixtures of dextran 
with sucrose. A formulation with 80 mg/mL sucrose was used as reference. Protein stability was 
analyzed with respect to soluble aggregate formation by SE-HPLC and changes in the distribution of 
charge variants by cIEF. The reference formulation with sucrose did not change in HMWs level after 
freeze-drying or storage (shown for mAb1 in Figure 2a). In contrast, formulations with 100% dextran 
40, 150, and 500 kDa showed slightly higher HMWs (∼1-3%) directly after freeze-drying. After storage 
at 40°C, the amount of HMWs strongly increased for all formulations. Dextran 500 kDa showed 12.4% 
HMWs which became even higher for lower MW dextrans with up to 60.7% HMWs (dextran 10 kDa). 
While the HMW peak of dextran 1 kDa increased only marginally by 0.35%, the monomer peak in the 
chromatogram was shifted to a higher MW (Figure 4a). Hence, less HMWs were formed in higher MW 
dextrans formulations during storage at elevated temperatures. Furthermore, the HMWs formed in 
formulations of higher dextran MW eluted earlier, i.e. were larger compared to the HMWs formed in 
formulations with lower MW dextrans. The same HMWs pattern was obtained for a second mAb 
(mAb2) in the same dextran formulations with increasing MW (s. Figure S1a in the supporting 
information). 
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Figure 2. Amount of HMWs by SE-HPLC. 10 mg/mL mAb1 formulated with 80 mg/mL of either (a) pure dextran 
or sucrose or (b) 1:1 dextran/sucrose mixtures. 
 
mAb1 formulated in equal mixtures of dextran and sucrose led to overall less HMWs (Figure 2b) 
compared to pure dextran formulations. No change in HMWs was observed directly after freeze-drying 
for any dextran/sucrose formulation. Upon storage at 40°C, the monomer peak of mAb1 in dextran 
1 kDa/sucrose showed a slight shift to a higher MW similar to the pure dextran 1 kDa formulation. All 
other mixtures of sucrose and dextran (10-500 kDa) showed approximately 5 times less HMWs 
compared to pure dextran formulations. mAb1 formulated with 1:1 dextran 10 kDa/sucrose mixtures 
showed the highest HMWs amount (13.8%), and HMWs of dextran 150 kDa/sucrose and dextran 
500 kDa/sucrose increased by only 1.1% and 0.8%, respectively. Similar results were observed for 
mAb2 (s. Figure S1b in the supporting information).  
Charge variants were characterized by cIEF. mAb1 formulation with pure dextran 1 kDa revealed an 
increase in acidic species of 13% directly after freeze-drying (Figure 3a) and a pronounced acidic shift 
was observed after storage at 40°C (Figure 4b). For mAb1 formulated with dextran 10 kDa or higher, 
no change in charge variants was observed upon freeze-drying (Figure 3a), but acidic peaks were higher 
after storage at 40°C. Similar to the change seen in SE-HPLC, acidic species decreased with increasing 
MW of the dextrans: whereas acidic species for mAb1 formulated with dextran 10 kDa increased by 
29.3% after storage, only 4-5% acidic species were formed for formulations with dextrans of higher 
MW. No change in acidic species was observed for mAb1 formulated in pure sucrose as well as in 1:1 
mixtures of dextran ( 40 kDa) and sucrose upon both freeze-drying and storage. Only mAb1 
formulated in 1:1 dextran/sucrose mixtures with dextran 1 and 10 kDa revealed increased acidic 
species during storage (Figure 3b). The instability of both formulations was less pronounced than for 
pure dextran formulations. 
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Figure 3. Amount of acidic species by cIEF. 10 mg/mL mAb1 formulated with 80 mg/mL of either (a) pure dextran 
or sucrose or (b) 1:1 dextran/sucrose mixtures. 
 
 
Figure 4. (a) Representative SE-HPLC chromatogram and (b) cIEF electropherogram. 10mg/mL mAb1 formulated 
with 80 mg/mL dextran or sucrose after storage at 40°C for 14 days. 
 
To elucidate the root cause of HMWs formation upon storage and the drastic changes seen in cIEF, 
HMWs were further characterized for mAb1. We hypothesized that the increase in HMW species might 
be a result of glycation due to covalent binding of dextran to the mAb. Emphasis was therefore placed 
on boronate affinity chromatography. This analysis was accompanied by SEC-MS and LC-ESI-MS to 
investigate modifications of mAb1. Storage of mAb1 formulated with dextran 1 kDa at different 
temperatures (5, 25, and 40°C) for 14 days resulted in an increase of the retained fraction in boronate 
affinity chromatography. The retained fraction increased from 6.3% initially after freeze-drying to 7.4% 
after 14 days at 5°C and up to 80.7% after 14 days at 40°C being indicative for glycated species (Table 4). 
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The reference formulation (sucrose) showed a retained fraction of 3.9% only, both after freeze-drying 
and after storage at 40°C.  
Table 4. Amount of glycated mAb by boronate affinity chromatography. 10mg/mL mAb1 formulated with 
80 mg/mL of dextran or sucrose or 1:1 dextran/sucrose mixtures.  
 
 
Native SEC-MS was performed in order to analyze the mass of the shifted monomer peak for the 
dextran 1 kDa formulation. Figure 5a shows no change in mass during storage at 40°C for mAb1 
formulated in sucrose. Figure 5b shows successive addition of multiple 162 Da units upon storage of 
mAb1 lyophilisates formulated with dextran 1 kDa. The MW increase was negligible directly after 
freeze-drying, but became more pronounced upon storage at 25 and 40°C. After storage at 40°C for 14 
days, mAb1 was fully converted to adducts. Maximal intensity was obtained at m/z of 6010-6040, 
which corresponds to an increase in MW of approximately 2.25-3 kDa as compared to the 148 kDa of 
the pure mAb. This suggests that most mAb1 molecules were conjugated with approximately 2-3 
dextran 1 kDa molecules. It is important to note that the MW of 1 kDa is a normative value. Given the 
polydispersity of the dextran MW, an absolute number of conjugated dextran molecules cannot be 
given. Finally, LC-ESI-MS, with prior reduction and alkylation of cysteines in order to break disulfide 
bonds, was utilized to confirm covalent conjugation of dextran 1 kDa to the mAb. Figure 6 shows mAb1 
glycation in both light (Figure 6a) and heavy (Figure 6b) chain by dextran 1 kDa by several mass changes 
of +162 Da. This is in contrast to mAb1 formulations with sucrose, where no mass changes were 
observed. 
For higher MW dextrans, distinct resolution of glycated species was not possible as shown exemplary 
in Figure S2 in the supporting information by SEC-MS for the dextran 40 kDa formulation. The weight 
distribution of HMWs of mAb1 were overlaid by a broad distribution of multiple charge states, which 
did not allow for precise assignment of charge states and thus calculation of protein mass. 
Nevertheless, the obtained spectrum markedly differed from a typical native MS spectrum of pure 
protein aggregates (i.e. dimers, tetramers) [31], suggesting that also the HMWs of higher MW dextran 
formulations are adducts between antibody and dextran. 
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Figure 5. Native SEC-MS spectra. mAb1 formulated with (a) 80 mg/mL sucrose or (b) 80 mg/mL dextran 1 kDa 
initially after freeze-drying or after storage for 14 days at different temperatures. Mass changes by glycation 
(+162 Da) are highlighted in dark grey. z = 25.  
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Figure 6. LC-ESI-MS spectra. (a) Light and (b) heavy chain of mAb1 formulated with 80 mg/mL sucrose or dextran 
1 kDa after storage at 40°C for 14 days.  
DISCUSSION 
Major constraints in freeze-drying of parenteral drug products are costs and duration of the 
lyophilization process. The formulations often contain sucrose (Tg’: -30°C) as protein stabilizer or 
bulking agent, requiring low primary drying temperatures for formulations without additional 
crystalizing bulking agent in order to avoid collapse. This results in low sublimation rates and time-
consuming freeze-drying cycles. Within this study, we investigated dextrans of different MW as 
potential excipients in freeze-dried formulations of mAbs, which would allow for more aggressive 
freeze-drying at higher Tp.  
Initially, Tg’ and Tc of the formulations were analyzed. Both BSA and mAb1/2 formulations with pure 
dextran 40, 150, and 500 kDa showed similarly high Tg’ values of approximately -11°C, leading to the 
assumption that all of them allow for similar primary drying conditions (Tp < -11°C). This finding for 
protein formulations containing only dextran as stabilizer was in good agreement with a previous study 
by Larsen et al., who characterized the Tg’ of 5% (w/V) solutions in water for 10 different dextrans 
between 1-500 kDa and also observed a plateau in Tg’ beginning at a MW of 40 kDa [20]. Dextran 1 kDa, 
in contrast, would require a more gentle freeze-drying cycle at Tp < -19°C, which is still approximately 
9°C higher than for pure sucrose formulations. In dextran/sucrose mixtures with dextrans of higher 
MW, this increase was already achieved by adding 60% of dextran 40, 150 and 500 kDa. Furthermore, 
we observed an increasing difference between Tg’ and Tc with increasing MW. A Tc significantly above 
Tg’, as frequently seen at higher protein concentrations, may be caused by higher viscosity of the 
solutions and their freeze concentrates [27, 32, 33]. This is supported by the increasing viscosity of the 
dextran formulations with higher MW. 
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Consequently, the impact of dextran on drug product quality attributes like cake appearance, residual 
moisture, and reconstitution time as well as mAb stability at elevated temperatures was investigated. 
BSA and mAb1/2 formulations with different dextran/sucrose ratios were freeze-dried using a single 
freeze-drying cycle with an aggressive shelf temperature of +10°C during primary drying challenging 
cake appearance. Process optimization to maximize efficiency was beyond the scope of the study. The 
resulting Tp in the steady state of sublimation was approximately -24°C and consequently the sucrose 
formulation collapsed. The dextran containing formulations resulted in elegant cakes, sometimes with 
cracks or dents. Cracks have been described previously to be a result of relieved stress when unfrozen 
water is removed during drying [34]. Patel et al. suggested in a commentary on acceptable cake 
appearance that cracks should not be considered as critical defects being only a result of the 
mechanical properties of a freeze-dried formulation and in most cases without impact on protein 
stability [14]. While shrinkage or dents may be caused by similar physical principles as cracks, dents at 
the bottom of the vial can also be attributed to early onset of collapse without necessarily being 
detrimental to protein stability. In the present study, the occurrence of dents correlated with lower 
Tc/ Tg’ of the formulation, i.e. indicated a Tp during primary drying close to the formulation’s Tc. 
Interestingly, the dextran/sucrose ratio required to reduce dents increased in the order of dextran 
40 < 150 < 500 kDa, although Tg’ and Tc for identical ratios were similar. This indicates that Tc may not 
be the only relevant factor impacting local mobility during drying. Colandene et al. reported 
comparable observations for highly concentrated protein formulations which showed no collapse 
when freeze-dried above Tg’ and even above the onset temperature for collapse, but below the 
temperature of full collapse. They hypothesized that higher viscosity may prevent macroscopic 
collapse due to limited freedom of movement [27]. The viscosity of our formulations increased for 
formulations with increasing MW as well as content of dextran. The same trend was observed for 
reconstitution times, with up to 15 min (100% dextran 150 kDa) and even up to more than 40 min 
(100% dextran 500 kDa). Long reconstitution times have been described in previous publications on 
highly concentrated protein formulations [35-37]. Viscosity levels of such highly concentrated protein 
formulations are e.g. ~16 mPa s for a 151 mg/mL antibody solution [33]. This corresponds to the 
viscosity of our 10 mg/mL BSA formulation with 100% dextran 500 kDa. Thus, we hypothesize that both 
improved cake appearance and longer reconstitution times can be attributed to the increased viscosity 
for formulations with dextrans of high MW. However, in regard to reconstitution time, viscosity is also 
not the only responsible factor. Wettability [38], cake density, and liquid penetration into the interior 
of the cake [36] are important, which are related to the pore structure of the cake. It is of general 
assumption that higher SSA leads to faster reconstitution times. However, it is important to consider 
that it is the combination of SSA and porosity that influences reconstitution time. For instance, recent 
literature reported shorter reconstitution times for lyophilisates with lower SSA, but large spherical 
pores [38, 39]. More precisely, Beech et al. and Shire et al. found longer reconstitution times for 
lyophilisates that showed dense, lamellar pores by SEM, although SSA for these samples was high [39, 
40]. In a previous study related to this work, we characterized cake structure of dextran/sucrose 
formulations and found that dextran used in lyophilized formulations resulted in cake structures with 
dense lamellar pores compared to sponge like spherical pores formed in sucrose formulations [41]. 
Correspondingly, our formulations showed both increased SSA and slow reconstitution with higher 
fraction and MW of dextran. Although, there are FDA approved products on the market that have 
reconstitution times up to 40 min [42-44], faster reconstitution is desirable, due to a higher patient’s 
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convenience and a reduced risk that patients may not receive the desired dose in case of incomplete 
reconstitution.  
Improved cake appearance and increased SSA for higher dextran proportion and MW correlated with 
lower residual moisture levels, which were below 1% for pharmaceutically elegant cakes. In particular, 
the higher SSA and thus smaller pores allow for enhanced desorption during secondary drying. For 
lower residual moisture levels, molecular mobility of proteins is reduced and stability increases when 
the freeze-dried product is stored in the glassy state below Tg. For our dextran formulations, Tg is a 
function of the molecular weight fraction of the dextran but also influenced by residual moisture. Tg 
decreases with higher residual moisture levels [45]. For formulations with sucrose, which generally 
have a lower Tg, this can be detrimental for protein stability if the lyophilisates are stored at elevated 
temperatures. Therefore, it is generally desired to have freeze-drying processes that result in low 
residual moisture (~1%) [46]. However, Breen et al. found that intermediate residual moisture levels 
of 2-3% provided optimal physical stability, while lower residual moisture was beneficial in terms of 
chemical stability [47]. Schersch et al. reported less soluble aggregates if a monoclonal antibody was 
stored with residual moisture higher than 1% and good stability for a 70 kDa enzyme even at more 
than 4% residual moisture [13]. Thus, whether the low residual moisture levels obtained by addition 
of dextran are advantageous requires further investigation. Previous studies have reported that 
storage temperature should be 10-20°C below Tg to ensure complete vitrification [16]. All types of 
dextran investigated, already at low fractions, rendered lyophilisates with a Tg higher than 60°C up to 
200°C which is far beyond intended storage temperatures. It is generally believed that there is a 
correlation between high Tg and improved storage stability of proteins at elevated temperature [16, 
48].Thus, the significantly higher Tg compared to sucrose based formulations might potentially allow 
for increasing storage temperature, which is currently under investigation. Considering both, the 
thermal properties as well as the solid state properties of the drug product, our findings suggest that 
high concentrations of >80% dextran 1 kDa may be used as Tg’ modifier to markedly increase Tg’, to 
accelerate primary drying at higher shelf temperature and provide elegant cakes. For dextran 40, 150, 
and 500 kDa ideal dextran/sucrose ratios might be between 40/60 and 80/20, as higher dextran 
fractions increased reconstitution times drastically up to more than 10 min. 
Dextran has been studied as excipient in lyophilisates for different types of molecules as described in 
the introduction section. However, its stabilizing properties have been discussed controversially [20, 
22, 24]. Within these studies protein stability was investigated only in terms of protein activity or 
change in secondary structure. However, further characterization is necessary to understand protein 
stability in detail. Within our study, we assessed antibody stability in terms of relative potency by ELISA. 
Furthermore, protein purity was analyzed as loss of monomer and formation of soluble aggregates as 
well as charge heterogeneity. Finally, we performed a detailed characterization of protein 
modifications by boronate affinity chromatography, native SEC-MS and LC-ESI-MS. 
No change in relative potency was found for mAb1 for dextran 1 kDa formulations after storage at 
elevated temperatures (see Table S2 in the supporting information). Similar findings were reported by 
Larsen et al. demonstrating improved retained activity of LDH in dextran 1 kDa formulations compared 
to sucrose, which was further increased for higher MW of dextran [20]. However, SE-HPLC results 
revealed slightly higher levels of HMWs already after freeze-drying for formulations with higher MW of 
dextran. A strong increase in HMW levels (or shift in monomer peak for formulations with dextran 
1 kDa) was obtained after storage at elevated temperatures, which correlated with the MW of dextrans. 
Typically, HMWs that are related to formation of protein aggregates result in increased levels of the 
Impact of dextran on thermal properties, product quality attributes, and monoclonal antibody stability 
in freeze-dried formulations 
 
 
58 
respective HMWs rather than in a change of the HMWs pattern or elution time. Thus, our observations 
rather suggest a chemical interaction between mAb1 and dextran than protein aggregation. As no 
monomer degradation was observed upon freeze/thaw with pure dextran formulations (data not 
shown), we hypothesize that the increase after freeze-drying could be attributed to protein aggregates 
as a result of insufficient protein stabilization by the large and rigid polysaccharide molecules. 
However, the increase in HMWs after storage in contrast, might be attributed to a chemical interaction 
between protein and dextrans. In addition, the fact that mAb1 revealed no change in acidic species 
directly after freeze-drying but after storage further supports this hypothesis. 
A shift in acidic species during storage was observed by cIEF, which again was more pronounced for 
dextrans of lower MW. An acidic shift in cIEF has been reported previously in a study by Quan et al. 
characterizing glycated forms of a rhumAb derived from cell culture [49]. This acidic shift was 
attributed to the formation of a Schiff base, which is the first reaction product of multiple steps of a 
Maillard reaction. Thus, we hypothesized that the terminal glucose units of dextran potentially led to 
glycation of mAb1 during storage at elevated temperatures, and manifests in the SE-HPLC 
chromatogram. This hypothesis was previously raised by Kanojia et al., who also reported diffuse 
HMWs in freeze-dried TNF formulations with dextran [50]. However, no further characterization to 
confirm this hypothesis was done. Dextran is a polysaccharide consisting of multiple α-1,6-linked 
glucose units with 1,3-branching. Glucose itself is well-known to have reducing properties, which can 
cause glycation by the reducing carbonyl group of the sugar and amino groups of the protein (e.g. 
lysine residues) [51]. In order to confirm this hypothesis, HMWs formed during storage were further 
characterized by a panel of analytics including boronate affinity chromatography, native SEC-MS, and 
LC-ESI-MS. This was performed exemplarily for mAb1/dextran 1 kDa formulations, which showed a 
shift of the monomer to a higher MW in SE-HPLC after storage. Boronate affinity chromatography is 
typically used to quantify the amount of sugar-bound (e.g. glycosylated [52] or glycated protein [51]) 
and unbound protein by interaction of the cis-diol groups of the sugar with the column. Indeed, 
boronate affinity chromatography demonstrated an increase of the retained (i.e. glycated) fraction 
with increasing storage temperature for dextran 1 kDa formulations. Eventually, covalent modification 
as a result of glycation was confirmed by LC-ESI-MS, which revealed mass changes by addition of 
multiple +162 Da units for both light and heavy chain of mAb1. Mass changes of +162 Da, as also 
suggested by SEC-MS, correspond to hexose units of the polydisperse dextran molecule. Thus, the 
monomer shift observed during storage was caused by glycation with oligo-glucose units, i.e. dextran 
molecules. The dependency of glycation on storage temperature is in line with previously published 
research investigating the time course of temperature dependent IgG glycation [53]. The observed 
trend of decreasing levels of HMWs formed in SE-HPLC, i.e. decreased glycation with increasing dextran 
MW, can be explained by the lower abundance of reactive terminal groups of dextran. This lower 
glycation level combined with the polydispersity and the high molecular weight of dextrans made proof 
of glycation by MS for the dextran with a MW of 40 kDa and above challenging: The SEC-MS spectrum 
of mAb1/dextran 1 kDa after storage at 40°C nicely revealed the polydispersity of the dextran. This 
became even more prominent with dextran 40 kDa and no spectral assignments and mass calculations 
could be performed (s. Figure S2 in the supporting information). Another analytical limitation for high 
MW dextrans was that boronate affinity chromatography could not be applied, as the number of 
available cis-diols groups, which could interact with the column, is limited for large 
polysaccharides [54].  
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Although, mAb potency did not change upon storage of the dextran 1 kDa formulations, HMW species 
and chemical modification are generally of concern in terms of immunogenicity [55-57]. Therefore, in 
order to use dextran in freeze-dried mAb formulations mitigation strategies to reduce glycation are 
needed. By mixing dextran with sucrose in a 1:1 ratio no increase in HMWs was observed for higher 
MW of dextrans directly after freeze-drying indicating enhanced lyoprotection by sucrose. This is in line 
with Allison et al., who reported prevention of protein unfolding during freeze-drying for combinations 
of sucrose and high MW dextran [22]. Furthermore, we could strongly reduce glycation for all dextrans 
as revealed by low HMW levels. For mAb1, glycation was for example reduced from 80.7% after storage 
at 40°C for 14 days in pure dextran 1 kDa formulations to 26.8% glycated fraction in formulations with 
1:1 dextran 1 kDa/sucrose mixtures. We hypothesize that the improved protein stability by addition of 
sucrose might potentially be due to “shielding” the protein and thereby protecting its surface from 
glycation by dextran.  
Finally, we postulate that the combination of dextran with disaccharides presents one possible 
mechanism to reduce glycation and thus such excipient combinations may potentially be of advantage 
in freeze-dried mAb formulations. Long-term stability studies of such formulations are currently 
ongoing. 
CONCLUSION 
The stepwise addition of dextran 1, 40, 150, and 500 kDa to sucrose as excipient in freeze-dried 
formulations of proteins increased the Tg’/Tc of protein formulations. A remarkable increase by 8°C 
was already achieved by 60% dextran fractions of dextran 40 kDa and was increased by even 18°C at 
100% dextran as demonstrated for BSA and two mAb formulations. This would allow for more 
aggressive freeze-drying cycles at higher Tp during primary drying resulting in shorter cycles and thus 
lower costs. The cake appearance was markedly improved, which facilitates visual inspection and leads 
to overall less rejects. Care should be taken for formulations with dextran 150 and 500 kDa as fractions 
of more than 60% lead to unacceptable long reconstitution times. Moreover, formulations with pure 
dextrans showed insufficient lyoprotection of the antibody upon freeze-drying. Furthermore, the study 
demonstrated antibody glycation in pure dextran formulations stored at elevated temperatures. In 1:1 
dextran/sucrose mixtures however, sucrose ensured protein stability upon freeze-drying and glycation 
during storage was strongly reduced.  
Formulations scientists should use dextrans in freeze-dried mAb formulations with caution especially 
when used as single stabilizer and bulking agent. A mixture of medium MW dextran with sucrose at an 
ideal sucrose to dextran ratio might provide the best compromise at all levels. Such excipient 
combinations might be used as alternative excipients for freeze-dried mAb formulations being superior 
compared to conventional formulations. They potentially allow for more aggressive freeze-drying 
cycles that result in elegant lyophilisates with good protein stability. Long-term stability studies of such 
formulations at room temperature and above are currently ongoing. During stability studies, it is 
recommended to use adequate analytical methods to detect possible glycation reactions. 
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SUPPORTING INFORMATION 
Table S1 shows the glass transition temperatures (Tg’) of the maximally freeze-concentrated antibody 
formulations. For the different dextrans, similar Tg’ values were observed independent of the type of 
protein (mAb1, mAb2, BSA). Tg’ values for BSA are presented in Table 2 in the main manuscript. 
Table S1. Tg’ of mAb formulations. 10 mg/mL mAb formulated in 80 mg/mL of either pure dextran or sucrose or 
1:1 dextran/sucrose mixtures. Tg’ is based on single measurements. 
Dextran Type 
Tg’ (°C) of mAb in pure dextran Tg’ (°C) mAb in 1:1 dextran/sucrose 
mAb1 mAb2 mAb1 mAb2 
None -28.5 -28.9 - - 
Dextran 1 kDa -20.5 -20.9 -25.6 -25.8 
Dextran 10 kDa -12.1 -12.1 -23.9 -23.6 
Dextran 40 kDa -10.6 -10.9 -24.2 -24.1 
Dextran 150 kDa -10.8 -10.7 -23.9 -23.9 
Dextran 500 kDa -10.5 -10.8 -23.5 -24.4 
 
 
Figure S1 shows HMWs for mAb2 formed upon freeze-drying and storage. The increase in HMWs 
revealed the same pattern as shown for mAb1 in Figure 2 in the main manuscript, thus highlighting 
that protein stability effects were not specific for only one antibody. 
       
Figure S1. Amount of HMWs of mAb2 by SE-HPLC. 10 mg/mL mAb2 formulated with 80 mg/mL of either (a) 
pure dextran or sucrose or (b) 1:1 dextran/sucrose mixtures. 
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Table S2 shows results of relative potency of mAb1 determined by ELISA. Despite that glycation of the 
antibody was observed, CDR binding was not impaired. 
Table S2. Potency by ELISA. Relative potency is given as mean % with standard deviation for mAb1 formulated 
in either 80 mg/mL sucrose or dextran 1 kDa. ELISA was performed in triplicates. 
Formulation Storage conditions Relative potency (%) 
mAb1/Suc Initial 111 ± 3 
mAb1/Dex1 kDa 
2 weeks at 5°C 110 ± 5 
2 weeks at 25°C 111 ± 4 
2 weeks at 40°C 109 ± 2 
 
 
Figure S2 shows a representative SEC-MS spectrum for mAb1 formulated in high MW dextran (40 kDa). 
HMWs were not attributed to protein aggregates, but revealed a diffuse mass spectrum due to 
multiple charge ions. The diffuse pattern originates from the glycated mAb due to polydispersity of 
dextran. 
 
Figure S2. Exemplary SEC-MS data of mAb1 formulated with dextran 40 kDa. (a) Total ion count chromatogram. 
(b) Diffuse mass spectrum of two selected regions of the HMW fraction.  
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Abstract 
Sucrose is a common cyro- and lyoprotectant to stabilize labile biopharmaceuticals during freeze-
drying and storage. Sucrose based formulations require low primary drying temperatures to avoid 
collapse and monoclonal antibody (mAb) containing products need to be stored refrigerated. The 
objective of this study was to investigate different excipients enabling storage at room temperature 
and aggressive, shorter lyophilization cycles. We studied combinations of 2-hydroxypropyl-beta-
cyclodextrin (CD), recombinant human albumin, polyvinylpyrroldione (PVP), dextran 40 kDa (Dex), and 
sucrose (Suc) using two mAbs. Samples were characterized for collapse temperature (Tc), glass 
transition temperature of the liquid (Tg’) and freeze-dried formulation (Tg), cake appearance, residual 
moisture, and reconstitution time. Freeze-dried formulations were stored at 5°C, 25°C, and 40°C for 
up to nine months and mAb stability was analyzed for color, turbidity, visible and sub-visible particles, 
and monomer content. Formulations with CD/Suc or CD/PVP/Suc were superior to pure Suc 
formulations for long-term storage at 40°C. When using aggressive freeze-drying cycles, these 
formulations were characterized by pharmaceutically elegant cakes, short reconstitution times, higher 
Tg’, Tc, and Tg. We conclude that the addition of CD allows for shorter freeze-drying cycles with 
improved cake appearance and enables storage at room temperature, which might reduce costs of 
goods substantially.  
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INTRODUCTION 
Formulation development of monoclonal antibodies (mAbs) aims to identify excipients that maintain 
the protein in its intact native state. This means that the protein is stabilized throughout the drug 
product manufacturing process, shipment, storage, and administration to the patient. If stability 
cannot be assured in the liquid state, freeze-dried formulations are pursued. The absence of water in 
lyophilized preparations limits the molecular mobility and hereby retards degradation mechanisms, 
which ultimately improves storage stability. Although freeze-drying is a gentle drying method, the mAb 
is exposed to additional stress including cryoconcentration during the freezing step, exposure to the 
ice-liquid interface as well as the removal of hydrogen bonds with water molecules. Excipients are 
needed since they protect the mAbs during freezing (cryoprotection), drying (lyoprotection), as well as 
throughout storage in the dried state. To date, the majority of freeze-dried biopharmaceuticals on the 
market contain trehalose and more commonly sucrose as excipient, which are well known to be potent 
stabilizers, providing both lyo- and cryoprotection [1]. The excellent protein stabilization by sucrose is 
attributed to its ability i) to form hydrogen bonds with protein molecules, which is described by the 
water replacement theory [2] and ii) to form a glassy matrix in the dried state in which protein 
molecules are immobilized as described by the vitrification theory [3].  
Recent literature demonstrates that stabilization via vitrification holds true as long as the storage 
temperature is at least 10 to 20°C below the glass transition temperature (Tg) of the freeze-dried 
product [4]. Dry sucrose itself has a Tg of ~60-70°C [5]. The Tg substantially decreases with increasing 
residual moisture of the lyophilisate [6]. For instance, a Tg of only ~42°C has been reported for a 
sucrose-based mAb lyophilisate with a residual moisture of ~2.5% [7]. Thus, marketed sucrose-based 
freeze-dried mAbs require refrigerated storage conditions at 2-8°C [8]. An exception is Mepolizumab 
(Nucala®) that can be stored at temperatures up to 25°C [9]. Overall, the need for refrigerated storage 
conditions is therefore not only related to the instability of the mAb, but is also attributed to the 
excipient sucrose. Being able to store freeze-dried biopharmaceuticals at room temperature would 
provide a considerable benefit by making cold chains redundant. Consequently, there is the strong 
need to look into novel excipients and excipient combinations, which combine water replacement with 
a high Tg enabling storage at room temperature. A higher Tg typically also comes along with a higher 
glass transition temperature of the maximally freeze-concentrated solution (Tg’). An increased Tg’ 
would allow for a more aggressive lyophilization at higher product temperature (Tp) during primary 
drying, shortening the freeze-drying cycle. Thus, formulations with a higher Tg’ and Tg will result in a 
strong reduction of the costs of goods of freeze-dried biopharmaceuticals by i) a shorter, more efficient 
manufacturing process and ii) avoiding cold chains throughout the supply chain of the drug product. 
Traditionally, mannitol is often added to low concentration protein formulations as a bulking agent to 
improve cake appearance and to enable primary drying temperatures above the Tg’ of sucrose. 
However, mannitol does not contribute to proteins stability due to its crystalline nature requiring a 
certain amount of amorphous stabilizer. On the other hand, a relatively high amount of mannitol, e.g. 
a 4:1 ratio of mannitol to sucrose, is needed to ensure complete crystallization of mannitol increasing 
the total excipient content [10, 11]. Incomplete crystallization of mannitol during freeze-drying can 
induce protein instability over storage. Moreover, mannitol can crystallize in different polymorphs 
depending on the freezing protocol and an annealing step is often used to improve crystallization and 
reduce primary and secondary drying times [12, 13]. Depending on the polymorph formed, protein 
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stability might be impaired. In the light of these challenges of mannitol containing formulations, 
amorphous excipients which increase the formulations Tg’ and contribute to protein stability would be 
beneficial as substitute or additives to sucrose.  
Regarding potential alternative amorphous excipients, high potential can be ascribed to 2-
hydroxypropyl-beta-cyclodextrin (CD). CD is a cyclic oligosaccharide, consisting of seven glucopyranose 
units, and is one of the few cyclodextrins approved for parenteral use. CD remains fully amorphous 
after freeze-drying and can interact with the protein through its multiple hydroxyl groups [14]. It is a 
non-reducing sugar, which is of utmost importance to avoid glycation and covalent aggregation during 
storage at elevated temperatures [7, 15]. A mAb lyophilisate based on CD at high concentrations 
showed similar stability at accelerated conditions as a trehalose based formulation [16]. Branchu et al. 
and Iwai et al. investigated the amphiphilic, surfactant like properties using low concentrations (up to 
1%) of CD to stabilize beta-galactosidase and lactate dehydrogenase upon spray- or freeze-drying. They 
found CD to be superior compared to sucrose or trehalose [17, 18]. To the best of our knowledge, no 
comprehensive study on the impact of CD on freeze-dried mAb formulations including long-term 
stability data has been reported. Furthermore, limited and controversial data is available on the Tg of 
CD formulations with 55°C reported for freeze-dried invertase with 10% (w/v) CD and 108°C for freeze-
dried IL-2 formulated with 0.5% (w/v) CD, although both formulations had a similar residual moisture 
level of approximately ~2.5% [19, 20]. Another excipient repeatedly utilized in freeze-drying is 
polyvinylpyrrolidone (PVP) [21-23]. PVP alone will most likely not sufficiently stabilize the protein due 
to the sterically limited potential for hydrogen bonding between the large polymer and the large 
protein molecules. But, it has been hypothesized that the combination of polymers with saccharides 
could further improve protein stability by strengthening the glassy matrix [24]. In particular, PVP K17 
is of interest as it is approved for parenteral use. Recently, human serum albumin has regained 
attention as excipient to stabilize therapeutic proteins with the availability of recombinant versions at 
larger scale and at reasonable costs. In particular, the high Tg of albumin makes it an interesting 
excipient for lyophilized formulations intended for storage at room temperature [25, 26]. In addition, 
for more than 20 years albumin is approved as excipient in parenteral protein formulations including 
lyophilisates like Avonex® [27]. Furthermore, dextran 40 kDa (Dex) has been shown to strongly increase 
Tg’ and Tg in mAb formulations. However, Dex alone failed to ensure sufficient protein stability at 
elevated temperatures, but stability was strongly improved when used in combinations with 
sucrose [7]. 
Hence, the objective of this research was to systemically study the impact of CD, recombinant human 
albumin (rHA), PVP K17, and Dex, mixtures thereof, as well as combinations with sucrose on the 
stability of mAb lyophilisates with a focus on storage at elevated temperatures (i.e. 9 months at 
temperatures up to 40°C). We investigated the critical formulation temperatures in the liquid (Tc, Tg’) 
as well as the freeze-dried state (Tg) of various formulations using two different proprietary model 
mAbs. Additionally, product quality attributes like cake appearance, residual moisture, and 
reconstitution time were analyzed after freeze-drying. Since therapeutic mAbs have a propensity to 
form aggregates, special emphasis was put on the analysis of loss of mAb monomer, the formation of 
visible and sub-visible particles, as well as changes in turbidity and color upon storage. 
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MATERIALS AND METHODS 
Materials 
Formulations 
Two proprietary model monoclonal antibodies, mAb1 (IgG1 pI ~9.4, 148 kDa) and mAb2 (IgG1 pI ~8.2, 
149 kDa), from F. Hoffmann-La Roche were formulated at a protein concentration of 10 mg/mL in 
20 mM His/His-HCl buffer (Ajinomoto, Tokyo, Japan) at pH 6.0 with 0.02% polysorbate 20 (Croda 
International, Snaith, UK). Additional excipients with a total solid content of 80 mg/mL were added as 
described and abbreviated in Table 1. These excipients included 2-hydroxypropyl-betacyclodextrin 
(CD; Roquette, Beinheim, France), recombinant human albumin (rHA; Sigma Aldrich, Steinheim, 
Germany), Kollidon® 17 PF (PVP; BASF, Ludwigshafen, Germany), dextran 40 kDa (Dex, Pharmacosmos, 
Holbaek, Denmark) as well as sucrose (Suc; Ferro Pfanstiehl Company, Mayfield Heights, Ohio). The 
formulations were sterile filtered through a 0.22 µm hydrophilic PVDF filter membrane (Millipore, 
Bedford, MA). A volume of 3.2 mL per formulation was filled into 6 mL Fiolax® vials (Schott, Müllheim, 
Germany) and partially stoppered with 20 mm Lyo-stoppers D777-1 (DAIKYO Seiko Ltd., Tokyo, Japan) 
before freeze-drying. 
Table 1. Formulation composition. All formulations contained 10 mg/mL of either mAb1 or mAb2 in 20 mM 
His/HCl buffer pH 6.0 with 0.02% polysorbate 20. Additional excipients used were sucrose (Suc), 2-hydroxypropyl-
betacyclodextirn (CD), polyvinylpyrrolidone 17 (PVP), recombinant human albumin (rHA), and dextran 40 kDa 
(Dex). 
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Freeze-drying 
A FTS LyoStar II (FTS Systems Inc, Stone Ridge, NY) was used. Samples were frozen at 0.3°C/min 
to -35°C. For primary drying, a vacuum of 133 µbar was applied and shelf temperature was increased 
by 0.2°C/min to +10°C. End of primary drying was determined when the chamber pressure monitored 
by a Pirani probe reached the same value as the capacitance probe. For secondary drying, vacuum 
remained unchanged and shelf temperature was increased by 0.2°C/min to +25°C and kept for 6 h. At 
the end of freeze-drying, vials were stoppered under nitrogen at 760 mbar and sealed with aluminum 
crimp-caps after unloading.  
Thermal properties  
Differential scanning calorimetry 
Differential scanning calorimetry was performed on a Tzero DSC Q2000 instrument (TA instruments Inc., 
New Castle, Delaware) to determine Tg’ and Tg. For determination of Tg’, 20 µL were transferred into 
Tzero aluminum pans and hermetically sealed. Samples were frozen to -50°C with a freezing rate of 
5°C/min followed by a 10 min isothermal phase and a heating step at the same rate up to 25°C. For 
determination of Tg of the lyophilized cake, 5-10 mg were weighed into Tzero aluminum pans under dry 
nitrogen and hermetically sealed. Samples were heated to either 100°C (Suc) or 150°C (all other 
formulations) at 20°C/min, cooled down to -20°C followed by a second heating step to 200°C or 250°C. 
Tg’ and Tg were determined at half height of the glass transition step. Measurements were performed 
in triplicates and data was reported as mean ± standard deviation. 
Freeze-drying microscopy 
Tc was determined by freeze-drying microscopy (FDM) according to Haeuser et al. [7]. A Linkam FDC196 
freeze-drying stage (Linkam Scientific Instruments, Surrey, UK) and a Zeiss Axio Imager A1 microscope 
(Carl Zeiss MicroImaging, Göttingen, Germany) with 20-fold magnification were used. Tc was reported 
as the onset of collapse. 
Viscosity 
Dynamic viscosity was determined using a MCR 301 plate and cone rheometer (Anton Paar AG, 
Zofingen, Switzerland) equipped with a 25 mm, 0.5° cone (Anton Paar AG). 70 µL were analyzed at 
20°C. The shear rate was increased from 0 to 1000 s-1 within 2 min and viscosity was reported as the 
mean of 24 measurement points at 1000 s-1. 
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Product quality attributes 
Cake appearance  
Lyophilized cakes were visually inspected and representative pictures of the lyophilisates were taken 
in front of a black background. Cake appearance was evaluated based on the presence of visible cracks, 
dents, and collapse. 
Reconstitution time 
For reconstitution, 3.0 mL water for injection (Fresenius Kabi, Oberdorf, Switzerland) were injected 
into the vial through the stopper using a disposable syringe with the syringe tip connected to a 0.22 µm 
Millex® GV sterile syringe filter (Millipore, Bedford, MA) and a 21G x 1.5” needle (BD, Franklin Lakes, 
New Jersey). The reconstitution time was determined for three lyophilisates per formulation using a 
stop watch and was reported as mean ± standard deviation. 
Residual moisture 
Residual moisture was analyzed in triplicates by Karl Fischer titration according to Haeuser et al. [7]. A 
C30 Coulometric Karl Fischer titrator (Mettler Toledo, Greifensee, Switzerland) was used.  
Protein stability 
Samples were analyzed directly after freeze-drying and after 1, 3, 6, and 9 months of storage at 5°C, 
25°C / 60% r.H., and 40°C / 75% r.H.. Prior to analysis, the lyophilisates were reconstituted as described 
above. For determination of color, turbidity, and sub-visible particles, ~2 mL of the reconstituted 
formulation were transferred into particle free glass tubes under laminar air flow conditions. 
Visible particles 
Visible particles of the reconstituted formulations were analyzed by visual inspection according to 
Ph. Eur. 2.9.20. in front of a black and white background [28]. Presence of visible particles was reported 
as I. “practically free from particles”, II. “with few particles”, and III. “with many particles”. 
Turbidity 
Turbidity of reconstituted formulations was determined using a 2100AN Turbidimeter (HACH, 
Dusseldorf, Germany) according to Ph. Eur. 2.2.1. [29]. Data were reported as Nephelometric Turbidity 
Unit (NTU). 
Color 
Color of reconstituted formulations was determined using a LICO 690 Colorimeter (HACH). Color was 
classified according to the color scale described in Ph. Eur. 2.2.2. [30]. 
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Size-exclusion chromatography 
Loss of monomer was determined by size exclusion high-performance liquid chromatography (SE-
HPLC) using an Alliance 2695 or an Alliance e2695 HPLC instrument (Waters Corporation, Milford, MA) 
equipped with a 2487 or 2489 UV/visible-detector (Waters Corporation), respectively. The 
autosampler was set to 5°C and the column oven to 25°C. 100 µg of mAb were injected on a 
TSKG3000SWxl, 7.8 × 300 mm column (Tosoh Bioscience, Stuttgart, Germany). The sample was eluted 
over 30 min with 0.2 M K2HPO4/ KH2PO4 and 0.25 M KCl of either pH 7.0 (mAb1) or pH 6.2 (mAb2) at a 
flow rate of 0.5 mL/min. Signal was detected as UV absorbance at 280 nm. Empower 3 
Chromatography Data System software (Waters Corporation) was used for data processing and the 
loss of monomer was reported as percentage of total peak area. 
Methods specific to data shown in the supporting information only are described in the supporting 
information. These methods comprise of sub-visible particle analysis according to USP <787> [31] and 
Ph. Eur. 2.9.19 [32], X-ray powder diffraction, and determination of water sorption isotherms. 
RESULTS 
Thermal properties and product quality attributes 
Tg’ and Tc were determined to assess the maximal product temperature during primary drying to avoid 
collapse. The data for mAb1 is summarized in Table 2 and reveal that all excipient combinations 
investigated within this study showed markedly higher Tg’ and Tc values compared to the pure Suc 
formulation. Data for mAb2 were not considerably different and are provided in Table S1 in the 
supplementary information. Complete substitution of Suc with CD resulted in a strong increase of Tg’ 
by 18.5°C. Addition of rHA to CD-based formulations resulted in even higher Tg’ values. CD/rHAhigh 
showed the highest Tg’ of -9.3°C and Tc of -7.5°C amongst all tested formulations. On the contrary, 
adding PVP to CD caused a decrease in Tg’. However, even at the highest PVP concentration of 
40 mg/mL, Tg’ was 13.3°C above Tg’ of the pure Suc formulation. The Tg’ values of the mAb formulations 
with CD only or a 1:1 mixture of Dex and CD were similar. For all excipient combinations, Tg’ was 
strongly reduced when Suc was added to the formulation with a negative linear correlation between 
sucrose content and Tg’. Consequently, the 48/32 mg/mL Suc/Dex formulations showed the smallest 
increase in Tg’ of ~4°C compared to the pure Suc formulations. The Tc values were determined for mAb1 
formulations and reflected the Tg’ results. Tc was generally slightly (1 - 4°C) above Tg’. The greatest 
difference of 4°C was found for Suc/Dex. 
Correspondingly to the different Tg’ and Tc values, freeze-drying of the formulation with the same 
aggressive cycle (+10°C shelf temperature during primary drying) resulted in different cake 
appearances: all pure Suc-based mAb formulations were collapsed. Cake appearance improved with 
lowering the Suc fraction. No collapse but major dents were observed for Suc/Dex (Tc: -21.6°C), which 
became less pronounced for CD/PVP/Suc (Tc: -18.7°C), and completely disappeared for formulations 
that had a Tc of -17.8°C or higher. Formulations with high amounts of CD demonstrated a “brittle” cake 
appearance (s. Figure 1a) and showed prominent cracks, when ≥24 mg/mL PVP or rHA were present. 
Lyophilisates without any visual defects were obtained for CD/Dex/Suc and CD/rHA/Suc formulations. 
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Table 2. Formulation attributes. Tg’, Tc, and viscosity of the liquid formulation, and reconstitution time, Tg, and 
residual moisture after freeze-drying. Data are shown for mAb1 formulations. 
 
 
 
Figure 1. Representative images of different cake appearances. a) Lyophilisates after freeze-drying and b) Suc 
lyophilisates after storage at 40°C for 9 months. 
 
Overall, viscosities for all formulations were similar and in the range of 1.3 to 2.2 mPa s (s. Table 2). 
Addition of Dex showed the strongest impact on viscosity and Suc/Dex was the formulation with the 
highest viscosity. A correlation between viscosity and Tc was not observed for the other formulations. 
Thus, there was also no clear correlation of viscosity and reconstitution time: all mAb1 lyophilisates 
were reconstituted within 5 min. Pure CD and Suc formulations had similar reconstitution times of 45 
and 51 s, respectively. Formulations with higher polymer content (PVP, Dex) showed increased 
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reconstitution times and had viscosities of 1.6 to 2.2 mPa s. Interestingly, reconstitution time for mAb1 
formulated with CD/rHAhigh was more than 4 min, although viscosity was slightly lower than that of 
polymer containing formulations. In general, reconstitution of mAb2 formulations took slightly longer 
compared to mAb1 formulations. This was most pronounced for Suc/Dex, where reconstitution of 
mAb1 lyophilisates took less than 4 min whereas it took more than 6 min for mAb2 cakes (s. Table S1 
in the supporting information). In contrast, mAb2 lyophilisates showed a trend to reconstitute slightly 
faster throughout all CD/rHA formulations compared to mAb1 lyophilisates.  
Another important product quality attribute of the freeze-dried formulation is residual moisture as it 
can be detrimental to protein stability, e.g. by acting as plasticizer increasing molecular mobility or as 
potential reaction partner. Formulations which showed major dents (Suc/Dex) and collapse (Suc) had 
increased residual moisture levels of 1.1 and 4.2 %, respectively. Residual moisture for all other 
lyophilisates was low between 0.1-0.3 %. 
The Tg of the freeze-dried product was one major product criteria investigated in this study as it is 
believed to be indicative for the allowable storage temperature. Except for the pure Suc formulation 
(Tg: ~43°C), all other excipient combinations resulted in Tg values between 96 and 200°C, which is far 
beyond intended storage temperatures of proteinaceous formulations. A strong increase in Tg was 
obtained when the mAb was lyophilized with pure CD, resulting in a Tg of ~200°C. Mixtures of CD with 
rHA or Dex did not change the Tg compared to pure CD formulations. When CD was used in 
combination with PVP, Tg decreased with higher PVP content to 162.5°C for the highest PVP fraction. 
As expected, when Suc was added to polymer formulations, Tg of the formulation decreased with 
increased Suc content. Overall Tg values followed the trend observed for Tg’. 
Protein stability  
Protein stability was assessed at 5°C, 25°C, and 40°C for up to 9 months in terms of formation of visible 
and sub-visible particles, changes in color and turbidity, as well as loss  of monomer content. Pure Suc 
formulations were analyzed as a reference. While all lyophilisates stored at 40°C were collapsed, some 
cakes turned brownish (Figure 1b). As a result, inconsistent stability behavior was observed. Hence, for 
time points of 6 or 9 months at 40°C, a brownish and a white lyophilisate were analyzed for Suc 
formulations. The visible change in color of the lyophilized cake was confirmed by color measurements 
of the reconstituted solution (Table 3). In addition, many visible particles were seen in the brownish 
vial for both mAbs, while no visible particles were formed in the white lyophilisates. Correspondingly, 
a markedly higher turbidity of 13.7 NTU (mAb1) and 11.6 NTU (mAb2) as well as a higher amount of 
sub-visible particles (s. Figure S1 in the supporting information) was obtained for brownish Suc 
formulations.  
The majority of the other formulations did not show signs of instability based on visible particles, color, 
and turbidity after 9 month storage at 5°C, 25°C, and  40°C (Table 3 and Table S2 in the supporting 
information). Pure CD and combinations with Suc, as well as PVP and Dex containing formulations did 
not show any visible particles (Table 3) and levels for sub-visible particles were low in general (s. 
Figure S1 in the supporting information). In addition, those formulations showed no considerable 
change in color and increase in turbidity after storage at 40°C for 9 months was less than 1 NTU. 
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Table 3. Storage stability of lyophilisates. Visible particles, turbidity, and color after storage at 40°C for 9 months. 
 
 
Formulations with rHA were less stable. After 9 months, visible particles were formed for all CD/rHA 
formulations independent of storage temperature (Table 3 and Table S2 in the supporting information) 
and an increase in turbidity of 13.7 NTU (mAb1) and 9.9 NTU (mAb2) was observed at 40°C. Even when 
stored at 5°C, CD/rHA formulations showed visible particles for both mAb (s. Table S2 in the supporting 
information). In general, CD/rHA formulations with mAb1 showed an earlier onset of particle 
formation. Already after 4 weeks at 40°C, all CD/rHA formulations of mAb1 showed many particles, 
whereas for mAb2 particles were only seen in CD/rHAhigh. After 3 months many visible particles were 
seen in all CD/rHA formulations for both mAbs stored at 40°C (data not shown). In addition, a high 
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amount of sub-visible particles was formed for all CD/rHA formulations for both mAbs. The total count 
per mL was higher for mAb1 as shown in Figure S1 in the supporting information compared to mAb2. 
Interestingly, CD/rHA formulations with mAb2 showed no considerable increase in number of particles 
≥ 10 µm. In general, formulations with increasing rHA content were less stable. However, when 30% 
sucrose was added to a mixture of CD/rHA, no particles and no increase in turbidity was observed after 
storage, although the rHA content in CD/rHA/Suc (16.8 mg/mL) was twice the amount of CD/rHAlow 
(8 mg/mL). 
Special emphasis to assess protein integrity was given to the loss of monomer content. Regarding the 
reference formulations with pure Suc, both mAbs were stable if stored at 5°C and 25°C (Figure 2a and 
Figure S3 in the supporting information). At 40°C, lyophilisates collapsed and those that remained 
white showed good protein stability with a monomer content of more than 96%, whereas a strong loss 
in monomer content occurred for brownish lyophilisates (Figure 2b). The decrease in monomer 
content correlated with a high amount of aggregates of around 20% for mAb1 and 30% for mAb2 after 
storage at 40°C for 9 months. Additional characterization by X-ray powder diffraction demonstrated 
that sucrose showed almost no tendency to crystallize in white lyophilisates, whereas in brownish 
lyophilisates sucrose had almost completely crystallized (s. Figure S2 in the supporting information). 
 
Figure 2. mAb stability in lyophilisates by SE-HPLC. Monomer loss of mAb1 (filled symbols) and mAb2 (open 
symbols) formulated with 80 mg/mL sucrose upon storage for 9 months at a) 25°C or b) 40°C. “B” indicates 
lyophilisates that had turned brownish upon storage. 
 
Figure 3 and 4 show the loss of monomer content for mAb1 and mAb2 upon storage at 25°C and 40°C, 
respectively, for formulations with CD and CD/Suc, rHA, PVP as well as Dex, which corresponded to an 
increase in high molecular weight species (Stability at 5°C shown in Figure S3 in the supporting 
information). Overall, loss of monomer was higher after storage at 40°C compared to 25°C. Similar 
stability behavior was observed for mAb1 and mAb2 with in general a slightly higher loss of monomer 
for mAb2. At 25°C, both mAbs remained stable in formulations with pure CD or in combination with 
Suc. At 40°C, the mAbs were better stabilized when a mixture of CD/Suc was used with a loss of 
monomer of less than 1% compared to pure CD, which showed a loss of monomer of ~3%. 
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Corresponding to the substantial particle formation, addition of rHA to CD-based formulations resulted 
in a pronounced loss of monomer, depending on the rHA concentration. While formation of visible and 
sub-visible particles was more pronounced for mAb1, the formation of higher molecular weight species 
was higher for mAb2 formulations. The monomer content decreased by 3% after 9 months at 25°C for 
CD/rHAhigh. Protein degradation was much faster at 40°C with 80% (mAb2) and 83% (mAb1) monomer 
content for CD/rHAhigh after 9 months. If 24 mg/mL Suc was added to a CD/rHA mixture, protein 
stability was strongly improved, resulting in a remaining monomer content of 94% after 9 months at 
40°C. Interestingly, although rHA content in this formulation (16.8 mg/mL) was twice the amount of 
CD/rHAlow (8 mg/mL), CD/rHA/Suc exhibited only a minor monomer loss of ~2% compared to ~4% for 
CD/rHAlow (Figure 4b). 
 
 
 
Figure 3. mAb stability in lyophilisates by SE-HPLC. Monomer loss of mAb1 (filled symbols) and mAb2 (open 
symbols) after storage at 25°C for formulations with a) CD, b) rHA, c) PVP, and d) Dex. 
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Figure 4. mAb stability in lyophilisates by SE-HPLC. Monomer loss of mAb1 (filled symbols) and mAb2 (open 
symbols) after storage at 40°C for formulations with a) CD, b) rHA, c) PVP, and d) Dex. 
 
All formulations with PVP demonstrated good protein stability at 25°C storage. Best mAb stability was 
achieved in CD/PVP/Suc without changes at 25°C and a minor decrease in monomer content of 1% at 
40°C after 9 months. Formulations with CD/PVP revealed similar stability as pure CD formulations with 
no change at 25°C and only a reduction of 2-3% in monomer content at 40°C after 9 months. For mAb2 
but not for mAb1, the decrease in monomer content after 9 months at 40°C appears to be less 
pronounced with higher PVP content. 
The Dex formulations were of inferior stability compared to the other excipient combination. Best mAb 
stability was achieved for the lowest dextran concentration of 16.8 mg/mL with a loss of monomer 
content of 3.1% for mAb1 and 3.6% for mAb2. 
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Overall, the stability differences between the mAb1 and the mAb2 formulations are marginal. They 
may be attributed to differences in the molecular properties like hydrophobicity and distribution of 
hydrophobic patch on the protein surface. This subject is beyond the scope of this study.       
DISCUSSION 
Review of existing literature on freeze-dried protein formulations reveals that the excipients included 
in the formulations have a major impact on the ideal freeze-drying cycle conditions, the resulting 
product quality attributes, as well as protein stability [4, 24, 33]. During formulation and process 
development, typically Tg’ of the liquid and Tg of the freeze-dried product are analyzed as important 
formulation characteristics. Tg’ is assessed to determine the maximum primary drying temperature to 
prevent collapse and Tg is believed to correlate with protein stability at a specific storage temperature. 
Most marketed freeze-dried mAb formulations contain trehalose or more commonly sucrose, potent 
lyo- and cryoprotectants but with moderate to low glass transition temperatures (Tg’ and Tg). We 
believe that this standard use of disaccharides as protein stabilizer is, at least partially, responsible for 
higher costs of goods due to time-consuming freeze-drying cycles and refrigerated storage conditions. 
In this light, the present study systemically investigated novel excipient combinations compared to 
pure sucrose with regards to their potential to i) run more aggressive freeze-drying cycles while 
obtaining pharmaceutically elegant lyophilisates and ii) enable long-term storage at room 
temperature. It is important to mention that the goal of the present study was not the development 
of an ideal freeze-drying cycle for each formulation. Within this study we employed an aggressive 
lyophilization cycle which results in a Tp of ~-21°C during primary drying, significantly above the Tc of 
Suc formulations. The freeze-drying cycle employed within the present study (Ts: +10°C) shortened 
primary drying time by 17% compared to a typical freeze-drying cycle with a Ts of -10°C during primary 
drying for sucrose-based formulations. By this, we evaluated the potential for alternative excipient 
combinations to perform faster freeze-drying processes while maintaining elegant cake appearance.  
In general, the Tg’ values were indicative for the resulting cake appearances. Formulations with a Tg’ 
markedly lower than Tp were fully collapsed (Suc), formulations with a Tg’ slightly below Tp showed 
major dents (Suc/Dex), and a Tg’ slightly above Tp resulted in minor dents (CD/PVP/Suc). While it has 
been shown that collapse does not necessarily harm protein stability [33], elegant cake appearance is 
often considered an important quality attribute included for lot release [34, 35]. The results also 
highlight the importance of determining Tc by FDM in addition to Tg’ for precise prediction of resulting 
cake appearance. Although CD/PVP/Suc and CD/Dex/Suc showed similar Tg’ values, the first showed 
minor dents while CD/Dex/Suc resulted in an elegant cake due to the small but considerable difference 
in Tc values (ΔTc = 1.1°C). The presence of major dents when Tp equals Tc has also been reported 
previously by Depaz et al. [34]. Formulations which contained a high fraction of CD resulted in brittle 
lyophilisates. This was also reported by Geidobler when a mAb was formulated with a 1% CD-based 
formulation [36]. Additionally, we observed formation of a film on the inner surface of the glass vial 
for formulations that contained mainly CD. We hypothesize that this phenomenon might be a 
combination of creeping, shrinkage and detachment and related to the amphiphilic nature of CD and 
investigations are ongoing whether cake appearance of formulations containing CD can be improved 
by using alternative vial types. 
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Besides enabling aggressive freeze-drying conditions, we targeted to enable storage at room 
temperature. Consequently, according to ICH guidance for drug product storage at 25°C, stability data 
for storage at 40°C for up to 6 months without significant changes is required [37]. Tg is associated with 
the transition from a glassy matrix to a viscous flow. Hence, at temperatures below Tg, immobilization 
of the protein is ensured and thus degradation mechanisms are expected to slow down. Several studies 
demonstrated strong correlation between increasing protein stability and higher glass transition 
temperatures [19, 38, 39]. Grasmeijer et al. reported that the storage temperature of freeze-dried 
formulations should be 10-20°C below Tg to ensure optimal protein stability [4]. However in some 
instances, it has been observed that protein stability does not necessarily or at least not only depend 
on Tg. Moorthy et al. found that the rank order of Tg was poorly correlated to the aggregation 
propensities of the formulations [40]. Pikal et al. found that Tg was predictive for the stability of 
lyophilized human growth hormone in disaccharide systems for storage temperatures near the 
formulations’ Tg, whereas for storage at temperatures far below Tg, stability behavior seemed to be 
unrelated to Tg [41]. Our results support the observations by Pikal et al.. 
All vials of the Suc formulation showed collapse. This collapse during lyophilization resulted in high 
residual moisture levels (4.2%) leading to a rather low Tg of 43.2°C as compared to typically reported 
values for sucrose [5], which was close to the storage temperature of 40°C. Consequently, 
inconsistency between vials with respect to stability was observed for Suc samples when stored at 
40°C. Some Suc samples showed remarkable loss in monomer content, formation of visible particles, 
and changes in color, starting already after 6 months of storage. Other vials remained stable over a 
time period of 9 months at 40°C. Performing a conventional freeze-drying cycle with Suc formulations, 
which did not introduce collapse but major dents, resulted in residual moisture levels of 1-2% and 
correspondingly higher Tg values of 65°C (data not shown). These conservatively freeze-dried 
lyophilisates remained stable during storage and remaining monomer content of mAb2 was 
comparable to white lyophilisates of the aggressive cycle (s. Figure S4 in the supporting information). 
However, for sucrose formulations this would require time-consuming freeze-drying cycles to avoid 
collapse and render lyophilisates of low residual moisture.  As mentioned above, the scope of the 
present study was to enable shorter freeze-drying cycles and therefore a Suc formulation freeze-dried 
with the same freeze-drying cycle served as a reference. Characterization of the morphology of 
brownish Suc lyophilisates revealed crystallization of sucrose and thus loss of the stabilizing 
amorphous matrix. A model developed by Bhugra et al. to predict the onset of crystallization of 
amorphous sucrose clearly showed that only small differences between storage temperature and Tg 
have a major impact on the onset of crystallization [42]. This might explain why some Suc vials did 
crystallize while others remained amorphous. The additional brownish appearance is likely to be 
ascribed to chemical modifications facilitated by the high residual moisture. Upon heat-stress, sucrose 
can hydrolyze into fructose and the reducing sugar glucose. Glucose can eventually lead to glycation 
of the protein [43, 44]. We confirmed mAb glycation by mass spectrometry showing an increased peak 
with a mass shift of +162 Da (s. Figure S5 in the supporting information). Slightly increased glycation 
levels were even found for white lyophilisates after 9 months at 40°C. These findings highlight the need 
for alternative excipients, enduring aggressive freeze-drying cycles without collapse and providing drug 
products with higher Tg. All tested excipient combinations within this study had much higher Tg values 
compared to Suc, suggesting sufficient immobilization of the mAb at storage temperatures of 25°C and 
40°C. Additionally, we determined the residual moisture after storage at 25°C for select CD-based 
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formulations (CD, CD/PVP/Suc, CD/Suchigh). The levels were marginally increased by approximately 0.2-
0.3%, and no increase was observed for pure sucrose formulations (s. Table S3 in the supporting 
information). Dynamic vapor sorption (DVS) measurements showed that residual moisture levels upon 
storage are far below moisture levels, where changes like crystallization become an issue. Changes in 
sorption behavior for CD-based formulations containing sucrose occurred at much higher moisture 
levels (approximately 15%) whereas onset of crystallization of pure sucrose occurred already at 
approximately 6-7% (s. Figure S6 in the supporting information). Thus, the low residual water content 
after storage and the low tendency of CD-based formulations to crystallize further support the 
possibility of room temperature storage. 
CD is a promising alternative excipient, as in contrast to the unmodified parent cyclodextrins, CD has 
been shown to be toxicologically safe without adverse effects for intravenous administration of 
250 mg/kg/day for 21 days [45]. However, care should be taken if drugs are intended for patients with 
kidney impairment due to renal toxicity concerns related to the unmodified parent cyclodextrin [46]. 
Moreover, CD does not only function as a bulking agent but also as amorphous stabilizer. Ressing et 
al. reported that CD preserves antigen-binding capacity of a freeze-dried mAb during storage at 56°C 
for up to 32 days better compared to sucrose [47]. These findings are partially in line with the results 
of our study. Storage at 25°C resulted in equally good mAb stability for both CD and Suc formulations. 
When lyophilisates were stored at 40°C, remaining mAb monomer content was much higher in CD 
formulations (94.6% mAb1, 94.0% mAb2) compared to brownish Suc lyophilisates (80.6% mAb1 67.6% 
mAb2), and slightly lower than in white Suc samples (96.5% mAb1, mAb2). However, no increase in 
mAb glycation levels was observed in CD samples compared to white Suc samples. mAb aggregation 
in pure CD was faster when stored at 40°C compared to storage at 25°C. The remaining monomer 
content after 3 months at 40°C was already lower than after 9 months at 25°C, although both storage 
conditions are far below the Tg of 200 °C. This is consistent with the results of a study by Faghihi et al., 
who found similar mAb stability in terms of aggregate formation for pure trehalose or CD formulations 
after storage at 40°C for 3 months, but with slightly higher aggregation rates for CD [16]. The fact that 
different stability behavior was observed when stored at 25°C or 40°C, although both temperatures 
are far below the Tg, suggests that protein stabilization by CD at storage temperatures far below Tg is 
unrelated to Tg. This is consistent with previous observations [41]. Addition of 30% Suc to CD improved 
stability, resulting in mAb formulations that were stable upon long-term storage at 40°C. This leads to 
the hypothesis that CD may be inferior in suppressing local motions (β-relaxations) compared to 
sucrose. β-relaxations were shown to account for protein stability at storage temperatures far below 
the Tg [48]. Using tetrahertz spectroscopy, Smoohl et al. could demonstrate a distinct transition 
temperature for mAb formulations, which was associated with the onset of local motions [49]. We 
speculate that storage at 40°C might be above this transition temperature for the pure CD formulation, 
causing local motions which lead to increased protein instability.  
Addition of PVP to CD formulations did not impact the mAb stability behavior compared to pure CD 
formulations with a monomer loss <1% when stored at 25°C and more pronounced aggregation at 
40°C. PVP acts as a bulking agent for low concentration protein formulations. Correspondingly, stability 
of a freeze-dried protein stored at 40°C for 12 days was shown to be inferior when formulated with 
pure PVP compared to sucrose [50]. In combination with sucrose, PVP enhances protein stability at 
elevated temperatures compared to pure sucrose due to formation of hydrogen bonds between 
sucrose and PVP resulting in a more stable, amorphous glass [22, 51]. Previous studies used PVP (K40) 
 
CHAPTER 3 
 
 
 
81 
or larger, which have a higher Tg compared to the PVP (K17) used in our study [22, 23, 39, 52]. However, 
these higher molecular weight PVPs are not approved for parenteral use, hence were not included in 
our study. In a preliminary experiment, we did not find a considerable impact of PVP (K17) addition to 
pure sucrose on Tg hence we investigated the use of PVP in combination with CD. This novel 
combination of PVP as a bulking agent with CD, which stabilizes the mAb upon storage at 25°C, or 
CD/Suc provide overall good protein stability at 40°C. CD/PVP/Suc resulted in similar, very good 
properties in terms of mAb stability, Tg’, reconstitution times, and residual moisture compared to 
CD/Suchigh, but with slightly reduced cake appearance due to minor dents. 
In contrast, addition of rHA to CD destabilized both mAbs, regardless of the storage temperature. 
Formation of visible particles was already observed after 4 weeks at 40°C. This is of concern since 
protein aggregates can reduce therapeutic efficacy and have a greater immunogenic potential [53, 54]. 
After 9 months, particles were present in all rHA formulations independent of the storage 
temperature. If stored at 40°C, mAb1 formulated with CD/rHAhigh even exceeded the compendial 
requirements for sub-visible particles of less than 6000 particles ≥10 µm per container [28]. 
Interestingly, particles were also present in placebo formulations, but no particle formation was 
observed if sucrose was present in the formulation. These observations point out that rHA itself is 
unstable in the presence of CD, but stable if combined with sucrose. These findings are consistent with 
a study by Costantino et al., who reported formation of insoluble aggregates for various freeze-dried 
excipient-rHA combinations. rHA stability was found to be strongly dependent on the chosen excipient, 
although a relationship between molecular structure of the excipient (e.g. presence of hydroxyl 
groups) and rHA stability was not shown [55]. Finally, although formulation stability was improved by 
the addition of Suc, CD/rHA/Suc was not superior to CD/Suchigh or CD/PVP/Suc. Hence, while human 
albumin has been successfully used as a stabilizer for freeze-dried cytokines [27], our results suggest 
that the addition of rHA does not add value to the stability of freeze-dried mAb formulations. 
Similarly, addition of Dex to CD decreased mAb stability. While dextran containing formulations did 
not show any significant changes in visible particles, SE-HPLC data revealed similar levels of loss of 
monomer for CD/Dex as for CD/rHAhigh formulations. This is consistent with our previous study. We 
reported impaired mAb stability due to glycation when formulated with dextrans only. Stability was 
improved when mixtures of Dex and Suc were used [7]. There is a marketed lyophilized antibody-drug 
conjugate available, formulated with a mixture of Dex and Suc, which is intended for refrigerated 
storage [56]. Hence, we included a formulation with a similar Dex to Suc ratio in the present study to 
test whether this combination would also allow for elevated storage temperatures. While we 
confirmed good mAb stability after 9 months at 2-8°C (s. Figure S3 in the supporting information), we 
observed loss in monomer content of 5% (mAb2) and 7% (mAb1) when stored at 40°C. Both Suc/Dex 
and CD/Dex formulations showed considerable loss of monomer content, while mAb stability in 
Suc/Dex appeared slightly superior to CD/Dex. Potentially, this could be explained by a hypothesis 
previously described suggesting a better protection of the mAb by sucrose (342 Da) molecules 
compared to the sterically larger CD (~1kda) [7]. This hypothesis requires further confirmation as the 
Dex fraction varies across the Suc/Dex and CD/Dex formulations.  
In summary, the present data set demonstrates that CD is a promising alternative excipient for freeze-
dried mAb formulations as it does not only increase the glass transition temperatures but in contrast 
to crystalline bulking agents such as mannitol also functions as amorphous stabilizer. In particular, 
combinations of CD/Suc or CD/PVP/Suc are highly attractive, enabling aggressive freeze-drying cycles 
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without adding additional complexity to the process leading to shorter cycle time. Further process 
optimization is subject of ongoing research. Moreover, they ensure protein storage stability at 25°C 
and higher, thereby overcoming constraints of pure sucrose formulations. These formulations with 
high Tg’ may be particularly interesting for potent, low concentrated novel therapeutic protein 
modalities such as antibody-drug conjugates or Fc-fusion proteins. Due to their increased complexity, 
they are often less stable in liquid dosage forms requiring freeze-dried formulations. However, the 
applicability and stabilizing properties of CD for such new formats needs to be investigated. 
CONCLUSION 
Biopharmaceutical formulations, which can be stored at room temperature, are highly attractive. 
Especially the possibility to freeze-dry under aggressive conditions while maintaining elegant cake 
appearance at the same time will further reduce costs of goods. Low concentration mAb formulations 
with pure sucrose are not adequate for aggressive freeze-drying cycles and product storage at room 
temperature. We investigated alternative excipients and demonstrated that low concentration mAb 
formulations with CD/Suc or CD/PVP/Suc endure aggressive freeze-drying cycles without collapse 
resulting in good product quality attributes such as cake appearance, residual moisture, and 
reconstitution time. Most importantly, these excipient combinations enable storage at room 
temperature or above for at least 9 months at the same time. While PVP acts as bulking agent only 
contributing to a stable amorphous matrix, CD is a particularly interesting excipient as it does not only 
increase the formulation’s Tg but is also able to stabilize the protein. Whether these formulations are 
able to stabilize new mAb derivatives is yet to be verified. We demonstrated that mAbs are well 
stabilized by CD for storage temperatures up to 25°C, whereas at higher temperatures the addition of 
30% sucrose to pure CD or mixtures of CD with PVP is beneficial for protein stability. We propose that 
the addition of CD in mAb formulations might reduce costs of goods of freeze-dried 
biopharmaceuticals by allowing for shorter freeze-drying cycles and making cold chain for drug product 
storage eventually redundant. 
  
 
CHAPTER 3 
 
 
 
83 
ACKNOWLEDGEMENTS 
The authors would like to thank Monika Gisin and Sonja Omlin for their help with the analysis of 
stability samples. We acknowledge Dr. Frank Stowasser for performing the XRPD analysis and Nikolaus 
Martin for the DVS measurements. We would like to thank Anja Bathke and Sina Hoelterhoff for the 
MS analysis. PVP was generously provided by BASF and we thank F. Hoffmann-La Roche for providing 
the monoclonal antibodies. 
REFERENCES 
1. V. Gervasi, R. Dall Agnol, S. Cullen, T. McCoy, S. Vucen, A. Crean, Parenteral protein formulations: An 
overview of approved products within the European Union, Eur J Pharm Biopharm, 131 (2018) 8-24. 
2. J.F. Carpenter, S.J. Prestrelski, T.J. Anchordoguy, T. Arakawa, Interactions of stabilizers with proteins 
during freezing and drying, in: J.L. Cleland, R. Langer (Eds.) Formulation and delivery of proteins and 
peptides, ACS Washington, (1994), 134-147. 
3. J.H. Crowe, J.F. Carpenter, L.M. Crowe, The role of vitrification in anhydrobiosis, Annu Rev Physiol, 60 
(1998) 73-103. 
4. N. Grasmeijer, M. Stankovic, H. de Waard, H.W. Frijlink, W.L.J. Hinrichs, Unraveling protein stabilization 
mechanisms: Vitrification and water replacement in a glass transition temperature controlled system, 
Biochim Biophys Acta, 1834 (2013) 763-769. 
5. K.D. Roe, T.P. Labuza, Glass transition and crystallization of amorphous trehalose-sucrose mixtures, Int 
J Food Prop, 8 (2005) 559-574. 
6. M.A. Mensink, H.W. Frijlink, K. van der Voort Maarschalk, W.L.J. Hinrichs, Inulin, a flexible 
oligosaccharide I: Review of its physicochemical characteristics, Carbohydr Polym, 130 (2015) 405-419. 
7. C. Haeuser, P. Goldbach, J. Huwyler, W. Friess, A. Allmendinger, Impact of dextran on thermal 
properties, product quality attributes, and monoclonal antibody stability in freeze-dried formulations, 
Eur J Pharm Biopharm, 147 (2020) 45-56. 
8. US Food and Drug Administration, Drugs@FDA: FDA approved drug products, 
https://www.accessdata.fda.gov/scripts/cder/daf/, (Accessed 03 January 2019). 
9. Nucala® (mepolizumab), for injection, for subcutaneous use, FDA label, (Cited  03 January 2019) 
10. R.E. Johnson, C.F. Kirchhoff, H.T. Gaud, Mannitol-sucrose mixtures - versatile formulations for protein 
lyophilization, J Pharm Sci, 91 (2002) 914-922. 
11. S. Passot, F. Fonseca, M. Alarcon-Lorca, D. Rolland, M. Marin, Physical characterisation of formulations 
for the development of two stable freeze-dried proteins during both dried and liquid storage, Eur J 
Pharm Biopharm, 60 (2005) 335-348. 
12. A.J. Cannon, E.H. Trappler, The influence of lyophilization on the polymorphic behavior of mannitol, PDA 
J Pharm Sci Technol, 54 (2000) 13-22. 
13. X. Lu, M.J. Pikal, Freeze-drying of mannitol-trehalose-sodium chloride-based formulations: The impact 
of annealing on dry layer resistance to mass transfer and cake structure, Pharm Dev Technol, 9 (2004) 
85-95. 
14. T. Serno, R. Geidobler, G. Winter, Protein stabilization by cyclodextrins in the liquid and dried state, Adv 
Drug Deliv Rev, 63 (2011) 1086-1106. 
15. B. Boll, J. Bessa, E. Folzer, A. Ríos Quiroz, R. Schmidt, P. Bulau, C. Finkler, H.-C. Mahler, J. Huwyler, A. 
Iglesias, A.V. Koulov, Extensive chemical modifications in the primary protein structure of IgG1 subvisible 
particles are necessary for breaking immune tolerance, Mol Pharm, 14 (2017) 1292-1299. 
16. H. Faghihi, S. Merrikhihaghi, A. Ruholamini Najafabadi, V. Ramezani, S. Sardari, A. Vatanara, A 
comparative study to evaluate the effect of different carbohydrates on the stability of immunoglobulin 
G during lyophilization and following storage, Pharm Sci, 22 (2016) 251-259. 
17. J. Iwai, N. Ogawa, H. Nagase, T. Endo, T. Loftsson, H. Ueda, Effects of various cyclodextrins on the 
stability of freeze‐dried lactate dehydrogenase, J Pharm Sci, 96 (2007) 3140-3143. 
 
Excipients for room temperature stable freeze-dried monoclonal antibody formulations 
 
 
84 
18. S. Branchu, R.T. Forbes, P. York, S. Petren, H. Nyqvist, O. Camber, Hydroxypropyl-beta-cyclodextrin 
inhibits spray-drying-induced inactivation of beta-galactosidase, J Pharm Sci, 88 (1999) 905-911. 
19. S.J. Prestrelski, K.A. Pikal, T. Arakawa, Optimization of lyophilization conditions for recombinant human 
interleukin-2 by dried-state conformational analysis using fourier-transform infrared spectroscopy, 
Pharm Res, 12 (1995) 1250-1259. 
20. P.R. Santagapita, L.G. Brizuela, M.F. Mazzobre, H.L. Ramirez, H.R. Corti, R.V. Santana, M.P. Buera, 
Structure/function relationships of several biopolymers as related to invertase stability in dehydrated 
systems, Biomacromolecules, 9 (2008) 741-747. 
21. J.C. Kasper, D. Schaffert, M. Ogris, E. Wagner, W. Friess, Development of a lyophilized plasmid/LPEI 
polyplex formulation with long-term stability - a step closer from promising technology to application, J 
Control Release, 151 (2011) 246-255. 
22. Å. Schoug, D. Mahlin, M. Jonson, S. Håkansson, Differential effects of polymers PVP90 and Ficoll400 on 
storage stability and viability of lactobacillus coryniformis Si3 freeze-dried in sucrose, J Appl Microbiol, 
108 (2010) 1032-1040. 
23. C. Kunz, S. Schuldt-Lieb, H. Gieseler, Freeze-drying from organic co-solvent systems, part 2: Process 
modifications to reduce residual solvent levels and improve product quality attributes, J Pharm Sci, 108 
(2019) 399-415. 
24. H. Oldenhof, W.F. Wolkers, F. Fonseca, S. Passot, M. Marin, Effect of sucrose and maltodextrin on the 
physical properties and survival of air-dried lactobacillus bulgaricus: An in situ fourier transform infrared 
spectroscopy study, Biotechnology Progress, 21 (2005) 885-892. 
25. L. Wei, The impact of formulation composition on the stability of freeze-dried proteins, Doctoral 
dissertation, (2000), Purdue University. 
26. M. Zhang, H. Oldenhof, B. Sydykov, J. Bigalk, H. Sieme, W.F. Wolkers, Freeze-drying of mammalian cells 
using trehalose: Preservation of DNA integrity, Scientific Reports, 7 (2017) 6198. 
27. Avonex® (interferon beta-1a), injection, for intramuscular injection, FDA label, (Cited 03 January 2019). 
28. Eur. Ph., 2.9.20. Particulate contamination: Visible particles, in European Pharmacopeia 9th ed. (2017), 
European directorate for the quality of medicines & health care. 
29. Eur. Ph., 2.2.1. Clarity and degree of opalescence of liquids, in European Pharmacopeia 9th ed. (2017), 
European directorate for the quality of medicines & health care. 
30. Eur. Ph., 2.2.2. Degree of coloration of liquids, in European Pharmacopeia 9th ed. (2017), European 
directorate for the quality of medicines & health care. 
31. USP Chapter <787>, Subvisible particulate matter in therapeutic protein injections, Unites States 
Pharmacopeial Convention, (2014). 
32. Eur. Ph., 2.9.19. Particulate contamination: Sub-visible particles, in European Pharmacopeia 9th ed. 
(2017), European directorate for the quality of medicines & health care. 
33. K. Schersch, O. Betz, P. Garidel, S. Muehlau, S. Bassarab, G. Winter, Systematic investigation of the effect 
of lyophilizate collapse on pharmaceutically relevant proteins, part 2: Stability during storage at elevated 
temperatures, J Pharm Sci, 101 (2012) 2288-2306. 
34. R.A. Depaz, S. Pansare, S.M. Patel, Freeze-drying above the glass transition temperature in amorphous 
protein formulations while maintaining product quality and improving process efficiency, J Pharm Sci, 
105 (2016) 40-49. 
35. S.M. Patel, S.L. Nail, M.J. Pikal, R. Geidobler, G. Winter, A. Hawe, J. Davagnino, S.R. Gupta, Lyophilized 
drug product cake appearance: What is acceptable?, J Pharm Sci, 106 (2017) 1706-1721. 
36. R. Geidobler, Cyclodextrins as excipients in drying of proteins and controlled ice nucleation in freeze-
drying, Doctoral dissertation, (2014), Ludwig-Maximilians-University Munich. 
37. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use 
(ICH) Guidelines Q1A (R2): Stability testing of new drug substances and products, in, 2003. 
38. S.P. Duddu, P.R. Dal Monte, Effect of glass transition temperature on the stability of lyophilized 
formulations containing a chimeric therapeutic monoclonal antibody, Pharm Res, 14 (1997) 591-595. 
39. C. Schebor, M. del Pilar Buera, J. Chirife, Glassy state in relation to the thermal inactivation of the 
enzyme invertase in amorphous dried matrices of trehalose, maltodextrin and PVP, J Food Eng, 30 
(1996) 269-282. 
40. B.S. Moorthy, I.E. Zarraga, L. Kumar, B.T. Walters, P. Goldbach, E.M. Topp, A. Allmendinger, Solid-state 
hydrogen–deuterium exchange mass spectrometry: Correlation of deuterium uptake and long-term 
stability of lyophilized monoclonal antibody formulations, Mol Pharm, 15 (2018) 1-11. 
 
CHAPTER 3 
 
 
 
85 
41. M.J. Pikal, D. Rigsbee, M.L. Roy, D. Galreath, K.J. Kovach, B. Wang, J.F. Carpenter, M.T. Cicerone, Solid 
state chemistry of proteins: II. The correlation of storage stability of freeze‐dried human growth 
hormone (hGH) with structure and dynamics in the glassy solid, J Pharm Sci, 97 (2008) 5106-5121. 
42. C. Bhugra, S. Rambhatla, A. Bakri, S.P. Duddu, D.P. Miller, M.J. Pikal, D. Lechuga-Ballesteros, Prediction 
of the onset of crystallization of amorphous sucrose below the calorimetric glass transition temperature 
from correlations with mobility, J Pharm Sci, 96 (2007) 1258-1269. 
43. H.S. Gadgil, P.V. Bondarenko, G. Pipes, D. Rehder, A. McAuley, N. Perico, T. Dillon, M. Ricci, M. Treuheit, 
The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations, J Pharm Sci, 96 
(2007) 2607-2621. 
44. J.F. Valliere-Douglass, P. Lewis, O. Salas-Solano, S. Jiang, Solid-state mAbs and ADCs subjected to heat-
stress stability conditions can be covalently modified with buffer and excipient molecules, J Pharm Sci, 
104 (2015) 652-665. 
45. European Medicines Agency. Cyclodextrins used as excipients (EMA/CHMP/333892/2013), Committee 
for Human Medicinal Products, (2017). 
46. V.J. Stella, Q. He, Cyclodextrins, Toxicologic Pathol, 36 (2008) 30-42. 
47. M.E. Ressing, W. Jiskoot, H. Talsma, C.W. van Ingen, E.C. Beuvery, D.J.A. Crommelin, The influence of 
sucrose, dextran, and hydroxypropyl-β-cyclodextrin as lyoprotectants for a freeze-dried mouse IgG2a 
monoclonal antibody (mn12), Pharm Res, 9 (1992) 266-270. 
48. M.T. Cicerone, J.F. Douglas, β-relaxation governs protein stability in sugar-glass matrices, Soft Matter, 8 
(2012) 2983-2991. 
49. T.A. Shmool, P.J. Woodhams, M. Leutzsch, A.D. Stephens, M.U. Gaimann, M.D. Mantle, G.S. Kaminski 
Schierle, C.F. van der Walle, J.A. Zeitler, Observation of high-temperature macromolecular confinement 
in lyophilised protein formulations using terahertz spectroscopy, Int J Pharm, 1 (2019) 100022. 
50. E.A. Kaisheva, A. Flores-Nate, S. Gupta, Stable lyophilized pharmaceutical formulation of igg antibodies. 
US Patent 7592004, (2009). 
51. L.S. Taylor, G. Zografi, Sugar–polymer hydrogen bond interactions in lyophilized amorphous mixtures, J 
Pharm Sci, 87 (1998) 1615-1621. 
52. E. Meister, S. Sasić, H. Gieseler, Freeze-dry microscopy: Impact of nucleation temperature and excipient 
concentration on collapse temperature data, AAPS PharmSciTech, 10 (2009) 582-588. 
53. S. Hermeling, D.J.A. Crommelin, H. Schellekens, W. Jiskoot, Structure-immunogenicity relationships of 
therapeutic proteins, Pharm Res, 21 (2004) 897-903. 
54. R.V. Cordoba-Rodriguez, Aggregates in mabs and recombinant therapeutic proteins: A regulatory 
perspective, BioPharm Int, 21 (2008) 44-53. 
55. H.R. Costantino, R. Langer, A.M. Klibanov, Aggregation of a lyophilized pharmaceutical protein, 
recombinant human albumin: Effect of moisture and stabilization by excipients, Biotechnology, 13 
(1995) 493-496. 
56. U.S. Food and drug administration. Mylotarg (gemtuzumab ozogamicin) for injection, for intravenous 
use FDA label, (Cited 10 February 2019). 
 
  
 
Excipients for room temperature stable freeze-dried monoclonal antibody formulations 
 
 
86 
SUPPORTING INFORMATION 
Methods 
This paragraph lists methods specific for data shown in the supporting information. Other methods are 
described in the main manuscript. 
Sub-visible particles 
Number and size distribution of sub-visible particles was analyzed by light obscuration in analogy to 
USP <787> [31] and Ph. Eur. 2.9.19. [32] requirements using a HIAC 9703+ liquid particle counter (Skan, 
Allschwil, Switzerland). After rinsing the system with 0.5 mL sample solution, 4 aliquots of 0.2 mL were 
analyzed. Analysis and classification of particles into  2 µm,  5 µm,  10 µm, and  25 µm was 
performed by the Pharmspec 3 software. The first measurement was discarded, and the mean ± 
standard deviation of run 2 to 4 was reported as cumulative particles per mL. 
X-ray powder diffraction 
X-ray powder diffraction (XRPD) was performed using a STOE STADI (Stoe & Cie, Darmstadt, Germany) 
powder diffraction system. Pure Kα1 radiation was produced using a copper generator (40 kV, 40 mA). 
Measurements were performed from 3° to 42° 2 − θ at a resolution of 0.5° 2 − θ and duration of 20 s 
per step. 
Water sorption isotherms 
Water sorption behavior was determined using a DVS Intrinsic Plus (SMS Surface Measurements 
Systems, Middlesex, UK) moisture balance system. 10-20 mg sample were weighed into the sample 
holder. After equilibration at 0% r.H. for 300 min, the sorption isotherms were measured in a range 
from 0% r.H to 90%-r.H. at 25°C with a dynamic increase of 5% r.H. per minute.  
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Table S1 shows formulation attributes of the liquid and freeze-dried mAb2 formulation. The values for 
Tg’, viscositiy, reconstitution time, Tg, and residual moisture were not considerable different from 
mAb1 formulations. Correspondingly, cake appearance for the different formulations was similar for 
mAb1 or mAb2 containing formulations. 
 
Table S1. Characterization of liquid formulation (Tg’, Tc, and viscosity), as well as quality attributes of the freeze-
dried product (reconstitution time, Tg, residual moisture) directly after freeze-drying. For abbreviations see 
Table 1. 
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Table S2 shows formulation stability in terms of visible particle formation, changes in turbidity or color 
for both mAbs stored at 5°C or 25°C for 9 months. In CD/rHA formulations visible particles were also 
formed when stored at 5 or 25°C for 9 months. All other formulations remained stable in terms of 
visible particles or changes in color and turbidity.  
 
Table S2. Storage stability of lyophilisates. Visible particles, turbidity, and color after storage at 5 or 25°C for 
9 months. 
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Table S3 shows residual moisture levels of mAb2 formulations after storage at 25°C for 15 months 
revealing a small but consistent increase in residual moisture for CD-based formulations upon storage, 
whereas no increase in residual moisture was observed for pure sucrose formulations.  
 
Table S3. Residual moisture of mAb2 lyophilisates after storage at 25°C for 15 months given as mean (n=3) with 
standard deviation. 
Formulation 
Residual moisture (%) 
after freeze-drying after storage at 25°C 
Suc 4.0 ± 0.4 3.8 ± 0.45 
CD 0.2 ± 0.06 0.5 ± 0.01 
CD/PVP/Suc 0.2 ± 0.01 0.5 ± 0.01 
CD/Suchigh 0.1 ±0.01 0.4 ± 0.11 
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Figure S1 shows sub-visible particles formed in mAb1 and mAb2 lyophilisates during storage at 40°C. 
Considerable and consistent increase in sub-visible particles is shown for rHA containing formulations 
for both mAbs as well as brownish Suc formulations. Increased particle counts (≥ 2 µm) for mAb1 
formulations after 1 month and for mAb2 formulations after 3 and 6 months can be ascribed to the 
high measurement variability of light obscuration. 
 
a mAb1 mAb2 
  
  
 
Figure S1. Analysis of particulate matter by light obscuration. Cumulative sub-visible particle count  2 μm (top 
row) and  10 μm (bottom row) are shown for mAb1 (left panel) and mAb2 (right panel) after storage at a) 40°C, 
b) 25°C and c) 5°C. Red triangle shows sub-visible particles of brownish Suc samples. Dotted line indicates upper 
limit of detector. 
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b mAb1 mAb2 
  
  
 
Figure S1 (continued). Analysis of particulate matter by light obscuration. Cumulative sub-visible particle count 
 2 μm (top row) and  10 μm (bottom row) are shown for mAb1 (left panel) and mAb2 (right panel) after storage 
at a) 40°C, b) 25°C and c) 5°C. Red triangle shows sub-visible particles of brownish Suc samples. Dotted line 
indicates upper limit of detector.  
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c mAb1 mAb2 
  
  
 
Figure S1 (continued). Analysis of particulate matter by light obscuration. Cumulative sub-visible particle count 
 2 μm (top row) and  10 μm (bottom row) are shown for mAb1 (left panel) and mAb2 (right panel) after storage 
at a) 40°C, b) 25°C and c) 5°C. Red triangle shows sub-visible particles of brownish Suc samples. Dotted line 
indicates upper limit of detector.  
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Figure S2 shows structural characterization by X-ray powder diffraction of Suc formulations for mAb1 
after storage at 40°C for 9 months revealing crystallization of sucrose in lyophilisates that turned 
brownish upon storage. 
    
Figure S2. Representative X-ray diffractograms. X-ray diffraction signals of a) white and b) brownish mAb1 
lyophilisates formulated with 80 mg/mL sucrose after storage at 40°C for 9 months. 
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Figure S3 shows loss of monomer at different time points for mAb1 and mAb2 formulations after 
storage at 5°C. Formulations with Suc, CD, or PVP show no loss of monomer after 9 months at 5°C. In 
general, rHA and Dex containing formulations are less stable. Formulations with 40 mg/mL rHA or 40 
mg/mL Dex in a 1:1 ratio with CD show a decrease in monomer content by approximately 1% after 9 
months.  
 
Figure S3. mAb stability in lyophilisates by SE-HPLC. Loss of monomer of mAb1 (filled symbols) and mAb2 (open 
symbols) after storage at 5°C for formulations with a) Suc, b) CD, c) rHA, d) PVP, and e) Dex. 
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Figure S4 shows monomer loss of mAb2 in pure Suc for a conservatively freeze-dried formulation, i.e. 
non-collapsed lyophilisate. Samples collapsed less compared to the aggressive freeze-dried 
lyophilisates upon storage and revealed comparable monomer levels to “white” aggressively freeze-
dried lyophilisates. 
 
Figure S4. mAb stability in non-collapsed sucrose lyophilisates. Loss of mAb2 monomer in pure Suc formulations 
after storage at 25 and 40°C.  
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Figure S5 reveals mAb glycation in pure Suc formulations when stored at 40°C for 9 months. Glycation 
in brownish lyophilisates is twice that of white lyophilisates.  
 
Figure S5. Representative mass spectrogram of mAb1 formulated with sucrose. a) directly after freeze-drying 
and b) white lyophilisate or c) brownish lyophilisate after 9 months at 40°C. z = 27. 
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Figure S6 shows dynamic vapor sorption behavior for mAb2 lyophilisates. Changes in sorption behavior 
for CD-based formulations containing sucrose occurred at much higher moisture levels (approximately 
15%) compared to pure sucrose (approximately 6-7%), thus ware far above moisture levels relevant 
during long-term storage at 25°C.  
 
Figure S6. Water sorption isotherms for mAb2 lyophilisates. 
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Be aggressive! Amorphous excipients enabling 
single-step freeze-drying of monoclonal 
antibody formulations 
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Authors:  
Christina Haeuser, Pierre Goldbach, Joerg Huwyler, Wolfgang Friess, Andrea Allmendinger 
Abstract 
Short freeze-drying cycles for biopharmaceuticals are desirable. Formulations containing an 
amorphous disaccharide, such as sucrose, are prone to collapse upon aggressive primary drying at 
higher shelf temperature. We used 2-hydroxypropyl-betacyclodextrin (HPBCD) in combination with 
sucrose and polyvinylpyrrolidone (PVP) to develop an aggressive lyophilization cycle for low 
concentration monoclonal antibody (mAb) formulations. Glass transition temperature and collapse 
temperature of the formulations were determined and increasingly aggressive cycle parameters were 
applied. Using a shelf temperature of +30°C during primary drying, the concept of combining 
sublimation and desorption of water in a single drying step was investigated. Cake appearance was 
evaluated visually and by micro-computed tomography. Lyophilisates were further analyzed for 
reconstitution time, specific surface area, residual moisture, and glass transition temperature. We 
demonstrated the applicability of single-step freeze-drying, shortening the total cycle time by 50% and 
providing elegant lyophilisates for pure HPBCD and HPBCD/sucrose formulations. HPBCD/PVP/sucrose 
showed minor dents, while good mAb stability at 10 mg/mL was obtained for HPBCD/sucrose and 
HPBCD/PVP/sucrose when stored at 40°C for 3 months. We conclude that HPBCD-based formulations 
in combination with sucrose are highly attractive, enabling aggressive, single-step freeze-drying of low 
concentration mAb formulations, while maintaining elegant lyophilisates and ensuring protein stability 
at the same time. 
Be aggressive! Amorphous excipients enabling single-step freeze-drying of monoclonal antibody 
formulations 
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INTRODUCTION 
Freeze-drying is frequently used to manufacture drug products of proteins which are unstable as 
liquids. Proteins are generally more stable in the dried immobilized state as physical (e.g. aggregation) 
and chemical (e.g. hydrolysis) degradation mechanisms are slowed down. Although around 40% of all 
biopharmaceuticals are freeze-dried, liquid formulations are often preferred due to a significantly less 
complex manufacturing process [1, 2]. Freeze-drying is a time-consuming low throughput batch 
process which usually takes several days up to weeks [3], requires much energy and is ultimately costly. 
Freeze-drying consists of three process steps, i) freezing, ii) primary drying, where crystallized water is 
removed under vacuum by sublimation, and iii) secondary drying, where desorption of the bound 
water takes place. Primary drying is the most time consuming of the three steps. Hence, efforts to 
optimize the lyophilization cycle time often focus on the primary drying step. 
During primary drying it is important that the product temperature (Tp) stays below the critical 
formulation temperature to avoid collapse. Collapse may [4, 5] or may not [6, 7] be detrimental to the 
storage stability of monoclonal antibodies, but in any case is often considered as a defect of the drug 
product, which might lead to rejects during 100% visual inspection [8]. The collapse temperature (Tc) 
is typically 1-3°C above the glass transition temperature (Tg’) of the maximally freeze concentrated 
solution of an amorphous formulation. Disaccharides such as sucrose and trehalose, which are 
commonly used in freeze-dried antibody formulations [1], have low Tg’ and Tc values of around -28°C 
to -32°C [9]. This makes low pressure and shelf temperature (Ts) during primary drying necessary, 
resulting in long primary drying time.  
Efforts to shorten freeze-drying cycle time have re-gained attraction and different approaches are 
described in recent literature. For example microwave assisted freeze-drying enables much faster 
primary drying compared to conventional freeze-drying [10]. With regards to conventional freeze-
drying, it is well-known that increasing Tp significantly impacts cycle time, e.g. an increase of Tp by 1°C 
may shorten primary drying by 10% [3]. In this light, Colandene et al., Bjelosevic et al., and Depaz et al. 
successfully optimized primary drying by freeze-drying above Tg’ without introducing collapse [11-13]. 
However, this approach is only applicable for formulations with high protein concentrations or high 
protein to sugar ratios, as they show a Tc which is markedly higher compared to Tg’. Another approach 
is to change the formulation composition in order to obtain a higher critical formulation temperature. 
To this end, crystalline excipients can be included as bulking agents in combination with amorphous 
sucrose as stabilizer. Recent publications by Horn et al. and Pansare et al. showed that combinations 
of crystalline and amorphous excipients allow for aggressive freeze-drying of low concentration 
protein formulations, while maintaining elegant lyophilisates [14, 15]. The ideal ratio of crystalline and 
amorphous excipients has to be chosen carefully. Crystallization has to be assured which asks for less 
amorphous excipient content. Yet, the crystalline excipients insufficiently stabilizes the protein [16], 
which makes a higher amorphous stabilizer necessary. Additional technical problems can arise, e.g. an 
excessive mannitol content can lead to glass breakage during freeze-drying [17].  
Little literature is available on the use of alternative amorphous excipients, such as polysaccharides or 
polymers, for aggressive cycle development. With their high Tg’ and Tc as well as potentially protein 
stabilizing properties due to their amorphous state, such excipients could enable aggressive, short 
freeze-drying cycles. Larsen et al. recently investigated dextrans, polysaccharides with a Tg’ of -21°C up 
to -9°C depending on their molecular weight, for freeze-drying of lactate dehydrogenase. The dextrans 
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enabled much faster primary drying and provided elegant lyophilisates with good protein stability [18]. 
In contrast, we found that dextrans were inferior stabilizers for mAbs compared to sucrose [19]. 
Another excipient of interest is 2-hydroxyproyl-betacyclodextrin (HPBCD), which has a Tg’ similar to 
dextan 40 kDa [20], and a Tc of -9 to -6.5°C [21]. It can be found in approved small molecule parenterals. 
Furthermore, the use of HPBCD to stabilize proteins in the dried state is described in literature [22]. 
HPBCD was able to stabilize an antibody during freeze-drying and supercritical fluid drying comparable 
to trehalose at protein to sugar ratios of 1:4 (w/w) [23, 24]. Additionally, HPBCD could provide protein 
stability during storage at elevated temperatures superior to sucrose [25, 26]. The high Tg’ and the 
protein stabilizing properties of HPBCD might allow for a high Tp during primary drying while resulting 
in elegant lyophilisates. To the best of our knowledge, so far no studies on freeze-drying cycle 
optimization for HPBD-based mAb formulations are available. 
This study aimed to shorten the lyophilization cycle time by using aggressive primary drying conditions 
for HPBCD-based low concentration mAb formulations (10 mg/mL) containing either pure HPBCD, or 
combinations with sucrose and polyvinylpyrrolidone (PVP) as excipients, which have all been shown to 
render amorphous lyophilisates [27-30]. For a comprehensive study, 50 mg/mL mAb formulations 
were included as well. The critical formulation temperatures, Tg’ and Tc, were determined and the 
formulations were freeze-dried with increasingly more aggressive process conditions. Shelf 
temperatures typically applied for secondary drying were used during primary drying and the 
hypothesis whether this might enable combining sublimation and desorption of water in one single 
drying step was tested. The lyophilisates were characterized with regards to cake appearance and 
structure, reconstitution time, specific surface area, residual moisture, and glass transition 
temperature of the freeze-dried formulation (Tg), as well as protein stability upon freeze-drying and 
after storage and compared to a conservatively freeze-dried reference formulation with pure sucrose. 
MATERIALS AND METHODS 
Materials 
A F. Hoffmann-La Roche proprietary monoclonal antibody (IgG1, pI ~8.2, 149 kDa) was used at 
10 mg/mL (low concentration) and 50 mg/mL (high concentration) in 20 mM histidine/histidine-HCl 
buffer pH 6.0 (Ajinomoto, Tokyo, Japan) with 0.02% polysorbate 20 (Croda International, Snaith, UK). 
Formulations (F) were prepared with different excipient concentrations (s. Table S1): FS contained 
80 mg/mL sucrose (Ferro Pfanstiehl Company, Mayfield Heights, Ohio), FCD 80 mg/mL 2-hydroxypropyl-
betacyclodextrin (HPBCD, Roquette, Beinheim, France), FCD/S 56 mg/mL HPBCD and 24 mg/mL sucrose, 
and FCD/P/S 39.2 mg/mL HPBCD, 16.8 mg/mL polyvinylpyrrolidone K17 (PVP, BASF, Ludwigshafen, 
Germany), and 24 mg/mL sucrose. Prior to filling, the formulations were filtered through a 0.22 µm 
PVDF sterile filter unit (Millipore, Bedford, MA, USA). 3.2 mL per formulation were filled into 6 mL 
TopLyo® vials (Schott, Müllheim, Germany) and partially stoppered with 20 mm Lyo-stoppers D777-1 
(DAIKYO Seiko Ltd., Tokyo, Japan). 
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Freeze-drying 
Freeze-drying was performed using a FTS Lyostar II (FTS Systems Inc., Stone Ridge, NY). Each freeze-
drying cycle was performed with one shelf fully loaded. The vials containing the different formulations 
were distributed randomly over the shelf. To reduce the impact of edge effects on the results, edge 
vials were excluded from further evaluation. Overall, six different freeze-drying cycles were employed 
with varying primary and secondary drying conditions as shown in Table 1. Product temperature was 
determined by three thermocouples in center vials. Chamber pressure (pc) was monitored using a 
Pirani and a capacitance probe. Cycle 0 (C0) represented a typical conservative freeze-drying cycle and 
was only performed for FS. Formulations FCD, FCD/S, and FCD/P/S at 10 mg/mL mAb were freeze-dried with 
cycles C1 to C5. FS was freeze-dried with C0 and with C1. C1 and C5 were employed for the 50 mg/mL 
mAb formulations. At the end of freeze-drying, vials were stoppered at 760 mbar under Nitrogen and 
sealed with aluminum crimp-caps after unloading. 
Table 1. Overview of process parameters of the different freeze-drying cycles employed. All cycles had a loading 
step of 60 min at 5°C prior to freezing. End of primary drying time was determined as ∆pc ≤ 1 mTorr between 
Pirani and capacitance probe. 
 
Cycle # 
 
Freezing 
Primary drying Secondary Drying 
Ramp 
(°C/min) 
Ts 
(°C) 
pc 
(mTorr) 
Ramp 
(°C/min) 
Ts 
(°C) 
Hold time 
(min) 
Pressure 
(mTorr) 
0 (Reference) Ramp 
0.3°C/min 
Temp. 
-35°C 
Hold 
180 min 
0.2 -10 100 0.2 +25 360 100 
1 0.2 +10 100 0.2 +25 360 100 
2 0.2 +30 100 0.2 +40 360 100 
3 1.0 +30 100 0.2 +40 360 100 
4 0.2 +30 155 0.2 +40 360 155 
5 0.2 +30 100 - 
Ts: shelf temperature, pc: chamber pressure 
 
Differential scanning calorimetry 
Tg’ and Tg were determined by differential scanning calorimetry according to Haeuser et al. [26]. 
Measurements were performed using a Tzero DSC Q2000 instrument (TA instruments Inc., New Castle, 
Delaware). Tg’ and Tg were determined in triplicates and reported as mean (Tg’, standard deviation 
<0.2°C) and as mean with standard deviation (Tg). 
Freeze-drying microscopy 
Freeze-drying microscopy (FDM) was used to determine Tc as the temperature of the onset of collapse. 
Measurements were performed according to Haeuser et al. using a Linkam FDC196 freeze-drying stage 
(Linkam Scientific, Instruments, Surrey, UK) and a Zeiss Axio Imager.A1 microscope (Carl Zeiss 
MicroImaging, Göttingn, Germany) at 20-fold magnification [19]. 
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Visual cake appearance  
Cake appearance of lyophilisates was evaluated by visual inspection. Representative pictures were 
taken using a camera in front of a black background. 
Micro-computed tomography  
Micro-computed tomography (µ-CT) was performed using an evolved version of the methodology 
introduced previously [31]. The lyophilisates were analyzed without any further sample preparation 
though the glass vial with a SkyScan 1272 X-Ray microtomograph (Bruker MicroCT, Kontich, Belgium). 
Scans were acquired using an acceleration voltage of 40 kV and a beam current of 250 µA. To ensure 
monochromatic X-rays with enough energy to pass through the glass vial, a 0.5 mm AI filter was 
applied. The vial was rotated over 360° with a step size of 0.1°. An exposure time of 2388 ms with 10 
averages per projection was applied. Projections were reconstructed using the NRecon software 
(Bruker, Kontich, Belgium) to obtain an image stack of tomographs. 
Reconstitution time  
For reconstitution, 3.0 mL or 2.9 mL of water for injection were added to the 10 mg/mL and 50 mg/mL 
mAb formulations, respectively, using a 5 mL disposable syringe equipped with a 21 G needle. 
Reconstitution time was determined in triplicates as described previously and reported as mean with 
standard deviation [19]. 
Specific surface area 
Specific surface area was determined in triplicates according to Brunauer-Emmett-Teller (BET) using 
the Quadrasorb evo surface are and pore size analyzer (Quantachrome, Odelzhausen, Germany) with 
Krypton as adsorbate. Analysis was performed in a 9 mm bulb sample cell filled with at least 100 mg 
lyophilisate. Prior to analysis, the samples were degassed overnight under vacuum at 40°C and overlaid 
with Nitrogen. Krypton adsorption was determined for nine measuring points at 77 K over a pressure 
range of 0.05 to 0.25 mbar. Specific surface area was determined by fitting the data points using the 
BET equation and reported as mean with standard deviation. 
Residual moisture 
Residual moisture was determined in triplicates according to Haeuser et al. using a C30 Coulometric 
Karl Fischer titrator (Mettler Toledo, Greifensee, Switzerland). Residual moisture was reported as 
mean with standard deviation [19]. 
Size-exclusion chromatography  
Stability of the mAb was analyzed by size-exclusion high-performance liquid chromatography (SE-
HPLC) using an Alliance e2695 HPLC instrument (Waters Corporation, Milford, MA) equipped with a 
2487 UV/visible detector (Waters Corporation). Samples were held at 5°C and the column temperature 
was set to 25°C. 50 mg/mL mAb formulations were diluted to 10 mg/mL with formulation buffer, 
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10 mg/mL mAb formulations were analyzed without further preparation. 10 µL of the sample were 
injected on a TSKG3000SWxl, 7.8×300 mm column (Tosoh Bioscience, Stuttgart, Germany) and eluted 
over 30 min with a 0.2 M K2HPO4/KH2O4 and 0.25 M KCl of pH 6.2. Signal was detected as UV 
absorbance at 280 nm. Data processing was done using the Empower 3 Chromatography Data System 
software (Waters Corporation) and monomer content was reported as percentage of total peak area. 
RESULTS 
Thermal properties of the liquid formulations 
To assess the critical Tp, Tg’ and Tc were determined for 10 mg/mL and 50 mg/mL mAb formulations 
(Table 2). The low concentration reference formulation (Fs) had a much lower Tg’ of -29.5°C compared 
to the other formulations. Similar Tg’ values were obtained for FCD/P/S (-19.2°C) and FCD/S (-18.6°C), which 
were both more than 10°C above the Tg’ of Fs. The highest Tg’ values among all formulations were 
obtained for pure HPBCD formulations with -10.9°C and -8.3°C for 10 mg/mL and 50 mg/mL mAb, 
respectively. In contrast to the other formulations where Tc was slightly above Tg’, FS had a Tc of -31.0°C, 
which was slightly lower than its Tg’. Generally, formulations with 50 mg/mL mAb showed markedly 
higher Tg’ and Tc values compared to 10 mg/mL mAb formulations. The impact of protein concentration 
on Tg’ was more pronounced the lower the Tg’ of the formulations compared to each other. This means 
that the Tg’ of FS increased by 4.1°C from -29.5 to -25.4°C when increasing the mAb concentration from 
10 mg/mL to 50 mg/mL compared to an increase of only 2.6°C for FCD for example. In addition, for FCD, 
FCD/P/S, and FCD/S with 50 mg/mL mAb, the difference between Tg’ and Tc was at least twice that of 10 
mg/mL mAb formulations. For instance, at low mAb concentration, Tc of FCD/P/S was 0.7°C and for high 
mAb concentrations 1.9°C above the Tg’. 
Table 2. Critical formulation temperatures. Glass transition temperature (Tg’) and onset of collapse temperature 
(Tc) of the liquid formulations.   
Formulation 
mAb concentration 
(mg/mL) 
Tg’ (C°) Tc (°C) 
FS 
10 -29.5 -31.0 
50 -25.4 -20.4 
FCD 
10 -10.9 -10.1 
50 -8.3 -6.3 
FCD/P/S 
10 -19.2 -18.5 
50 -16.5 -14.6 
FCD/S 
10 -18.6 -16.0 
50 -15.2 -10.9 
 
Impact of freeze-drying parameters on Tp and primary drying time  
As reference, a conservative freeze-drying cycle (C0), typically used for sucrose-based formulations, 
with pc = 100 mTorr and Ts = -10°C during primary drying was performed for FS. Freeze-drying with C0 
resulted in a Tp in the steady state of primary drying of ~-32°C and a primary drying time of ~35 h with 
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50.5 h total cycle time (Figure 1a). As a start, Ts during primary drying was increased to +10°C (C1), 
showing a much shorter steady state during primary drying with a mean Tp of ~-21°C, as shown in 
Figure 1b. Primary drying time, i.e. total cycle time, was shortened by 6 h, corresponding to a reduction 
of 12%. To further shorten the freeze-drying cycle time, FCD, FCD/P/S, and FCD/S were lyophilized with a Ts 
during primary drying of +30°C and a Ts of +40°C during secondary drying (C2). Figure 1c shows that 
increasing Ts from +10°C to +30°C resulted in a freeze-drying cycle with a very short steady state phase 
at a Tp of ~-20°C. Ultimately, primary drying time was reduced to ~19 h. Using a low ramp rate 
(0.2°C/min) from freezing to primary drying and the high temperature difference of 65°C to overcome, 
the ramping step contributed with ~17% markedly to the total cycle time of 32.2 h. Hence, C3 was 
performed using a ramp rate from freezing to primary drying of 1°C/min. Consequently, primary drying 
time was reduced by another 2 h and showed a slightly more pronounced steady sublimation phase 
compared to C2 (Figure 1d). Another approach to accelerate primary drying is to increase the pressure. 
To this end, primary and secondary drying in C4 were performed at a pc of 155 mTorr (Figure 1e). 
Increasing pc did only slightly increase Tp to ~-19.0°C, but did not result in a shorter primary drying 
phase compared to C2. The aggressive lyophilization cycles C2-C4 showed no increase in the Pirani 
signal (Figure 1c-e) during secondary drying, indicating that the desorption phase was already finished 
at the end of primary drying. Hence, a final single-step freeze-drying cycle was used without a 
secondary drying step, leading to a total cycle time of ~25 h (Figure 1f). This resulted in a 50% reduction 
of total cycle time compared to the conservative cycle. Highly concentrated mAb formulations were 
freeze-dried using only two cycles, the initial C1 and the final C5. In general, Tp in the steady state 
during primary drying was slightly higher compared to 10 mg/mL mAb formulations, with a Tp of ~-20°C 
compared to ~-21°C during C1 and a Tp of ~-17°C compared to ~-20°C during C5. Consequently, primary 
drying was completed earlier, i.e. after 24 h for C1 and after 17 h for C5 (Figure 1g-h). 
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Figure 1. Freeze-drying cycles. Process monitoring data of a-f) 10 mg/mL mAb formulations and of g-h) 50 mg/mL 
mAb formulations. a) shows the conservative cycle (C0), b) and g) C1, c) C2, d) C3, e) C4 and f) and h) C5. The 
arrow indicates end of primary drying. Ts = shelf temperature; Tp = product temperature determined by 
thermocouples. 
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Cake appearance and structure 
Cake appearance was investigated visually as well as by µ-CT to obtain a comprehensive evaluation of 
the structure. In preliminary experiments, better, less brittle or cracked cake appearance was obtained 
for all formulations when freeze-dried in TopLyo® vials compared to Fiolax® vials. Therefore, only 
TopLyo® vials were used for all experiments. FS with 10 mg/mL mAb showed major dents when freeze-
dried with the reference cycle (C0) (Figure 2a and Figure 3). The increase of Ts during primary drying to 
+10°C resulted in collapse (Figure 2a). µ-CT images of the internal structure revealed a total loss of 
cake structure in the upper half of the lyophilisate (Figure 3). FCD, FCD/P/S, and FCD/S at 10 mg/mL mAb 
resulted in elegant lyophilisates throughout all lyophilization cycles C1-C5, with only minor dents at 
the bottom of the vial for FCD/P/S as shown in Figure 2b. These dents were slightly more pronounced in 
C4. Differences in the internal cake structure between the formulations were detected by µ-CT. Pure 
HPBCD formulations rendered homogenous cakes. Some cracks formed in FCD/S and FCD/P/S formulations 
(Figure 4).  
At 50 mg/mL mAb FS resulted in pharmaceutically elegant lyophilisates (Figure 2) with internal cracks, 
as shown in (Figure 3), when freeze-dried with C1. At more aggressive conditions with a Ts of +30°C 
(C5), major dents were observed by visual inspection (Figure 2) and µ-CT revealed a collapsed internal 
cake structure in the upper half of the lyophilisate. FCD, FCD/P/S, and FCD/S at high mAb concentration 
resulted in visually elegant lyophilisates for both cycles C1 and C5. Interestingly, the internal cake 
structure of FCD at 50 mg/ml mAb was different compared to the 10 mg/mL mAb formulation. At higher 
mAb concentration, the cake showed a large lamellar like structure in the middle-bottom region and a 
smaller spherical structure, similar to 10 mg/mL formulations, in the upper half of the lyophilisate 
(Figure 4). To elucidate on the root cause of this observation was beyond the scope of this study. 
 
 
Figure 2. Cake appearance. Representative lyophilisates for 10 mg/mL formulations (upper row) and 50 mg/mL 
formulations (lower row). a) different cake appearances for FS depending on freeze-drying cycle and b) cake 
appearance obtained for FCD, FCD/S, and FCD/P/S exemplarily shown for C5. 
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Figure 3. Internal cake structure of FS. Representative µ-CT images for 10 mg/mL and 50 mg/mL formulations 
freeze-dried with different lyophilization cycles. 
 
 
Figure 4. Internal cake structure. Representative µ-CT images for 10 mg/mL and 50 mg/mL formulations freeze-
dried with C5 showing a) internal cake structure through a vertical cross section of FCD, FCD/S, and FCD/P/S and b) 
cake structure at the bottom of the vial through a horizontal cross section of FCD/P/S. 
Other product quality attributes 
Other important product quality attributes to study when optimizing lyophilization processes are 
reconstitution time, specific surface area, residual moisture, and Tg. All 10 mg/mL mAb formulations 
reconstituted fast (< 60 sec) without an effect of the lyophilization cycle employed (Figure S1a). For 
50 mg/mL mAb formulations, reconstitution was generally slower and took at least twice as long. 
Reconstitution of FS at 50 mg/mL mAb took the longest with ~80 sec compared to FCD, FCD/P/S, and FCD/S, 
independent of the cycle (Figure S1b). In general, no major differences were found in specific surface 
area for the different excipient combinations and freeze-drying cycles employed for both 10 mg/mL 
and 50 mg/mL formulations. (Figure S2). Only FS with 10 mg/mL mAb showed a markedly lower specific 
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surface area when freeze-dried with C1 compared to C0, indicating collapse. More pronounced 
differences were observed for the residual moisture as shown in Figure 5. For 10 mg/mL mAb 
formulations (Figure 5a), residual moisture of FCD, FCD/P/S, FCD/S was less than 0.5%, with marginal 
differences amongst the different formulations. In contrast, FS had a residual moisture of 1.2% when 
freeze-dried with the conservative cycle C0. When freeze-dried with the more aggressive cycle C1, 
residual moisture levels increased to 4.1%. For C2 to C4 (or C1 for 50 mg/mL mAb formulations), some 
vials were stoppered at the end of primary drying to evaluate the remaining moisture content at the 
end of primary drying. Residual moisture of these stoppered samples varied more between the 
different formulations but without a clear trend. Products from C3 showed the least variation in 
residual moisture at the end of primary drying. Overall, already after primary drying residual moisture 
was below 0.5%, supporting the observations for the Pirani signal (Figure 1c-e). 
Residual moisture of FS with 50 mg/mL mAb was generally higher compared to FCD, FCD/P/S, and FCD/S 
(Figure 5b). C1 resulted in a residual moisture for FS of 0.64%, while freeze-drying with C5 led to a 
residual moisture of 1.1%. FCD, FCD/P/S, and FCD/S with 50 mg/ml mAb showed low residual moisture levels 
of ~0.2%, identical for C1 and C5 and similar to the values for the 10 mg/ml mAb formulations. 
   
Figure 5. Residual moisture and Tg. Data is given for a) 10 mg/mL mAb formulations and b) 50 mg/mL mAb 
formulations for different formulations and freeze-drying cycle conditions. Residual moisture levels are shown 
as bars and lines. Lines show residual moisture level of vials stoppered after primary drying. Squares show Tg 
values of the lyophilisates. Values are means (n=3) ± standard deviation. 
The varying residual moisture levels of 10 mg/mL FS when freeze-dried with different cycles were 
reflected in different Tg values. While C0 resulted in lyophilisates with a Tg of 65°C, the Tg of the 
collapsed FS was considerably lower with 43.2°C. Tg values of FCD, FCD/P/S, and FCD/S were much higher 
than compared to FS and were comparable for all cycles employed. Tg of FCD/P/S and FCD/S showed a 
similar Tg at ~150°C, while FCD had a Tg of ~200°C. Corresponding to the Tg’ of the liquid formulations, 
Tg was generally higher for 50 mg/mL mAb formulations with differences in Tg for FS when freeze-dried 
with C1 or C5. 
Protein stability 
Protein stability was investigated as remaining monomer content by SE-HPLC directly after freeze-
drying as well as after storage at 40°C for 3 months (Figure 6). All formulations demonstrated sufficient 
cryo- and lyoprotection for both mAb concentrations, independent of the freeze-drying cycle 
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employed. Good storage stability was obtained for the 10 mg/mL mAb FS reference formulation after 
storage at 40°C for 3 months when freeze-dried with the conservative as well as the more aggressive 
cycle C1. Stability of FCD, FCD/P/S, and FCD/S at 10 mg/mL mAb was comparable to FS. FS, FCD/S, and FCD/P/S 
showed a marginally but consistent decrease in monomer content of 0.1-0.2% after storage (Figure 
4a), which went along with an increase in high molecular weight species (data not shown). FCD 
lyophilisates were less stable during storage (~1.5% loss of monomer) throughout all freeze-drying 
cycles. While 50 mg/mL mAb formulations also demonstrated good protein stability during freeze-
drying, they generally showed a higher loss of monomer during storage. A 1% decrease in monomer 
content was observed for Fs after storage for both freeze-drying cycles. The remaining monomer 
content after storage was much lower for FCD with levels of 80.7% and 84.3% for C1 and C5, 
respectively. Better and similar mAb stability was obtained for FCD/S and FCD/P/S, with a loss of monomer 
content of 4.1% for C1 and 2.7% for C5. Interestingly, for FCD, FCD/S, and FCD/P/S with 50 mg/mL mAb 
stability was generally slightly improved when lyophilized with C5 compared to C1. 
    
 
Figure 6. Protein stability by SE-HPLC. Percentage of remaining monomer for a) 10 mg/mL mAb formulations and 
b) 50 mg/mL mAb for different formulations and freeze-drying cycle conditions. Bars without pattern show 
monomer content directly after freeze-drying and bars with pattern show monomer content after storage at 
40°C for 3 months. Lines show the monomer content of the liquid formulation prior to freeze-drying. 
In an additional experiment, we investigated whether the aggressive freeze-drying cycle that we used 
might result in so-called overdrying of the mAb (i.e. ~0.2% residual moisture). Therefore, defined 
residual moisture levels were prepared for 10 mg/mL formulations by spiking of the lyophilisates with 
water droplets. Residual moisture dependent protein stability was subsequently investigated. Our data 
in Figure S3 shows similar protein stability for lyophilisates with a residual moisture of 0.2%, 0.5%, 1%, 
or 2% after 3 months at 40°C. 
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DISCUSSION 
The aim of this study was to develop an aggressive, thus short freeze-drying cycle for amorphous 
formulations with a higher Tg’ and Tc compared to pure sucrose that results in elegant cakes, low 
residual moisture levels, fast reconstitution time, and has no negative impact on protein stability. A 
sucrose-based formulation was included for reference purpose to i) compare cycle time and product 
quality attributes with traditional sucrose-based formulations and ii) demonstrate the limits of pure 
sucrose with regards to shortening freeze-drying. 
Correlation between Tg’, Tc, Tp, and cake appearance 
In a first step during formulation and freeze-drying cycle development, it is essential to determine Tg’ 
and Tc of the liquid formulation, as they are indicative for the Tp which should not be exceeded during 
primary drying to avoid collapse. Tc is commonly considered to be the more accurate predictor and is 
typically few degrees above Tg’ [32, 33]. For formulations with low protein concentrations, Tg’ and Tc 
may be used interchangeable. In fact, in our study Tc of FS was even slightly lower than the Tg’. This is 
consistent with data previously reported by Colandene et al. for sucrose-based 10 mg/mL protein 
formulations [11]. At higher protein concentrations, Tc is markedly higher than Tg’ and the difference 
(ΔT) increases with higher protein concentration. For a 50 mg/mL mAb formulation with 7-8% 
disaccharide, a ΔT of 5°C was reported and Depaz et al. found a Tc 14°C above the Tg’ for a 100 mg/mL 
mAb formulation [13, 15]. This is in line with our results of a ΔT of 5°C for the 50 mg/mL pure sucrose 
formulation. For formulations containing excipients which have a high Tg’ themselves, the effect of 
protein concentration on ΔT is less pronounced. For FCD/S and FCD/P/S both 10 mg/mL formulations 
showed very similar Tg’ values, but their Tc differed by 2.6°C. This directly translated into different cake 
appearance when freeze-dried with the same cycles with Tp close to Tg’ (C1-C5). Tc depends on several 
factors such as the solid concentration as well as sublimation rate. Thus collapse in the vial might occur 
at slightly higher temperatures during freeze-drying than the Tc determined by FDM [33]. Greco et al. 
used optical coherence tomography to determine Tc of a 5% sucrose solution in the vial during freeze-
drying and found it to be 3°C above that temperature determined by FDM [34]. This is in line with the 
cake appearance observed in our study. Fs at low protein concentration showed major dents when 
freeze-dried with the conservative lyophilization cycle, where Tp was close to Tc. Collapse occurred only 
when Tp was much higher than Tc, as it was the case for C1. In addition, our data suggests that Tp should 
ideally be at least 4°C below Tc in order to result in a throughout elegant lyophilisate. If the difference 
between Tc and Tp was less than 3°C, minor dents were introduced. In terms of internal cake structure, 
µ-CT analysis showed minor cracks in most lyophilisates independent of the cycle employed. Patel et 
al. suggested that cracks should not be considered cake defects as they are only process artefacts 
which are not detrimental to product quality [8]. In fact, internal cracks have been found to be a result 
of relieved stress during secondary drying, when unfrozen water is removed [35, 36]. Lam et al. 
suggested that the formation of splitted cakes might be linked to a complex interplay of events 
occurring during the freezing step. They also reported that the occurrence of cracks is highly variable, 
and observed that cracks can be present in lyophilisates that look pharmaceutically elegant from the 
outside [37], in line with our observations. More important are internal defects such as partial collapse, 
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which was revealed by µ-CT for e.g. 50 mg/mL FS when freeze-dried with C5. This highlighted in addition 
that the dents observed by visual inspection were truly correlated to the onset of collapse. 
Impact of process parameters 
It is well established that an increase of Ts during primary drying reduces cycle time [3]. 
Correspondingly, as we increased Ts during primary drying from -10°C to ultimately +30°C, we 
substantially shortened primary drying by 48%. Additional elimination of secondary drying shortened 
the overall cycle time by in total 50%. Although both increases in Ts, from -10°C to +10°C (C1) and from 
+10°C to +30°C (C2), strongly impacted process time, the latter only marginally increased Tp. Similar to 
our results, Depaz et al. reported that increasing Ts from -30°C to 0°C resulted in a marked increase of 
Tp for a 25 mg/mL mAb formulation, and led to a brief steady sublimation phase, whereas a further 
increase of Ts to +15°C further shortened the steady sublimation phase without impacting Tp [13]. In 
addition, aggressive primary drying temperatures resulted in a steeper drop of the Pirani signal. A fast 
drop of the Pirani signal implies a homogenously dried batch [38], which is desirable, in particular if 
aiming to omit secondary drying. Greater batch homogeneity was additionally demonstrated by 
smaller variations within the temperature probes for aggressive lyophilization conditions. When 
aiming for aggressive freeze-drying cycles at high Ts, the ramping step contributes markedly to the total 
cycle time. Typically, ramp rates of less than 1.0°C/min are applied, but faster ramp rates of e.g. 
1°C/min are also suitable. Horn et al. found no negative impact when increasing the ramp rate into 
primary drying from 0.5°C to 1°C/min [14]. Ohio et al. demonstrated that faster ramp rates might result 
in even better cake appearance for high Ts conditions during primary drying compared to very slow 
ramp rates [39, 40]. In contrast, Pansare et al. reported more pronounced shrinkage for lyophilisates 
that were freeze-dried using a ramp rate of 0.5°C/min compared to 0.1°C/min [15]. In the present 
study, although product quality attributes like residual moisture, specific surface area, reconstitution 
time, and qualitative internal cake structure did not show any differences for C3 compared to C2, we 
visually observed some lifted cakes after freeze-drying. However, the time point when lifting occurred 
remained unknown. In the light of these observations and a potential gain of only 2 h in overall cycle 
time, we decided to stick with the low ramp rates for the following cycles C4 and C5. In general, 
selection of the optimal pc is a balance between batch homogeneity and prevention of collapse or 
meltback [3, 41]. Previous studies demonstrated an increase of pc to be advantageous for shorter 
freeze-drying cycles, leading to higher Tp and thus shorter cycle times [14]. However, in the present 
study, although Tp was slightly higher in C4 compared to C2, no impact on primary drying time was 
observed when using a pressure of 155 mTorr compared to 100 mTorr. At 155 mTorr, Tp showed a 
slight drop after a short steady state (C4) prior to its increase. It has been speculated that this might 
be indicative for micro-collapse [13, 15]. For all aggressive cycles (C2-C4), the Pirani signal indicated 
end of overall drying, i.e. sublimation and desorption, already at the end of primary drying. Finally, FS, 
FCD/P/S, and FCD/S allowed for a single-step freeze-drying, resulting in comparable product quality 
attributes to a conservative cycle. Pansare et al. also applied a single step freeze-drying for amorphous 
formulations, but their disaccharide-based formulations resulted in product shrinkage and partial 
collapse for formulations with 25 mg/mL or less protein and minor shrinkage at 50 mg/mL. Addition of 
a crystalline excipient was necessary to obtain elegant lyophilisates, which however led to slightly 
higher aggregation rates compared to purely amorphous formulations during storage [15]. 
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Protein stability 
When optimizing freeze-drying processes, it is of utmost importance to ensure protein stability. In our 
study, no negative impact of the process parameters on protein stability, including Ts of +30 °C during 
primary drying and +40 °C during secondary drying was observed for any formulation, which is in line 
with previous studies [13-15]. Tang and Pikal reported that dried protein formulations will not undergo 
denaturation at temperatures up to 100°C for short periods [3]. In terms of storage stability, collapse 
is often of concern as it may result in higher residual moisture and lower Tg. Various studies report that 
collapse itself did not reduce protein stability during storage [6, 7]. On the contrary, Lueckel et al. 
demonstrated that collapse resulted in increased aggregation of an IL-6 lyophilisate in a 
sucrose/glycine formulation after storage [5]. Correspondingly, Passot et al. reported 25% loss of 
activity for lyophilized toxins in a PVP/sucrose or PVP/mannitol matrix after 6 months of storage, when 
freeze-dried with a Tp above Tg’ during primary drying [4]. The results of the present study showed 
good and comparable storage stability for FCD/P/S and FCD/S. Collapse did not impact protein stability of 
FS when stored at 40° for 3 months. However, we previously found substantial protein degradation for 
a collapsed 10 mg/mL sucrose-based formulation when stored at 40°C for 6 months or longer [26]. 
At 50 mg/mL mAb, all formulations showed a higher loss of monomer compared to the 10 mg/mL 
formulation after 3 months at 40°C. The increase in aggregates was more pronounced for FCD/S, FCDP//S, 
and FCD compared to Fs. Within this study the excipient solid content was kept constant at 80 mg/mL 
for both low and high mAb concentrations. Thus, for the 50 mg/mL mAb formulations the excipient to 
protein ratio was too low to adequately protect the protein. Similarly, Lewis et al. reported good mAb 
stability when formulated at 5 mg/mL but observed protein aggregation at 20 mg/mL in 25 mg/mL 
sucrose lyophilisates [42]. Their excipient to protein ratios of 4:1 and 1.2:1 (w/w) are close to our 7:1 
and 1.6:1 ratio for 10 mg/mL and 50 mg/mL mAb. Cleland et al. reported that a molar excipient to 
protein ratio of at least 360:1 is necessary in order to ensure good protein stability at 40°C for 3 months 
[43]. This ratio was easily exceeded for the 10 mg/ml mAb formulations in our study. For the 50 mg/mL 
mAb formulations, only FS (695:1) was at this level, whereas FCD/S, FCDP//S, and FCD reflected ratios of only 
290:1, 321:1, and 163:1, respectively. Interestingly, we achieved a better storage stability for 
50 mg/mL mAb formulations freeze-dried with C5 compared to C1, although no differences were 
observed in the physico-chemical product quality attributes. To elucidate the influence of excipient to 
protein ratio and process parameters on formulations with a mAb concentration above 50 mg/ml was 
beyond the scope of the present study. 
In summary, a binary combination of HPBCD and sucrose at a 7:3 ratio (w/w) provides a highly 
attractive amorphous formulation. This formulation allows for a 50% cycle time reduction compared 
to the conventional reference cycle through single-step freeze-drying of low concentration 
biopharmaceuticals, resulting in elegant lyophilisates with short reconstitution times, low residual 
moisture, high Tg, and good protein stability during storage. Moreover, the actual effect on cycle time 
might be even more pronounced as the reference cycle with sucrose formulations at a mAb 
concentration of 10 mg/mL would require even lower primary drying in order to eliminate dents. 
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CONCLUSION 
Within the present study we demonstrated that scientists can be very aggressive during freeze-drying, 
using HPBCD-based formulations in combination with sucrose or PVP/sucrose. We were able to reduce 
cycle time by 50%, obtaining pharmaceutical elegant lyophilisates for pure HPBCD and HPBCD/sucrose, 
while HPBCD/PVP/sucrose showed minor dents. All other product quality attributes were similar, 
acceptable, and comparable to the conservatively freeze-dried sucrose formulation. Protein stability 
was ensured for all formulations upon freeze-drying and combinations of HPBCD/sucrose and 
HPBCD/PVP/sucrose at 10 mg/mL mAb provided good stability during storage at 40°C for 3 months. We 
believe that the proposed excipient combinations can be applied for higher concentrated protein 
formulations as well by adjustment of excipient to protein ratio. We conclude that the proposed single-
step freeze-drying cycle using a binary mixture of HPBCD/sucrose has the potential to significantly 
reduce costs of goods due to more efficient freeze-drying, while maintaining elegant lyophilisates and 
ensuring protein stability. 
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SUPPORTING INFORMATION 
Table S1 shows the composition of the different formulations. FS served as reference formulation 
throughout this study.  
Table S1. Formulation composition. All formulations were prepared in 20 mM histidine/histidine-HCl buffer pH 
6.0 containing 0.02% polysorbate 20. 
Formulation 
mAb 
(mg/mL) 
Sucrose 
(mg/mL) 
HPBCD 
 (mg/mL) 
PVP 
(mg/mL) 
FS 
10 
50 
80 - - 
FCD 
10 
50 
80 - - 
FCD/P/S 
10 
50 
24 39.2 16.8 
FCD/S 
10 
50 
24 56 - 
HPBCD: 2-hydroxypropylbetacyclodextrin 
PVP: Polyvinylpyrrolidone 
 
Figure S1 shows the reconstitution times of 10 mg/mL and 50 mg/mL mAb formulations freeze-dried 
with different cycle parameters. For 10 mg/mL mAb formulations reconstitution times were 
comparable for all formulations and cycle conditions. Reconstitution of 50 mg/mL mAb formulations 
took generally longer and reconstitution of FS took around 80 seconds (sec) longer compared to FCD, 
FCD/P/S, and FCD/S, independent of the cycle employed. 
 
Figure S1. Reconstitution time of lyophilisates. a) 10 mg/mL mAb formulations and b) 50 mg/mL mAb 
formulations freeze-dried with different cycles. 
 
 
Figure S2 shows the specific surface areas of 10 mg/mL and 50 mg/mL mAb formulations freeze-dried 
with different cycle parameters. In general, FS showed a slightly lower specific surface area compared 
to FCD, FCD/P/S, and FCD/S. In addition, FS at 10 mg/mL mAb, when freeze-dried with C1 had a lower specfic 
surface area, which is indicative for the collapsed lyophilisate.  
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Figure S2. Specific surface area of lyophilisates. a) 10 mg/mL mAb formulations and b) 50 mg/mL mAb 
formulations freeze-dried with different cycles.   
 
Figure S3 shows mAb stability after 3 months 40°C of 10 mg/mL lyophilisates that were spiked to 
different residual moisture levels to investigate whether very low residual moisture levels might be 
detrimental to mAb stability during storage. Stability was not affected in a moisture level range 
between 0.2% and 2%.  
 
Figure S3. Protein stability dependent on residual moisture (in %). Monomer content by SE-HPLC is given for 
10 mg/mL formulations after freeze-drying and after storage for 3 months at 40°C.  
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DISCUSSION AND OUTLOOK 
Freeze-drying is a unit operation during drug product manufacturing used to increase stability, if 
proteins are unstable as liquids. However, typical disaccharide-based formulations have low glass 
transition temperatures. Particularly for low concentrated antibody formulations, this poses 
challenges for freeze-drying cycle development due to an increased risk of collapse. Collapse increases 
the risk of rejects and complaints, and may be detrimental to protein stability.   
The aim of this work was to investigate amorphous excipients as alternatives to sucrose for low 
concentrated freeze-dried antibody formulations. The main objectives were to investigate the 
excipients with regards to their ability to stabilize antibodies during freeze-drying and particularly 
during storage at elevated temperatures, while enabling short freeze-drying cycles that provide 
pharmaceutically elegant lyophilisates. To address the impact of different excipients and freeze-drying 
cycles on the lyophilisate, µ-CT was established to visualize differences in cake appearance and 
structure. 
Cake appearance by µ-CT: Opportunities and limitations 
Objective evaluation of cake appearance can be difficult and is dependent on the training of the 
operator. In commercial manufacturing, automated visual inspection machines are often used, which 
help to bring the evaluation of cake appearance to a more objective and reproducible process. 
However, lyophilized products can provide challenges for camera-based inspection systems, e.g. for 
fogging, necessitating re-inspections [1, 2]. Moreover, during freeze-drying cycle development, not 
only cake appearance, but also internal cake structure and morphology are investigated to detect 
characteristics that may influence drug product quality attributes such as reconstitution time or 
protein stability. This is typically done through PDMS embedding and scanning electron microscopy. 
Because of their destructive nature only select regions of the lyophilisate can be investigated. 
Moreover, this approach limits the possibility to directly link the individual cake structure of a 
lyophilisate to its impact on product quality attributes. In light of these challenges, µ-CT was introduced 
as an alternative method in Chapter 1. It enabled imaging of the cake structure and morphology of the 
entire lyophilisate with one single measurement, thus being advantageous compared to PDMS 
embedding and scanning electron microscopy. Moreover, this method was applied to evaluate the 
impact of different excipients on the lyophilisates, investigated in Chapters 2 and 3, and to detect 
collapsed regions in the lyophilisates upon development of an aggressive freeze-drying cycle 
(Chapter 4). 
Quantitative characterization   
In addition to qualitative imaging, the applicability of µ-CT to quantitatively differentiate between cake 
appearances resulting from different formulations freeze-dried with the same lyophilization cycle was 
demonstrated in Chapter 1. Performing the X-ray scan with a resolution of 10 µm, surface/volume ratio 
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and pixel count/slice were calculated to achieve a quantitative measure for collapse. This additional 
quantitative characterization of lyophilisates can be valuable during freeze-drying cycle development 
and process transfers. For instance, Parker et al. used a resolution of 4.5 µm to compare porosity of 
lyophilisates, which were freeze-dried with aggressive or conservative conditions [3]. Izutsu et al. 
performed µ-CT with a high resolution of 0.5 µm to study the impact of freezing protocols on the 
morphology of freeze-dried solids [4]. Recent studies by Pisano et al. and Foerst et al. used µ-CT images 
with a resolution of 6 µm and 1 µm, respectively, to calculate the pore size of lyophilisates for 
estimation of the mass transfer rate during primary drying [5, 6]. On the one hand, these studies 
highlight the potential of µ-CT for a quantitative characterization, while on the other hand the different 
acquisition parameters, e.g. resolution, simultaneously reveal its limitations. Any quantification is 
based on binary images, meaning prior processing of the tomographs is needed. The outcome of this 
is dependent on image quality, i.e. the contrast of the µ-CT image, resolution, and thresholding 
algorithms. As the glass vial, which needs to be penetrated by the X-rays, has a much higher density 
than the lyophilisate, obtaining images of high contrast is challenging. For this reason, the above 
mentioned studies removed the lyophilisate from the glass vial for analysis. In the study presented in 
Chapter 1, we used a custom-made plastic container, which was overlaid with nitrogen and sealed to 
avoid structural changes due to water uptake. Besides contrast, the resolution of the X-ray scan has 
considerable impact on the quantification of pore size, as a resolution that is lower than the size of 
individual pores will make any quantification of pores inaccurate. Additionally, the different available 
thresholding algorithms further influence the accuracy of the quantitative information, turning the 
idea of objective quantification into subjective evaluation. Therefore, caution should be taken when 
comparing data from different studies using different acquisition parameters. Nevertheless, the 
relative comparison of quantitative characteristics of lyophilisates within one study can be of great 
advantage during development, for example to compare different formulations or process parameters. 
However, the use of µ-CT to characterize morphology is not a high-throughput method. Measurement 
time increases strongly with higher resolutions and larger vial sizes. Dependent on the µ-CT equipment, 
i.e. detector and field of view, analysis of one lyophilisate can easily take more than a day. The 
lyophilization process is known to result in inter-vial heterogeneities [7], requiring a representative 
sample size of the batch for statistical significant analysis. This leads to time-consuming analysis and 
immense data sets, limiting the applicability for routine quantitative process characterization. 
Non-invasive imaging 
As mentioned above, µ-CT of the lyophilisate through the glass vial is more challenging due to the 
different X-ray intensities needed for the glass vial and lyophilisate. In Chapter 1, the feasibility of µ-CT 
for a non-invasive analysis of the internal cake structure to qualitatively identify cake defects, or intra- 
and inter-vial heterogeneities was demonstrated. The method presented in Chapter 1 resulted in 
considerable loss of contrast and marked appearance of so called beam hardening artefacts [8]. Over 
the course of this work, using another µ-CT instrument and adapting the measurement as well as 
reconstruction parameters, non-invasive imaging with much higher quality and without strong 
artefacts was achieved, as shown by µ-CT images in Chapter 4. Nevertheless, reductions in obtained 
contrast are expected and would be considered acceptable for a purely qualitative approach. It is 
possible that further method development, or tools such as phase contrast enhancement would 
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enable quantitative analysis of µ-CT images that were acquired through the glass vial. While most 
research focuses on a quantitative readout, qualitative evaluation is already beneficial, as in contrast 
to scanning electron microscopy it comprehensively visualizes the entire cake structure. Most 
importantly, the non-invasive imaging allows to directly link the structure or morphology to other 
product quality attributes by using the same lyophilisate for further characterization, being highly 
beneficial during formulation and process development, and transfers. In addition, for the qualitative 
evaluation of macroscopic defects in cake appearance, such as collapsed regions, a considerably lower 
resolution than used in the presented studies might be sufficient and thus increase throughput. Such 
qualitative evaluation could also provide a promising in-process control for commercial production 
complementary to visual inspection, revealing internal critical defects such as meltback or partial 
collapse. To implement µ-CT as a routine analysis, further studies would be needed to first identify an 
ideal µ-CT instrument suitable to cover all typical vial dimensions and second to establish the optimal 
acquisition parameters with minimal measurement to achieve the resolution needed to identify 
macroscopic cake defects. The full potential of µ-CT goes beyond imaging of cake structures. For 
example, µ-CT has been reported to detect container closure integrity issues [9, 10] and an X-ray based 
system that detects external particles, such as glass or fibers within lyophilisates, was presented [11]. 
Future µ-CT instruments may potentially enable a combined analysis of these different aspects. 
Potential and challenges of alternative amorphous excipients  
Sucrose is the most frequently used excipient in lyophilized protein formulations. Despite its excellent 
protein stabilizing properties, its low glass transition temperature provides limitations, leading to time-
consuming freeze-drying cycles and potentially requiring refrigerated storage conditions. As proteins 
increase the formulation’s glass transition temperature, these challenges are less pronounced for high 
concentrated antibody formulations. However, as new mAb derivatives such as ADCs, bispecific mAbs, 
and Fc-fusion proteins often require lower doses, development of a short freeze-drying cycle providing 
elegant lyophilisates becomes challenging. Chapter 2 and 3 investigated alternative amorphous 
excipients, which are known to have high glass transition temperatures to a) render elegant 
lyophilisates upon a freeze-drying cycle that demonstrated collapse in Chapter 1 for a pure sucrose 
formulation and b) stabilize the two model mAbs during freeze-drying and in particular during storage 
at elevated temperatures. Chapters 2 and 3 studied the impact of dextrans of different molecular 
weight (1 to 500 kDa) and HPBCD-based formulations on freeze-dried mAb formulations. 
Impact on properties of freeze-dried formulations 
The excipients (and combinations thereof) investigated in the presented work rendered formulations 
that exhibited markedly higher glass transition temperatures of both the liquid and the freeze-dried 
formulation compared to the pure sucrose formulation, which served as the reference throughout this 
work. Comparing the glass transition temperatures obtained for dextrans and HPBCD illustrates that 
besides molecular weight, structural aspects like cross-linking and branching strongly influence the 
glass transition temperature. The glass transition temperature of HPBCD (Tg’: -10.8°C), a cyclic 
oligosaccharide of approximately 1 kDa with hydroxypropyl side chains, was similar to that of high 
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molecular weight dextrans (dextran 40-500 kDa, Tg’: -10.5°C). Within this work it was shown that a 
smaller molecule with a similar higher glass transition temperature might be preferable with regards 
to product quality attributes and antibody stability. A drawback of higher molecular weight dextrans 
was their increased viscosity, which correlated with much longer reconstitution times. In contrast, 
HPBCD rendered formulations with the same glass transition temperature, but did not contribute to 
viscosity, providing lyophilisates with short reconstitution times. Both, dextran and HPBCD-based 
lyophilisates significantly improved cake appearance and provided lower residual moisture levels 
(Chapters 2, 3) compared to a non-collapsed sucrose formulation (Chapter 4).  
Antibody stability: glass dynamics and molecular interactions 
During freeze-drying HPBCD (Chapter 3) and smaller dextrans (Chapter 2) better stabilized the two 
model mAbs compared to high molecular weight dextrans (≥40 kDa), which showed a loss of monomer 
content after freeze-drying. In general, two mechanisms for protein stabilization are discussed, namely 
vitrification and water replacement, which have been described in the ‘Introduction’ section in detail. 
Stabilization through water replacement has been reported to depend on the molecular ratio of 
excipient to protein, which at a constant excipient content of 80 mg/mL used within this work, was 
lower for large dextrans in comparison to smaller dextrans. However, this raises the question whether 
the molecular ratio of the dextran or of the single glucose unit might account for the interaction. The 
molar ratio of glucose units to antibody would be the same for all dextran formulations. To fully 
elucidate this question, further studies with varying antibody/dextran ratios would be needed. 
Presumably, a better explanation for the observed lower stability might be that high molecular weight 
dextrans are only able to stabilize via vitrification. Their rigid nature, which increases with higher 
molecular weight, might prevent dextrans from interacting via hydrogen bonds. Vitrification of the 
protein is important for stability in the dried state during storage, as for storage temperatures below 
the glass transition temperature molecular mobility (α-relaxation) is reduced, slowing down 
degradation mechanisms. Stability studies at elevated temperatures within this work showed that 
protein stability during storage is not exclusively linked to the glass transition temperature of the 
formulations. Storage of the collapsed sucrose formulation close to its glass transition temperature 
resulted in sudden, strong degradation of both mAbs. For dextran and HPBCD formulations, the 
storage temperature of 40°C was far below their glass transition temperature of approximately 200°C. 
According to the vitrification theory, good and comparable mAb stability would have been expected 
for both formulations. However, dextrans could not stabilize the mAbs during storage at elevated 
temperatures (which will be outlined in more detail below). On the other hand, HPBCD stabilized the 
mAb during freeze-drying and provided significantly better stability during storage, while best stability 
was obtained with the addition of 30% sucrose. Addition of PVP did not further contribute to mAb 
stability. It has been described previously that at storage temperatures far below the glass transition 
temperature, water replacement rather than vitrification is the dominating stabilizing mechanism [12]. 
These findings highlight that sucrose is superior to HPBCD in stabilizing the antibody by molecular 
interactions. Recently, Tonnis et al. reported that not only the size, but rather the flexibility of a sugar 
accounts for its ability to stabilize proteins via hydrogen bonds [13]. 
To address the ability of molecular interactions, Mensink et al. proposed solid-state nuclear magnetic 
resonance spectroscopy (NMR) to characterize the 1HT1ρ and 1HT1 relaxation times as an indirect 
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measure for the miscibility of protein and sugars in the lyophilisate [14]. Solid-state NMR studies to 
assess the antibody-sugar interactions in dextran and HPBCD formulations are subject of ongoing 
research. A direct measure for hydrogen bonds can be given by Fourier-transform infrared 
spectroscopy (FTIR) to investigate the ability of a sugar and/or the mass fraction needed to maintain 
the secondary structure of a protein [15]. Good protection of the native confirmation of a freeze-dried 
antibody by HPBCD was reported by Faghihi et al. [16]. Additional studies with the formulations 
established within this work would help to get a profound understanding whether HPBCD shows less 
interaction via hydrogen bonds compared to sucrose. If close interactions were given, fast molecular 
motions have been described to contribute to protein stability at storage temperatures far below the 
glass transition temperature. Using neutron scattering, Pikal et al. demonstrated that sucrose, despite 
its high molecular mobility (i.e. α-relaxation), strongly depresses fast β-relaxations, which might 
explain its outstanding stabilizing properties [17]. Thus, additional studies using neutron scattering 
would be useful to get a deeper understanding of fast dynamics in HPBCD formulations. Depending on 
these outcomes, the ratio of HPBCD and sucrose with regards to optimal mAb stability could potentially 
be derived.  
Risk of antibody glycation at elevated storage temperatures 
Besides physical instability of the antibody if stored at temperatures close to the glass transition 
temperature, some chemical modifications are particularly accelerated at elevated temperatures. 
Chapter 2 highlighted the risk of antibody glycation at elevated storage temperatures for dextrans. 
Although our results showed no impact on potency, glycation and particularly the formation of 
accelerated glycation end-products is of concern with regards to immunogenicity [18]. Moreover, 
Mensink et al. reported impaired affinity for an antibody due to glycation [14]. Thus the impact on 
protein affinity, immunogenicity, and safety has to be evaluated on a case-by-case basis. Most 
importantly, Chapter 3 showed that glycation can also occur in lyophilisates with sucrose at elevated 
storage temperatures. Particularly at higher residual moisture levels, sucrose can hydrolyze, eventually 
leading to antibody glycation. This finding is of key importance regarding the possibility of storage at 
room temperature and demonstrates the limitations of dextrans and sucrose as excipients. On the 
contrary, HPBCD is a non-reducing sugar that does not hydrolyze unless exposed to extreme acidic 
conditions, thus being beneficial for room temperature stable formulations. Whether glycation by 
sucrose would be an issue in binary formulations of HPBCD and sucrose and therefore limit the amount 
of sucrose, needs to be investigated.  
Applicability for antibody formulations 
The findings of the studies in Chapter 2 and 3 showed that sucrose is and will be an important excipient 
for stabilization of the two model mAbs. However, for short freeze-drying cycles of low concentrated 
mAb formulations and potential storage at room temperature, sucrose alone will likely result in 
impaired cake appearance and stability. Based on that, the addition of alternative excipients becomes 
relevant. Dextrans were found to be not suitable due to glycation of the antibody. On the other hand, 
HPBCD with addition of sucrose was found to provide good stability at elevated temperatures. Having 
a high fraction of HPBCD, the advantage of the high glass transition temperature was maintained, 
resulting in overall good product quality attributes. This can be beneficial with regards to development 
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of short lyophilization cycles, leading to more elegant lyophilisates, which would cause less rejects. The 
potential of storage at room temperature would allow to make costly cold chains redundant and in 
particular enable a better supply of developing countries, where maintaining controlled storage 
temperatures can be challenging.  
Due to the possible different modes of interaction with the protein, it is essential to determine the 
influence of HPBCD on in vitro affinity and in vivo pharmacokinetic in toxicological studies. In general, 
HPBCD is parenterally approved and its use can be considered save up to a daily dose of 250 mg/kg/day 
for more than two weeks [19]. Due to the short t1/2 of HPBCD, a longer administration period with less 
frequent administrations, as is often the case for biopharmaceuticals is likely to be without adverse 
effects. HPBCD is eliminated through the kidney without being metabolized, thus literature emphasizes 
that caution might be needed for application in patient groups with impaired renal activity, due to 
accumulation of HPBCD [19]. Beyond toxicology, HPBCD-based formulations are expected to be 
hypotonic, which needs to be taken into account during administration. However, this can be easily 
counteracted by reconstitution with 0.9% sodium chloride solution.  
Single-step freeze-drying   
Freeze-drying is a time-consuming batch process requiring a lot of energy, resulting in an expensive 
drug product manufacturing process. The lengthy process is mainly ascribed to the primary drying step, 
which can last several days. Increasing the shelf temperature or chamber pressure during primary 
drying would shorten the primary drying phase. However, the increase of shelf temperature is 
considerably limited by the glass transition/collapse temperature of common sucrose-based 
formulations. To this end, Chapter 2 and 3 investigated alternative excipients that render freeze-dried 
antibody formulations with much higher glass transition temperatures than sucrose formulations. The 
best performing formulations across all aspects, developed in Chapter 3, were used for freeze-drying 
process development.  
Shortening the freeze-drying cycle   
Chapter 4 focused on freeze-drying cycle optimization by shortening primary drying time through 
optimization of the two adjustable process parameters: shelf temperature and chamber pressure. It is 
well-established that increasing the shelf temperature rather than the chamber pressure renders 
higher sublimation rates at lower product temperatures [20]. Therefore, the main parameter varied 
was shelf temperature. The HPBCD-based formulations enabled the usage of much higher shelf 
temperatures during primary drying, shortening the required time by 48% compared to a reference 
cycle without leading to collapse. An additional increase in chamber pressure was tested, but did not 
further shorten primary drying time. In addition, the use of high shelf temperatures enables the 
initiation of the desorption phase of unfrozen water already during the primary drying step, making a 
separate secondary drying step redundant. Thus, the applicability of a single-step freeze-drying cycle 
for HPBCD-based formulations could ultimately be demonstrated. Single-step freeze-drying is a rarely 
studied concept transforming the conventional freeze-drying cycle outlined in the ‘Introduction’ 
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section. So far, this principle has been demonstrated successfully twice in literature for sucrose-based 
formulations at protein concentrations above 50 mg/mL [21, 22]. At lower protein concentrations 
however, it was detrimental to cake appearance and necessitated the addition of a crystalline bulking 
agent. The presented work developed alternative amorphous formulations that enabled single-step 
freeze-drying for low concentrated (10 mg/mL) protein formulations.  
This single-step freeze-drying process ultimately shortened the total cycle time by 50% compared to 
the conservative reference cycle. However, it is important to understand that the 50% cycle time 
reduction may not be considered universal. For instance, batch size and fill volume per vial impact the 
primary drying time. A higher fill height will increase product resistance and thereby reduce the mass 
transfer. Moreover, Pansare et al. observed partial collapse when increasing the fill height, concluding 
that the fill height has a considerable impact on cake appearance for a single-step freeze-drying cycle 
[22]. This might as well apply for the studied formulations in Chapter 4 and would require further 
investigation.  
Besides focusing on optimization of the primary drying step itself, recent literature highlights the 
impact of the freezing step and proposes strategies to manipulate the freezing behavior, improving 
the efficacy of primary drying [23]. In conventional shelf cooling, nucleation occurs randomly, leading 
to inter-vial heterogeneity and typically small ice crystals, both contributing to a longer primary drying 
time. Recently, techniques have been introduced that enable controlled nucleation during the freezing 
step. It has been shown that controlled nucleation reduces inter-vial heterogeneity [7], leads to 
formation of larger ice crystals that allow for faster sublimation during primary drying and thus shorten 
the primary drying step [24-26]. Whether and how controlled nucleation would impact the primary 
drying of a single-step freeze-drying cycle cannot be fully answered at this point in time, as in contrast 
to conventional lyophilization cycles, there is no steady sublimation period during primary drying. In 
addition, large ice crystals reduce efficiency of water desorption due to a lower specific surface area 
available for desorption [25]. Consequently, higher residual moisture levels have been reported for 
lyophilisates that were controlled nucleated [24]. Dependent on the magnitude of the increase in 
residual moisture, this could potentially impact protein stability during storage. Therefore, further 
studies would be needed to elucidate the applicability and potential of controlled nucleation for single-
step freeze-drying to further shorten the cycle time.  
Scale-up considerations 
As much as short freeze-drying cycles are desired, it is important to be aware that the lyophilizer itself 
has limitations as well. In Chapter 4, only one third of the lyophilizer’s capacity was loaded. Aiming for 
efficient freeze-drying, lyophilization should be carried out at full load, which in turn results in overall 
higher sublimation. This becomes particularly important in scale-up to pilot plant and eventually 
production freeze-dryers. Depending on the lyophilizer’s design and capacity, freeze-dryer overload 
can become an issue for high sublimation rates. Freeze-dryer overload can occur either via choked flow 
[27] or condenser overload. The cross-sectional area and aerodynamic properties of the gas flow path 
between the vials and the condenser impose an upper limit to the maximum sublimation rate that a 
lyophilizer can handle. At sublimation rates exceeding that upper limit, the water vapor flow is choked, 
meaning the required mass transfer through the duct cannot be maintained at the set pressure, leading 
to an increase in chamber pressure above the set point and eventually an out-of-control process. 
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Condenser overload refers to the situation where water vapor in the chamber is generated at a faster 
rate than the condenser can trap it, leading to an increase in condenser temperature. Hence, the 
applicability of the developed single-step freeze-drying cycle for production scale has to be 
investigated carefully and process parameters potentially need to be adapted. If a short single-strep 
freeze-drying process can be implemented, this will strongly increase the throughput, which is 
generally limited by the capacity of the lyophilizer due to the batch process. Consequently, further 
increases of throughput would trigger intensive research into continuous freeze-drying concepts, 
which are already evaluated by some researchers [28, 29].  
Process robustness and transfer aspects 
In general, transfer of a freeze-drying process either during scale-up or from one site to another is 
challenging. Often, modeling is used to facilitate process transfer. However, modeling approaches 
might be difficult for single-step freeze-drying cycles, as there is no steady sublimation phase and 
secondary drying already takes place during the primary drying phase. Besides changes to batch size 
and capacity, differences in radiation, pressure variation within the chamber, as well as differences in 
heating due to variances in the course of the fluid flow are examples of typical parameters that might 
change during a transfer. Here, the single-step freeze-drying cycle (Chapter 4) and the formulations 
proposed (Chapter 3) might be beneficial. We demonstrated, that drying with the single-step freeze-
drying process is more homogenous compared to a conservative cycle. Additionally, there is a smaller 
potential for premature initiation of secondary drying before primary drying was finished for all vials, 
as secondary drying is triggered by completed primary drying for each vial individually. Moreover, 
Pansare et al. have shown that single-step freeze-drying is less influenced by radiation compared to a 
conventional freeze-drying cycle [22]. Furthermore, the high collapse temperatures of the 
formulations developed in the presented work allow to design a freeze-drying process with a strong 
safety margin for considerable chamber pressure or shelf temperature variations, while still rendering 
a short freeze-drying cycle.  
Outlook: Next steps to implement future freeze-dried antibody formulations 
For implementation of HPBCD-based freeze-dried antibody formulations in the future, there are still 
open questions that need to be answered with regards to protein stability and single-step freeze-
drying. Important next steps include the investigation of the molecular interactions between the 
protein and HPBCD. Investigation of the miscibility of HPBCD and the antibody using solid-state NMR 
is currently being initiated. Further investigation by FTIR and neutron scattering would be valuable to 
understand the protein stabilizing mechanisms for HPBCD. A thorough characterization using these 
analytical techniques will help to optimize the ratio of HPBCD and sucrose, which is essential to 
maximize protein stability. Studying the deuterium uptake of lyophilisates might provide a valuable 
tool to predict long-term antibody stability in formulations with different HPBCD to sucrose ratios [30]. 
Subsequently, real life stability studies for up to 24 months at 25°C and higher are essential to address 
whether such formulations would enable storage at controlled room temperature (20-25°C), or maybe 
even higher ambient temperatures. In addition to the standard analytics used to investigate physical 
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and chemical stability during storage, characterization by boronate affinity chromatography and mass 
spectrometry would be important to evaluate the risk of antibody glycation by sucrose at elevated 
temperatures for HPBCD-based formulations. Potentially, strategies to mitigate the risk of antibody 
glycation might become relevant, e.g. by using a scavenger which is the subject of current 
investigations. Ultimately, due to the possible different modes of interaction with the protein, the 
influence of HPBCD on in vitro affinity using e.g. ELISA or cell-based assays and in vivo pharmacokinetic 
in toxicological studies need to be addressed. Most importantly, to thoroughly elucidate the potential 
of HPBCD for future freeze-dried mAb formats, its impact on cake appearance and particularly protein 
stability for formulations with mAb derivatives such as ADCs and Fc-fusion proteins needs to be 
investigated. For implementation of the developed single-step freeze-drying cycle, the impact of 
different vial sizes and fill heights and most importantly aspects relevant for process scale up such as 
choked flow and condenser overload have to be evaluated.  
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CONCLUSIONS  
The presented work investigated alternative amorphous excipients to sucrose-based formulations to 
achieve high glass transition temperatures. The aim was to enable short freeze-drying cycles while 
providing pharmaceutically elegant lyophilisates. We demonstrated that the combined use of HPBCD 
with sucrose was particularly suitable, reducing cycle time by 50% and enabling improved storage 
stability at elevated temperature. 
As a first step, µ-CT was introduced as an imaging technique that allows for visualization of cake 
appearance, such as partial collapse, cake structure, and morphology. Most importantly, it enabled a 
non-invasive imaging of the entire lyophilisate. It was demonstrated that µ-CT can also be used for 
quantitative characterization of cake appearance. However, the long measurement times at high 
resolution limit its applicability for the high throughput measurements needed for statistically 
significant quantitative information. Nevertheless, qualitative imaging will be beneficial for future 
process development and transfers. In addition, it may be useful in commercial production as a 
selective in-process control measurement complementary to visual inspection. 
Investigation of alternative excipients initially focused on dextrans of 1 to 500 kDa. The results showed 
that while dextran formulations improved cake appearance, the increasing viscosity at higher 
molecular weights strongly impacted reconstitution time. Furthermore, dextrans of 40 kDa or higher 
did not sufficiently stabilize the two model mAbs upon freeze-drying. Most importantly, dextrans 
provided overall inferior protein stability compared to a pure sucrose reference formulation during 
storage due to antibody glycation. Using a mixture of equal fractions of dextrans and sucrose did 
improve protein stability of the formulation, however the data indicated that high amounts of sucrose 
may be needed for sufficient protein stability, which will reduce the formulation’s glass transition 
temperature and therefore reduce the positive effect on cake appearance. 
Therefore, in a next step, HPBCD-based formulations were investigated and the impact of the addition 
of other excipients was studied. It was shown that HPBCD provided elegant lyophilisates with good 
physico-chemical product quality attributes that stabilized the model mAbs. However, best protein 
stability during long-term storage was achieved when sucrose was added. These findings highlight that 
the excipients investigated within this work alone can not fully surpass the excellent stabilizing 
properties of sucrose, and the addition of sucrose will remain mandatory in antibody formulations. 
The combined use of HPBCD and sucrose may enable storage at elevated temperature or room 
temperature. 
Based on the most promising HPBCD-based formulations, the last part of this work focused on the 
development of a short freeze-drying cycle, using aggressive primary drying conditions. The study 
showed, that the HPBCD-based formulation with addition of sucrose allowed for a shelf temperature 
during primary drying of +30°C. This enabled the development of a single-step freeze-drying cycle 
reducing cycle time by 50%. The obtained lyophilisates were characterized using µ-CT and 
demonstrated homogenous cake structures without defects. In contrast, a formulation that 
additionally contained PVP showed dents while having similar protein stability. 
Overall, the presented work demonstrated the relevance of looking into alternative excipients, which 
in contrast to crystalline bulking agents add to protein stability while avoiding additional complexity in 
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the freeze-drying cycle. HPBCD with the addition of sucrose was found to be a promising formulation 
for future freeze-dried antibodies. This formulation with high collapse temperature facilitates 
development of short freeze-drying processes and may be beneficial during transfers. Providing 
elegant lyophilisates with short freeze-drying cycles, it avoids the uncertainties regarding the 
acceptance of products showing collapse. In addition, short single-step freeze-drying cycles would 
reduce costs of drug product manufacturing and increase throughput. The potential of room 
temperature storage would be a considerable improvement for pharmaceutical antibodies overall. In 
particular, it would make market access to developing countries easier by making complex cold chains 
redundant. 
